CA2504766A1 - 2-pyridone derivatives as inhibitors of neutrophile elastase - Google Patents

2-pyridone derivatives as inhibitors of neutrophile elastase Download PDF

Info

Publication number
CA2504766A1
CA2504766A1 CA002504766A CA2504766A CA2504766A1 CA 2504766 A1 CA2504766 A1 CA 2504766A1 CA 002504766 A CA002504766 A CA 002504766A CA 2504766 A CA2504766 A CA 2504766A CA 2504766 A1 CA2504766 A1 CA 2504766A1
Authority
CA
Canada
Prior art keywords
carboxamide
oxo
methyl
phenyl
dihydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504766A
Other languages
French (fr)
Inventor
Haekan Bladh
Tomas Klingstedt
Joakim Larsson
Karolina Lawitz
Matti Lepistoe
Hans Loenn
Grigorios Nikitidis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203348A external-priority patent/SE0203348D0/en
Priority claimed from SE0300388A external-priority patent/SE0300388D0/en
Priority claimed from SE0302120A external-priority patent/SE0302120D0/en
Application filed by Individual filed Critical Individual
Publication of CA2504766A1 publication Critical patent/CA2504766A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

There are provided novel compounds of formula (I) wherein R1, R4, R5, G1, G2, X, L, Y1, Y2 and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.

Description

2-pyridone derivatives as inhibitors of neutrophile elastase Field of the Inyention This invention relates to novel 2-pyridone derivatives, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy.
Background of the Invention ro Elastases are possibly the most destructive enzymes in the body, having the ability to degrade virtually all connective tissue components. The uncontrolled proteolytic degradation by elastases has been implicated in a number of pathological conditions.
Human neutrophil elastase (hNE), a member of the chymotrypsin superfamily of serine proteases is a 33-KDa enzyme stored in the azurophilic granules of the neutrophils. In is neutrophils the concentration of NE exceeded 5 mM and its total cellular amount has been estimated to be up to 3 pg. Upon activation, NE is rapidly released from the granules into the extracellular space with some portion remaining bound to neutrophil plasma membrane (See Kawabat et al. 2002, Eur. J. Pharmacol. 451, 1-10). The main intracellular physiological function of NE is degradation of foreign organic molecules phagocytosed by ao neutrophils, whereas the main target for extracellular elastase is elastin (Janoff and Scherer, 1968, J. Exp. Med. 128, 1137-1155). NE is unique, as compared to other proteases (fox example, proteinase 3) in that it has the ability to degrade almost all extracellular matrix and key plasma proteins (See Kawabat et al., 2002, Eur. J. Pharmacol.
451, 1-10). It degrades a wide range of extracellular matrix proteins such as elastin, Type 3 and type 4 as collagens laminin, fibronectin, cytokines etc. (Ohbayashi, H., 2002, Expert Opin. Investig.
Drugs, 11, 965-980). NE is a major common mediator of many pathological changes seen in chronic lung disease including epithelial damage (Stockley, R.A. 1994, Am.
J. Resp.
Crit. Care Med. 150, 109-113).
so The destructive role of NE was solidified almost 40 years ago when Laurell and Eriksson reported an association of chronic airflow obstruction and emphysema with deficiency of serum al-antitrypsin (Laurell and Eriksson, 1963, Scand. J. Clin. Invest. 15, 132-140).
Subsequently it was determined that al-antitrypsin is the most important endogenous inhibitor of human NE. The imbalance between human NE and endogenous antiprotease is believed to cause excess human NE in pulmonary tissues which is considered as a major °
s pathogenic factor in chronic obstructive pulmonary disease (COPD). The excessive human NE shows a prominent destructive profile and actively takes part in destroying the normal pulmonary structures, followed by the irreversible enlargement of the respiratory airspaces, as seen mainly in emphysema. There is an increase in neutrophil recruitment into the lungs which is associated with increased lung elastase burden and emphysema in al-proteinase io inhibitor-deficient mice (Cavarra et al., 1996, Lab. Invest. 75, 273-280).
Individuals with higher levels of the NE-al protease inhibitor complex in bronchoalveolar lavage fluid show significantly accelerated decline in lung functions compared to those with lower levels (Betsuyaku et al. 2000, Respiration, 67, 261-267). Instillation of human NE
via the trachea in rats causes lung haemorrhage, neutrophil accumulation during acute phase and is emphysematous changes during chronic phase (Karaki et al., 2002, Am. J.
Resp. Crit. Care Med., 166, 496-500). Studies have shown that the acute phase of pulmonary emphysema and pulmonary haemorrhage caused by NE in hamsters can be inhibited by pre-treatment with inhibitors of NE ( Fujie et a1.,1999, Inflamm. Res. 48, 160-167).
ao Neutrophil-predominant airway inflammation and mucus obstruction of the airways are major pathologic features of COPD, including cystic fibrosis and chronic bronchitis. NE
impairs mucin production, leading to mucus obstruction of the airways. NE is reported to increase the expression of major respiratory mucin gene, MUCSAC (Fischer, B.M
&
Voynow, 2002, Am. J. Respir. Cell Biol., 26, 447-452). Aerosol administration of NE to is guinea pigs produces extensive epithelial damage within 20 minutes of contact (Suzuki et al., 1996, Am. J. Resp. Crit. Care Med., 153, 1405-1411). Furthermore NE
reduces the ciliary beat frequency of human respiratory epithelium in vitro (Smallman et al., 1984, Thorax, 39, 663-667) which is consistent with the reduced mucociliary clearance that is seen in COPD patients (Currie et al., 1984, Thorax, 42, 126-130). The instillation of NE
so into the airways leads to mucus gland hyperplasia in hamsters (Lucey et al., 1985, Am.
Resp. Crit. Care Med., 132, 362-366). A role for NE is also implicated in mucus hypersecretion in asthma. In an allergen sensitised guinea pig acute asthma model an inhibitor of NE prevented goblet cell degranulation and mucus hypersecretion (Nadel et al., 1999, Eur. Resp. J., 13, 190-196).
NE has been also shown to play a role in the pathogenesis of pulmonary fibrosis.
NE: ccI_protenase inhibitor complex is increased in serum of patients with pulmonary fibrosis, which correlates with the clinical parameters in these patients (Yamanouchi et al., 1998, Eur. Resp. J. 11, 120-125). In a murine model of human pulmonary fibrosis, a NE
inhibitor reduced bleomycin-induced pulmonary fibrosis (Taooka et al., 1997, Am. J. Resp.
Crit. Care Med., 156, 260-265). Furthermore investigators have shown that NE
deficient io mice are resistant to bleomycin-induced pulmonary fibrosis (Dunsmore et al., 2001, Chest, 120, 35S-36S). Plasma NE level was found to be elevated in patients who progressed to ARDS implicating the importance of NE in early ARDS disease pathogenesis.
(Donnelly et al., 1995, Am. J. Res. Crit. Care Med., 151, 428-1433). The antiproteases and NE
complexed with antiprotease are increased in lung cancer area (Merchandise et al., 1989, is Eur. Resp. J. 2, 623-629). Recent studies have shown that polymorphism in the promoter region of the NE gene are associated with lung cancer development (Taniguchi et al., 2002, Clin. Cancer Res., 8, 1115-1120.
Acute lung injury caused by endotoxin in experimental animals is associated with elevated zo levels of NE ( Kawabata, et al., 1999, Am. J. Resp. Crit. Care, 161, 2013-2018). Acute lung inflammation caused by intratracheal injection of lipopolysaccharide in mice has been shown to elevate the NE activity in bronchoalveolar lavage fluid which is significantly inhibited by a NE inhibitor (Fujie et al., 1999, Eur. J. Pharmacol., 374, 117-125; Yasui, et al., 1995, Eur. Resp. J., 8, 1293-1299). NE also plays an important role in the neutrophil-zs induced increase of pulmonary microvascularpermeability observed in a model of acute lung injury caused by tumor necrosis factor oc (TNFa.) and phorbol myristate acetate (PMA) in isolated perfused rabbit lungs (Miyazaki et al., 1998, Am. J. Respir. Crit.
Care Med., 157, 89-94).
so A role for NE has also been suggested in monocrotoline-induced pulmonary vascular wall thickening and cardiac hypertrophy (Molteni et al., 1989, Biochemical Pharmacol. 38, 2411-2419). Serine elastase inhibitor reverses the monocrotaline-induced pulmonary hypertension and remodelling in rat pulmonary arteries (Cowan et al., 2000, Nature Medicine, 6, 698-702). Recent studies have shown that serine elastase, that is, NE or vascular elastase are important in cigarette smoke-induced muscularisation of small pulmonary arteries in guinea pigs (Wright et al., 2002, Arn. J. Respir. Crit.
Care Med., 166, 954-960).
NE plays a key role in experimental cerebral ischemic damage (Shimakura et al., 2000, Brain Research, 858, 55-60), ischemia-reperfusion lung injury (Kishima et al., 1998, Ann.
Thorac. Surg. 65, 913-918) and myocardial ischemia in rat heart (Tiefenbacher et al., 1997, io Eur. J. Physiol., 433, 563-570). Human NE levels in plasma are significantly increased above normal in inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis (Adeyemi et al., 1985, Gut, 26, 1306-1311). In addition NE has also been assumed to be involved in the pathogenesis of rheumatoid arthritis (Adeyemi et al., 1986, Rheumatol. Int., 6, 57). The development of collegen induced arthritis in mice is is suppressed by a NE inhibitor (Kakimoto et al., 1995, Cellular Immunol. 165, 26-32).
Thus, human NE is known as one of the most destructive serine proteases and has been implicated in a variety of inflammatory diseases. The important endogenous inhibitor of human NE is al-antitrypsin. The imbalance between human NE and antiprotease is ao believed to give rise to an excess of human NE resulting in uncontrolled tissue destruction.
The protease/ antiprotease balance may be upset by a decreased availability of al-antitrypsin either through inactivation by oxidants such as cigarette smoke, or as a result of genetic inability to produce sufficient serum levels. Human NE has been implicated in the promotion or exacerbation of a number of diseases such as pulmonary Zs emphysema, pulmonary fibrosis, adult respiratory distress syndrome CARDS), ischemia reperfusion injury, rheumatoid arthritis and pulmonary hypertension.
WO 02/053543 discloses pyridone derivatives having affinity for cannabinoid 2-type receptor.

S
The present invention discloses novel 2-pyridone derivatives that are inhibitors of human neutrophil elastase and homologous serine proteases such as proteinase 3 and pancreatic elastase, and are thereby useful in therapy.
s Disclosure of the Invention The present invention provides a compound of formula (I) Y1~Y NFL-G2 ~4 R' N R
G' \R5)17 io wherein X represents O or S;
is Y1 represents N or CR2; and when R1 represents OH, Y1 may also, in the tautomeric form, represent NR6;
Y2 represents CR3; and when Yl represents CR2, then Y2 may also represent N;
2o Rl represents H or C1 to 6 alkyl; said alkyl being optionally substituted by one or more substituents selected independently from halogen, CN, CHO, ORS, NR8R9, S(O)mRl~ and O
z X

S02NR R ;

and, when Y1 represents N, Rl may also represent OH;
R~ represents H, C1 to 6 alkyl or phenyl; said phenyl being optionally further substituted by halogen, C 1 to 6 alkyl and C 1 to 6 alkoxy;
s RZ represents H, halogen or C1 to 6 alkyl;
R3 represents H or F;
io G1 represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; or Gl represents a five-or six-membered saturated or partially unsaturated cycloalkyl ring; or Gl represents a five- or six-membered saturated or partially unsaturated heterocyclic ring containing one heteroatom selected from O, S and NR~3 where R13 represents H or C1 to 6 alkyl;
is RS represents H, halogen, C1 to 6 alkyl, CN, C1 to 6 alkoxy, NO2, NR14RI5~ C1 to 3 alkyl substituted by one or more F atoms or C 1 to 3 alkoxy substituted by one or more F atoms;
R14 and R15 independently represent H or C1 to 3 alkyl; said alkyl being optionally further ao substituted by one or more F atoms;
n represents an integer 1, 2 or 3 and when n represents 2 or 3, each RS group is selected independently;
as R4 and R6 independently represent H or C1 to 6 alkyl; said alkyl being optionally further substituted by OH or C1 to 6 alkoxy;

or R4 and L are joined together such that the group -NR4L represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and ~16~
s L represents a bond, O, NR29 or C1 to 6 alkyl; said alkyl optionally incorporating a heteroatom selected from O, S and NR16; and said alkyl being optionally further substituted by OH or OMe;
G~ represents a monocyclic ring system selected from:
io i) phenyl or phenoxy, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or is iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR1~ and optionally further incorporating a carbonyl group; or GZ represents a bicyclic ring system in which each of the two rings is independently zo selected from:
i) phenyl, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, zs iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatorns independently selected from O, S(O)p and NRl~ and optionally further incorporating a carbonyl group;

and the two rings are either fused together, or are bonded directly together or are separated by a linker group selected from O, S(O)q or CHz, said monocyclic or bicyclic ring system being optionally further substituted by one to three s substituents independently selected from CN, OH, C1 to 6 alkyl, C1 to 6 alkoxy, halogen, NR18R19~ N02, OS02R38, C02R2~, C(=NH)NH2, C(O)NR21R22, C(S)NR23R24~
SC(=NH)NH~, NR31C(=NH)NHz, S(O)SR25, SOZNR~6R2~, C1 to 3 alkoxy substituted by one or more F atoms and C1 to 3 alkyl substituted by S02R3g or by one or more F atoms;
or io when L does not represent a bond, G~ may also represent H;
m, p, q, s and t independently represent an integer 0, 1 or 2;
is Rg and R9 independently represent H, CI to 6 alkyl, formyl or C2 to 6 alkanoyl; said alkyl being optionally further substituted by phenyl optionally substituted by halogen, C 1 to 6 alkyl, C1 to 6 alkoxy or S02R30;
or the group NR~R9 together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR28;
zo R1g and R~9 independently represent H, C1 to 6 alkyl, formyl, C2 to 6 alkanoyl, S(O)tR32 or S02NR33R34~ std alkyl group being optionally further substituted by halogen, CN, C1 to 4 alkoxy or CONR41R~~;
zs R25 represents H, C1 to 6 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, CONR35R36, C02R37, OCOR4~, C3 to 6 cycloalkyl, a C4 to 7 saturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR43 and phenyl or a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N; said aromatic ring being optionally further substituted by one or more substituents selected independently from halogen, CN, Cl to 4 s alkyl, Cl to 4 alkoxy, OH, CONR~R45, C02R46, S(O)SR4~ and NHCOCH3;
R26 and R2~ independently represent H, C1 to 6 alkyl, formyl or C2 to 6 alkanoyl;
R32 represents H, C1 to 6 alkyl or C3 to 6 cycloaIkyl;
io R38 represents H, Cl to 6 alkyl or phenyl; said phenyl being optionally further substituted by halogen, C1 to 6 alkyl or C1 to 6 alkoxy;
R10 Rll R12 R16 R17 R20 R21 R22 R23 R24 R28 R29 R30 R31 R33 R34 R35 > > > > > > > > > > > > > > > > >
is R36~ R37~ R39~ R40~ R41~ R42~ R43' R44~ R45~ R46 and R4~ independently represent H or C I to 6 alkyl;
and pharmaceutically acceptable salts thereof, with the proviso that the following compounds are disclaimed:
ao N-benzyl-5,6-dimethyl-2-oxo-1-phenyl-2,2-dihydropyridine-3-carboxamide;
N-(2-phenethyl)-5,6-dimethyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide;
N-(2-hydroxyethyl)-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide;
N-[2-(dimethylamino)ethyl]-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide;
as 4-[2-[[[1,2-dihydro-1-(4-methylcyclohexyl)-2-oxo-3-pyridinyl]carbonyl]amino]ethyl]-benzoic acid; and 4-[2-[[(1-cyclohexyl-1,2-dihydro-2-oxo-3-pyridinyl]carbonyl]amino]ethyl]-benzoic acid.

The compounds of formula (I) may exist in enantiomeric forms. It is to be understood that all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention.
Compounds of formula (I) may also exist in various tautomeric forms. Thus, for example, compounds of formula (I) wherein R1 represents OH and Yl represents N, are tautomers of compounds of formula (Ia) wherein R6 represents H.
R~N~Y N~~-G2 ~ ~4 O' 'N

/~
(R5)n (la) All possible tautomeric forms and mixtures thereof are included within the scope of the invention. Compounds of formula (Ia) wherein R6 represents H or optionally substituted C1 to 6 alkyl are thus specifically included within the scope of the invention.
is Unless otherwise indicated, the term "C1 to 6 alkyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl and hexyl. The terms "C1 to 3 alkyl" and "Cl to 4 alkyl" are to be interpreted analogously.
zo Examples of "C1 to 3 alkyl substituted by one or more F atoms" include fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, pentafluoroethyl O

X
and 3,3,3-trifluoropropyl.

Unless otherwise indicated, the term "C1 to 6 alkoxy " referred to herein denotes an oxygen substituent bonded to a straight or branched chain alkyl group having from 1 to 6 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy and s-butoxy. The terms "C 1 to 3 alkoxy" and "C 1 to 4 alkoxy" are to be interpreted analogously.
Examples of "C1 to 3 alkoxy substituted by one or more F atoms" include fluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy and 3,3,3-trifluoropropoxy.
io Unless otherwise indicated, the term "C2 to 6 alkanoyl" referred to herein denotes a straight or branched chain alkyl group having from 1 to 5 carbon atoms bonded to the molecule via a carbonyl group. Examples of such groups include acetyl, propionyl and pivaloyl.
is Unless otherwise indicated, the term "halogen" referred to herein denotes fluorine, chlorine, bromine and iodine.
Examples of a five or six membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N include furan, thiophene, pyrrole, oxazole, 20 oxadiazole, isoxazole, imidazole, thiazole, triazole, thiadiazole, pyridine, pyrimidine and pyrazme.
Unless otherwise indicated, the term "C3 to 6 saturated or partially unsaturated cycloalkyl"
referred to herein denotes a 3 to 6 membered non-aromatic carbocyclic ring optionally as incorporating one or more double bonds. Examples include cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl. The term "five- or six-membered saturated or partially unsaturated cycloalkyl ring" is to be interpreted analogously.
Unless otherwise indicated, the term "C4 to 7 saturated or partially unsaturated so heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR~~ and optionally further incorporating a carbonyl group" referred to herein denotes a 4 to 7 membered non-aromatic heterocyclic ring optionally incorporating one or more double bonds and optionally incorporating a carbonyl group. Examples include tetrahydrofuran, thiolane I,1-dioxide, tetrahydropyran, 4-oxo-4H-pyran, pyrrolidine, pyrroline, imidazolidine, 1,3-dioxolane, piperidine, piperazine, morpholine, perhydroazepine, pyrrolidone and piperidone. The term "five- or six-membered saturated or partially unsaturated heterocyclic ring containing one heteroatom selected from O, S and X13" is to be interpreted analogously.
Examples of a "5 to 7 membered azacyclic ring optionally incorporating one further io heteroatom selected from O, S and NR16" include pyrrolidine, piperidine, morpholine, thiomorpholine and piperazine.
In the definition of L, "C1 to 6 alkyl; said alkyl optionally incorporating a heteroatom selected from O, S and NR16" embraces a straight or branched chain arrangement of 1 to 6 is carbon atoms in which any two carbon atoms are optionally separated by O, S
or NR16 The definition thus includes, for example, methylene, ethylene, propylene, hexamethylene, ethylethylene, -CH~CH20-CHI-, -CH2CH20-CH2-CH2-, -CH2CH2S- and zo Examples of bicyclic ring systems in which the two rings are either fused together, or are bonded directly together or are separated by a linker group selected from O, S(O)q or CHI, include biphenyl, thienylphenyl, pyrazolylphenyl, phenoxyphenyl, naphthyl, indanyl, quinolyl, tetrahydroquinolyl, benzofuranyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, isoquinolyl, chromanyl, zs indenyl, quinazolyl, quinoxalyl, chromanyl, isocromanyl, 3H-indolyl, 1H-indazolyl, quinuclidyl, tetrahydronaphthyl, dihydrobenzofuranyl, morpholine-4-ylphenyl, 1,3-benzodioxolyl, 1,I-dioxido-2,3-dihydro-1-benzothienyl, 2,3-dihydro-1,4-benzodioxinyl and 3,4-dihydro-isochromenyl .

Examples of bicyclic ring systems in which the two rings are separated by a linker group S(O)q include 4-(piperazin-1-ylsulfonyl)phenyl, 4-(morpholin-4-ylsulfonyl)phenyl, 4-(piperidin-1-ylsulfonyl)phenyl, 4-(pyrrolidin-1-ylsulfonyl)phenyl, 4-(4-pyridinylsulfonyl)phenyl, 4-(phenylsulfonyl)phenyl, 4-(thiazolylsulfonyl)phenyl, s 4-(pyrimidin-2-ylsulfonyl)phenyl, 4-(imidazolylsulfonyl)phenyl, 4-(triazolylsulfonyl)phenyl and 4-(oxazolylsulfonyl)phenyl, In one embodiment, RS represents H, halogen, C1 to 6 alkyl, CN, C1 to 6 alkoxy, C1 to 3 alkyl substituted by one or more F atoms or C1 to 3 alkoxy substituted by one or more F
io atoms. In another embodiment, RS represents halogen, C1 to 6 alkyl, CN, Cl to 6 alkoxy or C I to 3 alkyl substituted by one or more F atoms. In another embodiment, RS represents halogen, CH3, CN, OCH3 or CF3.
In one embodiment, n represents an integer I or 2. In another embodiment, n represents the is integer 1.
In one embodiment, R$ represents halogen, CN or CF3; n represents the integer 1; and Gl represents phenyl.
2o In one aspect, the invention provides compounds of formula (I) wherein X
represents O;
Y1 represents CR2; YZ represents CR3; R1 represents optionally substituted C1 to 6 alkyl;
Gl represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; R4 represents H; L
represents C1 to 6 alkyl; and GZ represents an optionally substituted monocyclic ring system selected from:
i) phenyl, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR1~ and optionally further incorporating a carbonyl group.
s In another aspect the invention provides compounds of formula (I) wherein X
represents O; Yl represents CR2; Y~ represents CR3; R1 represents C1 to 6 alkyl; R2 and R3 each represent H; Gl represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; R4 represents H; L
represents C1 to 6 alkyl; and G2 represents an optionally substituted monocyclic ring io system selected from:
i) phenyl, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, is iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or iv) a C4 to 7 saturated ar partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR1~ and optionally further incorporating a carbonyl group.
zo In another aspect the invention provides compounds of formula (I) wherein X
represents O; Y1 represents N or NR6 and R1 represents OH or a tautomer thereof; Y2 represents CR3; G1 represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatorns independently selected from O, S and N; R4 represents H; L
represents CI
to 6 alkyl; and G2 represents an optionally substituted monocyclic ring system selected as from:
i) phenyl, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NRl~ and optionally further incorporating a carbonyl group.
s In another aspect the invention provides compounds of formula (I) wherein X
represents O; Yl represents CRS; Y2 represents CR3; R1 represents C1 to 6 alkyl; RZ and R3 each represent H; GI represents phenyl or pyridyl; R4 represents H; L represents C1 to 6 alkyl;
and G2 represents optionally substituted phenyl.
io In another aspect the invention provides compounds of formula (I) wherein X
represents O; Y1 represents CR2; Y2 represents CR3; R1 represents C1 to 6 alkyl; R2 and R3 each represent H; Gl represents phenyl or pyridyl; R4 represents H; L represents methylene; and G~ represents optionally substituted phenyl.
is In one embodiment, X in formula (I) represents O.
In one embodiment, the invention discloses compounds of formula (I) in which represents CR2 and Y~ represents CR3. In another embodiment, the invention discloses zo compounds of formula (I) in which Y1 represents CRZ and YZ represents CR3 and R2 and R3 each represent H.
In another embodiment, Yl represents N. In another embodiment, Rl represents OH in the tautomeric form and Y1 represents NR6.
zs In one embodiment, Rl represents optionally substituted Cl to 6 alkyl. In another embodiment, Rl represents C1 to 6 alkyl, particularly methyl.

In one embodiment, G1 represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N. In another embodiment, G1 in formula (I) represents phenyl or pyridyl. In another embodiment, Gt in s formula (I) represents phenyl. In another embodiment, Gl in formula (I) represents phenyl and (R5)n represents a CF3 group in the 3-position.
In one embodiment, R4 represents H.
io In one embodiment, L represents Cl to 6 alkyl. In another embodiment, L
represents -CHI-. In another embodiment, L represents NR29 and R29 represents H.
In one embodiment, G2 represents an optionally substituted monocyclic ring system selected from:
is i) phenyl, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or zo iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR17 and optionally further incorporating a carbonyl group.
In another embodiment, GZ represents optionally substituted phenyl. In another as embodiment, G2 represents phenyl substituted by OS02R38, S(O)SR25, SO~NR26R27 NR18R1~ (wherein at least one of R1g and Rl~ represents S(O)tR32 or S02NR33R34) or C1 to 3 allcyl substituted by SOZR3~.

In another aspect, the invention specifically provides one or more compounds as described in the Examples herein, or the non-salt form thereof or a pharmaceutically acceptable salt thereof.
s Particular compounds include:
N-(4-chlorobenzyl)-1-(4-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide io 6-methyl-N-(4-morpholin-4-ylbenzyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[4-(methylsulfonyl)phenyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(dimethylamino)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-i5 dihydropyridine-3-carboxamide N-[4-(aminosulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-methoxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide zo N-benzyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-1-(2-fluoro-5-methylphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(3-chlorobenzyl)-1-(2-fluoro-5-methylphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-zs carboxamide 1-(2-fluoro-5-methylphenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(4-methoxybenzyl)-1-(3-methoxyphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide so N-(3-chlorobenzyl)-1-(3-methoxyphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide I~
N-(4-chlorobenzyl)-1-(3-methoxyphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-[4-(aminosulfonyl)benzyl]-1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide s N-(4-chlorobenzyl)-1-(3-chloro-4-methylphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-chloro-4-methylphenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-1-(2,3-dimethylphenyl)-6-methyl-2-oxo-I,2-dihydropyridine-3-io carboxamide N-(4-chlorobenzyl)-1-(3-chloro-4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-chloro-4-fluorophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide is N-(4-chlorobenzyl)-1-(3-ethylphenyl)-6-methyl~2-oxo-1,2-dihydropyridine-3-carboxamidew.
1-(3-bromophenyl)-N-(4-chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-bromophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide ao N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-bromobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-zs carboxamide N-(4-chlorophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-methoxybenzyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide so N-(4-chlorobenzyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-1-(3,5-dimethylphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-[4-(aminosulfonyl)benzyl]-1-(3,5-dirnethylphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3,5-dimethylphenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-carboxamide s N-benzyl-1-(3,5-dimethylphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide N-(4-methoxybenzyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide io N-(3-chlorobenzyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(3-chlorobenzyl)-1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-is carboxamide 1-(3-chlorophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide methyl 4-[({ [1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]carbonyl } amino)methyl]benzoate ao 4-[({ [1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]carbonyl}amino)methyl]benzoic acid 1-(3-cyanophenyl)-N-(cyclohexylmethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2-furylmethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide zs 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(pyridin-3-ylmethyl)-1,2-dihydropyridine-carboxamide N-benzyl-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-2,3-dihydro-1H-inden-1-yl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide s 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(3,4,5-trimethoxybenzyl)-1,2-dihydropyridine-3-carboxamide I-(3-cyanophenyl)-N-(2,5-dimethoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3,4-dimethoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-io carboxamide 1-(3-cyanophenyl)-N-[(1-ethylpyrrolidin-2-yl)methyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxarnide N-(4-chlorobenzyl)-I-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxaxnide is 1-(3-cyanophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(3-chlorobenzyl)-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(thien-2-ylmethyl)-1,2-dihydropyridine-3-ao carboxaxnide 1-(3-cyanophenyl)-N-(cyclopropylmethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(pyridin-4-ylmethyl)-1,2-dihydropyridine-carboxamide 1-(3-cyanophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-2-oxo-1,2-3o dihydropyridine-3-carboxamide N-[2-(3-chlorophenyl)ethyl]-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(2-pyridin-2-ylethyl)-1,2-dihydropyridine-3-carboxamide N-[2-(4-chlorophenyl)ethyl]-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide s 1-(3-cyanophenyl)-N-[2-(2-methoxyphenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-[2-(2-chlorophenyl)ethyl]-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-[2-(3-methoxyphenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-io carboxamide 1-(3-cyanophenyl)-N-[2-(4-fluorophenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-[2-(2,4-dichlorophenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide is 1-(3-cyanophenyl)-N-[2-(3-fluorophenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-[2-(2-fluorophenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2-cyclohex-1-en-1-ylethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-zo carboxamide N-[2-(4-bromophenyl)ethyl]-1-(3'-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(3-bromobenzyl)-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide zs N-(4-bromobenzyl)-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-(2-bromobenzyl)-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3,4-dihydro-2H-pyran-2-ylmethyl)-6-methyl-2-oxo-1,2-so dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-N-(4-methylbenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-N-(1-naphthylmethyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2-ethoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide s 1-(3-cyanophenyl)-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-N-(3-methylbenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(4-fluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-io carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2,4-dichlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide is 1-(3-cyanophenyl)-6-methyl-N-(2-methylbenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3,4-difluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3,4-dichlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-ao carboxamide 1-(3-cyanophenyl)-6-methyl-N-[(5-methyl-2-furyl)methyl]-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-1,2,3,4-tetrahydronaphthalen-1-yl-1,2-dihydropyridine-3-carboxamide as 1-(3-cyanophenyl)-N-(2,3-dimethoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3,5-dimethoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-[ 1-(4-fluorophenyl)ethyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-so carboxamide N-[1-(4-chlorophenyl)ethyl]-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2,5-difluorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-6-methyl-2-oxo-I,2-dihydropyridine-3-carboxamide s methyl4-[({[1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]carbonyl } amino)methyl]benzoate 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(4-phenoxybenzyl)-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-[(1 S)-2,3-dihydro-1H-inden-1-yl]-6-methyl-2-oxo-1,2-io dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(thien-3-ylmethyl)-I,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-N-[(5-methylisoxazol-3-yl)methyl]-2-oxo-1,2-dihydropyridine-3-carboxamide is 1-(3-cyanophenyl)-N-[(2,5-dimethyl-3-furyl)methyl]-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-(3-furylmethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxaW ide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-[4-(1H-pyrazol-1-yl)benzyl]-1,2-dihydropyridine-3-carboxamide ao 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(4-thien-2-ylbenzyl)-1,2-dihydropyridine-carboxamide N-[4-(aminosulfonyl)benzyl]-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-as dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-(2-thien-2-ylethyl)-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-N-[2-(2,4-dimethylphenyl)ethyl]-6-methyl-2-oxo-I,2-dihydropyridine-3-carboxamide so 1-(3-cyanophenyl)-6-methyl-N-[2-(4-methylphenyl)ethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-{ 2-[4-(aminosulfonyl)phenyl)ethyl }-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(3-cyanophenyl)-6-methyl-2-oxo-N-[(1S)-1-phenylethyl]-1,2-dihydropyridine-3-carboxamide s N-(cyclohexylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-furylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(pyridin-3-ylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide N-2,3-dihydro-1H-inden-1-yl-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-methoxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is 6-methyl-2-oxo-N-(tetrahydrofuran-2-ylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-N-(3,4,5-trimethoxybenzyl)-1,2-dihydropyridine-3-carboxamide N-(3-fluorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-ao carboxamide N-(2,5-dimethoxybenzyl)-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[(1-ethylpyrrolidin-2-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-(2-chlorobenzyl)-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(3-chlorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-so carboxamide 6-methyl-2-oxo-N-(thien-2-ylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(cyclopropylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(3-methoxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s 6-methyl-2-oxo-N-(pyridin-4-ylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(3,4-dimethoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(4-methoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(2-phenylethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is N-[2-(3-chlorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(2-pyridin-2-ylethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(2-methoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-zo dihydropyridine-3-carboxamide N-[2-(2-chlorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(3-methoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-[2-(4-fluorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(2,4-dichlorophenyl)ethyl]-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-I,2-dihydropyridine-3-carboxamide N-[2-(3-fluorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-I,2-3o dihydropyridine-3-carboxamide N-[2-(2-fluorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-cyclohex-1-en-1-ylethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(4-bromophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s 6-methyl-2-oxo-N-[(1S)-1-phenylethyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(3-bromobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-bromobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-io carboxamide N-(2-bromobenzyl)-6-methyl-2-oxo-1-j3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(3,4-dihydro-2H-pyran-2-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is 6-methyl-N-(4-methylbenzyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-(1-naphthylmethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-ethoxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-zo carboxamide 6-methyl-N-(3-methylbenzyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-fluorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-(1,3-benzodioxol-5-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2,4-dichlorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-(2-methylbenzyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-3o carboxamide N-(3,4-difluorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-fluorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-chloro-4-fluorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s N-(3,4-dichlorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[(5-methyl-2-furyl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-1,2,3,4-tetrahydronaphthalen-1-yl-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide N-(2,3-dimethoxybenzyl)-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[ 1-(4-chlorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is N-(2,5-difluorobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide methyl 4-{ [({ 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridin-yl } carbonyl)amino]methyl }benzoate 6-methyl-2-oxo-N-(4-phenoxybenzyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-ao 3-carboxamide N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[(5-methylisoxazol-3-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide zs N-[(2,5-dimethyl-3-furyl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(3-furylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(1H-pyrazol-1-yl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-3o dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(4-thien-2-ylbenzyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(1,3-benzodioxol-5-yl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(2-thien-2-ylethyl)-1-[3-(trifluoromethyl)phenyl]-I,2-dihydropyridine-3-carboxamide s N-[2-(4-tert-butylphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[2-(4-methylphenyl)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 2-[4-(aminosulfonyl)phenyl]ethyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[(1R)-1-phenylethyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 3-{ [4-(2-methoxyphenyl)piperazin-I-yl]carbonyl }-6-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2( 1H)-one is N-[(4-cyanocyclohexyl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 3-{ [4-(4-fluorophenyl)piperazin-I-yl]carbonyl }-6-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N-[2-(4'-fluoro-I, I'-biphenyl-4--yl)ethyl]-b-methyl-2-oxo-1-[3-(triflnoromethyl)phenyl]-zo 1,2-dihydropyridine-3-carboxamide N-(2-hydroxy-I-phenylethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[(2R)-2-phenylcyclopropyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-[1-(4-chlorobenzyl)piperidin-4-yl]-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-(2-morpholin-4-ylethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-I,2-dihydropyridine-3-carboxamide N-[2-(4-chlorophenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-so dihydropyridine-3-carboxamide N-(2-hydroxy-2-phenylethyl)-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-cyclopentyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-carboxamide N-[2-(1H-imidazol-4-yl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s N-(3,5-dimethoxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-hydroxycyclohexyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(2-pyridin-2-ylethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-1H-1,2,4-triazol-3-yl-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(hydroxymethyl)-2-methylpropyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is 3-{[3-(3,4-dichlorophenoxy)pyrrolidin-1-yl]carbonyl}-6-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one 6-methyl-2-oxo-N-(pyridin-3-ylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-zo carboxamide N-(2-hydroxypropyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide ethyl 4-[( { 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl] -1,2-dihydropyri din-yl } carbonyl)amino]piperidine-1-carboxylate zs N-[3-(1H-imidazol-1-yl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-ca.rboxamide N-(4-chlorobenzyl)-6'-methyl-2-oxo-2H-1,2'-bipyridine-3-carboxamide N-(4-methoxybenzyl)-1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 3o methyl 4-[({ [1-(3-methylphenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl } amino)methyl]benzoate 4-[({[1-(3-methylphenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl}amino)methyl]
benzoic acid N-(4-chlorobenzyl)-1-(2-fluoro-5-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide s 1-(2-fluoro-5-methylphenyl)-N-(4-methoxybenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide N-[4-(dimethylamino)benzyl]-1-(2-fluoro-5-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide N-[4-(aminosulfonyl)benzyl]-1-(2-fluoro-5-methylphenyl)-2-oxo-1,2-dihydropyridine-3-to carboxamide N-(4-chlorobenzyl)-4'-methyl-2-oxo-2H-1,2'-bipyridine-3-carboxamide N-(4-chlorobenzyl)-1-(2,5-dimethylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 1-(2,5-dimethylphenyl)-N-(4-methoxybenzyl)-2-oxo-I,2-dihydropyridine-3-carboxamide N-[4-(dimethylamino)benzyl]-1-(2,5-dimethylphenyl)-2-oxo-1,2-dihydropyridine-3-is carboxamide N-(4-chlorobenzyl)-1-[2-methyl-5-(trifluoromethyl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-(4-methoxybenzyl)-1-[2-methyl-5-(trifluoromethyl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide zo N-[4-(dimethylamino)benzyl]-1-[2-methyl-5-(trifluoromethyl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-benzyl-5-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2-chlorobenzyl)-5-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-as carboxamide 5-methyl-2-oxo-N-(2-phenylethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-chlorophenyl)-5-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide so 6-ethyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-I,2-dihydropyridine-3-carboxamide N-[4-(methylsulfonyl)benzyl]-2-oxo-6-propyl-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-butyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxami de s 6-(methoxymethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-(hydroxymethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(aminosulfonyl)benzyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-io tetrahydropyrimidine-5-carboxamide N-[4-(dimethylamino)benzyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-c arboxamide N-(4-chlorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide is N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-bromobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-zo 5-carboxamide N-(4-methoxybenzyl)-2,4-dioxo-3-[3-(trifluorornethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(1,3-benzodioxol-5-ylmethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide zs N-(3-chlorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-(2-methoxyethyl)-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-so (trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-methyl-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-(trifluorornethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-ethyl-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-chlorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 5-iodo-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-chlorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-methoxybenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-io 1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-(2-methoxyethyl)-2,4-dioxo-N-(pyridin-4-ylmethyl)-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2-methoxyethyl)-2,4-dioxo-3-[3-.
(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide is 1-(2-methoxyethyl)-N-[2-(3-rnethoxyphenyl)ethyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-(2-methoxyethyl)-N-(4-methylbenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-I,2,3,4-tetrahydropyrimidine-5-carboxamide 1-(2-methoxyethyl)-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-zo (trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-fluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide zs N-(2-chloro-4-fluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(3,4-dichlorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide methyl 4-{ [({ 1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-so tetrahydropyrimidin-5-yl }carbonyl)amino]methyl }benzoate 1-(2-methoxyethyl)-N-[(5-methylisoxazol-3-yl)methyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-(2-methoxyethyl)-2,4-dioxo-N-[4-(1H-pyrazol-1-yl)benzyl]-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-chlorobenzyl)-3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 3-(3-chlorophenyl)-N-(4-methoxybenzyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-S-carboxamide 3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-N-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2-methoxyethyl)-2,4-dioxo-io 1,2,3,4-tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-1-(2-methoxyethyl)-N-[2-(3-methoxyphenyl)ethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-c arboxamide N-(3-bromobenzyl)-3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide is 3-(3-chlorophenyl)-1-(2-methoxyethyl)-N-(4-methylbenzyl)-2,4-dioxo-1,2,3,4=
tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-1-(2-methoxyethyl)-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-N-(4-fluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-zo tetrahydropyrimidine-5-carboxamide N-(1,3-benzodioxol-5-ylmethyl)-3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-N-(3,4-difluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as N-(2-chloro-4-fluorobenzyl)-3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-N-(3,4-dichlorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide methyl 4-[({ [3-(3-chlorophenyl)-1-(2-rnethoxyethyl)-2,4-dioxo-1,2,3,4-so tetrahydropyrimidin-5-yl]carbonyl } amino)methyl]benzoate 3-(3-chlorophenyl)-1-(2-methoxyethyl)-N-[(5-rnethylisoxazol-3-yl)methyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-N-[4-(1H-pyrazol-1-yl)benzyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(4-chlorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 1-butyl-3-(3-methoxyphenyl)-N-[2-(3-methoxyphenyl)ethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(3-bromobenzyl)-1-butyl-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(4-fluorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-io 5-carboxamide N-( 1,3-benzodioxol-5-ylmethyl)-1-butyl-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(2,4-dichlorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide is 1-butyl-N-(3,4-difluorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-c arboxamide 1-butyl-N-(2-chloro-4-fluorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-ao tetrahydropyrimidine-5-carboxamide 1-butyl-N-(4-chlorobenzyl)-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(4-methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as 1-butyl-3-(3-chlorophenyl)-2,4-dioxo-N-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxarnide 1-butyl-3-(3-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-[2-(3-methoxyphenyl)ethyl]-2,4-dioxo-1,2,3,4-so tetrahydropyrimidine-5-carboxamide N-(3-bromobenzyl)-1-butyl-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-bromobenzyl)-1-butyl-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(4-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 1-butyl-3-(3-chlorophenyl)-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-io tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(2,4-dichlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-c arboxamide is 1-butyl-N-(2-chloro-4-fluorobenzyl)-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(3,4-dichlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-2,4-dioxo-1,2,3,4-ao tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-[(4-cyanocyclohexyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-N-[(5-methylisoxazol-3-yl)methyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as 1-butyl-3-(3-chlorophenyl)-2,4-dioxo-N-[4-(1H-pyrazol-1-yl)benzyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-chlorophenyl)-2,4-dioxo-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(4-chlorobenzyl)-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-so carboxamide 1-butyl-3-(3-cyanophenyl)-N-(4-methoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide I-butyl-3-(3-cyanophenyl)-2,4-dioxo-N-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 1-butyl-3-(3-cyanophenyl)-N-[2-(3-methoxyphenyl)ethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(3-bromobenzyl)-1-butyl-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(4-bromobenzyl)-1-butyl-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-io carboxamide 1-butyl-3-(3-cyanophenyl)-N-(4-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide is 1-butyl-3-(3-cyanophenyl)-N-(4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-N-(2,4-dichlorobenzyl)-2,4-dioxo-1,2,3,4-zo tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-N-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(2-chloro-4-fluorobenzyl)-3-(3-cyanophenyl)-2,4-dioxo-I,2,3,4-tetrahydropyrimidine-5-carboxamide as 1-butyl-3-(3-cyanophenyl)-N-(3,4-dichlorobenzyl)-2,4-dioxo-I,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-[(4-cyanocyclohexyl)methyl]-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-N-[(5-methylisoxazol-3-yl)methyl]-2,4-dioxo-1,2,3,4-so tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-2,4-dioxo-N-j4-(1H-pyrazol-1-yl)benzyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-3-(3-cyanophenyl)-2,4-dioxo-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(4-chlorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 1-butyl-N-(4-methoxybenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-2,4-dioxo-N-(pyridin-4-ylmethyl)-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-io 1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-[2-(3-methoxyphenyl)ethyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(3-bromobenzyl)-1-butyl-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide is N-(4-bromobenzyl)-1-butyl-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrirnidine-5-carboxamide 1-butyl-N-(4-methylbenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-[4-(methylsulfonyl)benzyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-zo tetrahydropyrimidine-5-carboxamide 1-butyl-N-(4-fluorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide N-(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide zs 1-butyl-N-(2,4-dichlorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(3,4-difluorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(2-chloro-4-fluorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-so tetrahydropyrimidine-5-carboxamide 1-butyl-N-(3,4-dichlorobenzyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-N-[(4-cyanocyclohexyl)methyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide s 1-butyl-N-[(5-methylisoxazol-3-yl)methyl]-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-2,4-dioxo-N-[4-(1H-pyrazol-1-yl)benzyl]-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1-butyl-2,4-dioxo-N-[3-(2-oxopyrrolidin-1-yl)propyl]-3-[3-(trifluoromethyl)phenyl]-io 1,2,3,4-tetrahydropyrimidine-5-carboxamide 6-(chloromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-c arboxamide N-[4-(methylsulfonyl)benzyl]-6-[(methylthio)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is N-[4-(methylsulfonyl)benzyl]-6-({ [4-(methylsulfonyl)benzyl]amino}methyl)-2-oxo-1-[3=
(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(methylsulfonyl)benzyl]-6-(morpholin-4-ylmethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-(cyanomethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-ao dihydropyridine-3-carboxamide 6-isopropyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(ethylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is N-[3-chloro-4-(methylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-1-(3-trifluoromethyl-phenyl)-1,2-dihydro-pyridine-3-carboxylic acid 4-cyclopropanesulfonyl-benzylamide N-[3-methoxy-4-(methylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-30 1,2-dihydropyridine-3-carboxamide N-[3-bromo-4-(methylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[3-cyano-4-(methylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[3-methyl-4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2-dihydropyridine-3-carboxamide s 6-methyl-N-[4-(methylthio)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[4-(methylsulfinyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(benzylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(propylsulfonyl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(butylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is N-[4-(isobutylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(sec-butylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(isopropylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-ao dihydropyridine-3-carboxamide 6-methyl-N-{ 4-[(3-methylbutyl)sulfonyl]benzyl }-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{4-[(cyclopropylmethyl)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide zs 6-methyl-2-oxo-N-{4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]-benzyl}-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{4-[(2-hydroxyethyl)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{4-[(cyanomethyl)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-3o dihydropyridine-3-carboxamide N-{ 4-[(2-amino-2-oxoethyl)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{4-[(4-cyanobenzyl)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{4-[(2-cyanoethyl)sulfonyl]benzyl }-6-methyl-2-oxo-I-[3-(trifluoromethyl)phenyl]-I,2-dihydropyridine-3-carboxamide s N-{4-[(3-hydroxypropyl)sulfonyl]benzyl}-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-{ [2-(dimethylamino)-2-oxoethyl] sulfonyl } benzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide ethyl 3-[(4-{ [({ 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridin-3-io yI}carbonyl)amino]methyl}phenyl)sulfonyl]propanoate 2-[(4-{ [({ 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridin-3-yl}carbonyl)amino]methyl}phenyl)sulfonyl]ethyl acetate N-{ 4-[(3-cyanobenzyl)sulfonyl]benzyl } -6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is methyl3-[(4-{[({6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridin-3-yl }carbonyl)amino]methyl }phenyl)sulfonyl]propanoate 6-methyl-N-(4-{ [(2-methyl-1,3-thiazol-4-yl)methyl]sulfonyl } benzyl)-2-oxo-1-[3-' (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-{ 4-[(pyridin-4-ylmethyl)sulfonyl]benzyl }-1-[3-ao (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 4-[(3-cyanopropyl)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-{ [(3,5-dimethylisoxazol-4-yl)methyl]sulfonyl}benzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-(4-{ [4-(acetylamino)benzyl]sulfonyl}benzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[4-({ 2-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-2-oxoethyl }
sulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[4-(methylsulfonyl)phenoxy]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-3o dihydropyridine-3-carboxamide 6-methyl-2-oxo-I-(3-trifluoromethyl-phenyl)-1,2-dihydro-pyridine-3-carboxylic acid (4-bromo-phenoxy)-amide 6-methyl-2-oxo-N-phenoxy-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-aminobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydroproline-3-carboxamide s 6-methyl-N-{4-[(methylsulfonyl)amino]benzyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 4-[bis(methylsulfonyl)amino]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[[4-[[(dimethylamino)sulfonyl]amino]phenyl]methyl]-1,2-dihydro-6-methyl-2-oxo-1-io [3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide 6-methyl-N-{ 4-[methyl(methylsulfonyl)amino]benzyl }-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[[4-[butyl(methylsulfonyl)amino]phenyl]methyl]-1,2-dihydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide is 1,2-dihydro-6-methyl-N-[[4-[(1-methylethyl)(methylsulfonyl)-amino]phenyl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide N-{ 4-((2-methoxyethyl)(methylsulfonyl)amino]benzyl }-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 4-[(2-cyanoethyl)(methylsulfonyl)amino]benzyl }-6-methyl-2-oxo-1-[3-ao (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 4-[ethyl(methylsulfonyl)arnino]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 1,2-dihydro-6-methyl-N-[[4-[(methylsulfonyl)propylamino]-phenyl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide as N-[[4-[(3-amino-3-oxopropyl)(methylsulfonyl)amino]phenyl]-methyl]-1,2-dihydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide 1,2-dihydro-6-methyl-N-[[4-[(methylsulfonyl)oxy]phenyl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide 2-propanesulfonic acid, 4-[[[[1,2-dihydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-so 3-pyridinyl]carbonyl]amino]methyl]phenyl ester N-[(1,1-dioxido-2,3-dihydro-1-benzothien-5-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[(1,1-dioxido-2,3-dihydro-1-benzothien-5-yl)methyl]-5-iodo-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 5-iodo-N-{ 4-[isopropyl(methylsulfonyl)amino]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s 1,2-dihydro-6-methyl-N-[[4-[(methylsulfonyl)methyl]phenyl]-methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide 6-chloro-5-methyl-4-(3-methylphenyl-N-[4-(methylsulfonyl)benzyl]-3-oxo-3,4-dihydropyrazine-2-carboxamide 5-bromo-6-(difluoromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-io (trifluorornethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-(difluoromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is 6-methyl-N-[3-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N'-[4-(methylsulfonyl)phenyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2 dihydropyridine-3-carbohydrazide N'-(4-bromophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-ao 3-carbohydrazide N-[(5-methoxy-4-oxo-4H-pyran-2-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(4-cyanobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-{ [3-(4-methoxyphenyl)isoxazol-5-yl]methyl }-6-methyl-2-oxo-1-[3-(trifluorornethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N'-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carbohydrazide 6-methyl-2-oxo-N-[(1-phenyl-1H-pyrazol-4-yl)methyl]-1-[3-(trifluoromethyl)phenyl]-so 1,2-dihydropyridine-3-carboxamide N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluorornethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-{ [1-(3-methylphenyl)-1H-pyrazol-4-yl]methyl }-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N'-(4-chlorophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carbohydrazide s 6-methyl-2-oxo-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[(1-ethyl-1H-pyrazol-4-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2 dihydropyridine-3-carboxamide .
N-[(4-benzylmorpholin-2-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2 io dihydropyridine-3-carboxamide 6-methyl-N-[3-(2-methylpiperidin-1-yl)propyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide methyl 2-{ [({ 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridin-yl }carbonyl)amino]methyl }-3-furoate is 6-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(3-azepan-1-ylpropyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-(3-morpholin-4-ylpropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-ao dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(3-piperidin-1-ylpropyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as N-[3-(2-ethylpiperidin-1-yl)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-[2-(1-methyl-1H-imidazol-5-yl)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[(1-ethyl-3-methyl-1H-pyrazol-4-yl)methyl]-6-methyl-2-oxo-1-[3-so (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(acetylamino)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-c arboxamide 6-methyl-2-oxo-N-[3-(1H-pyrazol-1-yl)propyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(pyridin-2-ylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s 6-methyl-N-{[1-(4-methylphenyl)-IH-pyrazol-4-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N'-(4-methylphenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carbohydrazide 6-methyl-N-[3-(4-methylpiperidin-1-yl)propyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-io dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[3-(5-oxo-4,5-dihydro-1H-pyrazol-4-yl)propyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide ethyl 5-methyl-4-{ [({ 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridin-3-yl } c arbonyl)amino]methyl }-2-furoate is N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(2-pyridin-3-ylethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-methyl-2-oxo-1-[3-zo (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-(2-pyridin-4-ylethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N'-(4-fluorophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carbohydrazide as 6-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N'-phenyl-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carbohydrazide N-[(1-ethyl-5-methyl-1H-pyrazol-4-yl)methyl]-6-methyl-2-oxo-1-[3-30 (trifluoromethyl)phenyl]-I,2-dihydropyridine-3-carboxamide 6-methyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(1,3-dioxolan-2-yl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(1-benzothien-3-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide s N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[2-(3,5-dimethylisoxazol-4-yl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-io 1,2-dihydropyridine-3-carboxamide N-(3,4-dihydro-1H-isochromen-1-ylmethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ [(2R)-1-ethylpyrrolidin-2-yl]methyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is 6-methyl-2-oxo-N-[(2R)-tetrahydrofuran-2-ylmethyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 5-chloro-N-{ 4-[(dimethylamino)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3.-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 4-[(dimethylamino)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-ao I,2-dihydropyridine-3-carboxarnide 5-chloro-6-methyl-2-oxo-N-[4-(piperazin-1-ylsulfonyl)benzyl]-1-[3-(trifluoro-methyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(piperazin-1-ylsulfonyl)benzyl]-1-[3-(trifluoromethyl)-phenyl]-1,2-dihydropyridine-3-carboxamide as 6-methyl-N-[4-(morpholin-4-ylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(piperidin-1-ylsulfonyl)benzyl]-1-[3-(trifluoromethyl)-phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-{ 4-[(methylamino)sulfonyl]benzyl }-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2-so dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(pyrrolidin-1-ylsulfonyl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 5-chloro-6-methyl-2-oxo-N-[4-(pyrrolidin-1-ylsulfonyl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 5-chloro-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2-dihydropyridine-3-carboxamide N-{ 4-[(acetylamino)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(isopropylsulfonyl)benzyl]-5-iodo-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(cyclopropylsulfonyl)benzyl]-5-iodo-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-io 1,2-dihydropyridine-3-carboxamide 1,2-dihydro-6-methyl-N-[[4-[(methylsulfonyl)oxy]phenyl]methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinecarboxamide N-[4-(1,1-dioxidoisothiazolidin-2-yl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide is 6-methyl-2-oxo-N-[[4-(4-pyridinylsulfonyl)phenyl]methyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(phenylsulfonyl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(1,3-thiazol-2-ylsulfonyl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-ao dihydropyridine-3-carboxamide 6-methyl-2-oxo-N-[4-(pyrimidin-2-ylsulfonyl)benzyl]-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-[4-(1H-imidazol-2-ylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide as 6-methyl-N-{4-[(1-methyl-1H-1,2,4-triazol-5-yl)sulfonyl]benzyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-{ 4-[(5-methyl-1,3-oxazol-4-yl)sulfonyl]benzyl }-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 6-methyl-N-{ [6-(methylsulfonyl)pyridin-3-yl]methyl }-2-oxo-1-[3-so (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 5-fluoro-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-c arboxamide N-[4-(methylsulfonyl)benzyl]-2-oxo-6-(2-oxoethyl)-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide 5-ethyl-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide and pharmaceutically acceptable salts thereof.
The present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts io of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, malefic, methanesulphonic and benzenesulphonic acids.
is In a further aspect the invention provides a process for the preparation of a compound of formula (I) which comprises:
reacting a compound of formula (II) O

Y' ~ ~ L
R' N ~X
G' ~R5~n zo wherein R1, R5, y1, y2, X, G1 and n are as defined in formula (I) and L1 represents a leaving group, with an amine of formula (III) or a salt thereof H~N~L-G2 (III) wherein R4, G~ and L are as defined in formula (I), s and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (n; and where desired converting the resultant compound of formula (I] into an optical isomer thereof.
to The process is carned out at a suitable temperature, generally between 0 °C and the boiling point of the solvent, in a suitable solvent such as dichloromethane or N-methylpyrrolidinone. The process is optionally carried out in the presence of a base and/or a coupling reagent such as HATU, HOAT, HOBT or DIEA. Suitable leaving groups Ll include OH and halogen, particularly OH.
is Compounds of formula (II) wherein Y1 is CR2, YZ is CR3, L1 is OH and R~ and R3 are both hydrogen can be prepared by condensing a compound of formula (IV) O

O R
(IV) ao wherein R1 is as defined in formula (I), with a compound of formula (V) O O
G II II
(R )n (V) wherein G1, R5 and n are as defined in formula (I), in the presence of a suitable base, such as sodium methoxide, in a suitable solvent, such as ethanol, followed by hydrolysis using a s suitable base such as sodium hydroxide.
In general, compounds of formulae (IV) and (V) are either known or may be prepared using methods that will be readily apparent to the man skilled in the art. For example, compounds of formula (IV) can be prepared according to the methods of S.M
Brombridge io et al., Synthetic Communicatiorzs, 1993, 23, 487-494. And compounds of formula (V) can be prepared according to the methods of Igor V. Ukrainets et al., Tetrahedron, 1994, 50, 10331-10338.
Compounds of formula (II) wherein Y~ is CR2, Y~ is CR3, L1 is OH and R1 is hydrogen is can be prepared by reacting a compound of formula (VI) (R5)n ~NH2 (VI) wherein Gl, R5 and n are as defined in formula (I), with a compound of formula (VII) ao O
R3 ~ O
O
~O R2 O
full) wherein R2 or R3 are as defined in formula (I), at a suitable temperature, such as 160 °C, followed by base promoted cyclisation and acid hydrolysis. Compounds of formula (VII) s ~ can be prepared according to US 3,~3~,155.
Compounds of formula (II) wherein Yl is CRS, Y2 is CR3, Ll is OH, R1 is methyl and R~
and R3 are both hydrogen can be prepared by condensing a compound of formula (VIII) p /G~N~CN
(R5)n H
(VIII) wherein G1, R5 and n are as defined in formula (I), with 4-methoxy-3-buten-2-one in the presence of a suitable base, such as 1,4-diazabicyclo[2.2.2]octane, at a suitable temperature in a suitable solvent such as diethyleneglycol monomethyl ether, followed by acid is hydrolysis.
Compounds of formula (II) wherein Rl is OH, Y1 is nitrogen and Y2 is CR3 can be prepared by condensing a compound of formula (IX) /G
(R5)n wH NH2 (IX) wherein G1, RS and n are as defined in formula (I), with a compound of formula (X) O
O

(x) in the presence of a suitable base, such as sodium ethoxide, at a suitable temperature in a suitable solvent such as ethanol.
io A compound of formula (IX) can be prepared from the corresponding isocyanate derivative by treatment with ammonia in acetonitrile.
Salts of compounds of formula (I) may be formed by reacting the free base or a salt, enantiomer, tautomer or protected derivative thereof, with one or more equivalents of the is appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble, or in a solvent in which the salt is soluble followed by subsequent removal of the solvent in vacuo or by freeze drying. Suitable solvents include, for example, water, dioxane, ethanol, 2-propanol, tetrahydrofuran or diethyl ether, or mixtures thereof. The reaction may be a metathetical process or it may be carried out on an ion exchange resin.
Compounds of formula (I) and intermediate compounds thereto may be prepared as such or in protected form. The protection and deprotection of functional groups is, for example, described in 'Protective Groups in Organic Chemistry', edited by J. W. F.
McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 3rd edition, T. W.
Greene & P. G. M. Wuts, Wiley-Interscience (1999).
The compounds of the invention and intermediates may be isolated from their reaction mixtures, and if necessary further purified, by using standard techniques.
The compounds of formula (I) may exist in enantiomeric or diastereoisomeric forms or mixtures thereof, all of which are included within the scope of the invention.
The various io optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation or HPLC.
Alternatively, the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction conditions that will not cause racemisation.
is Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures thereof.
According to a further aspect of the invention we provide a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a medicament.
The compounds of formula (1), and their pharmaceutically acceptable salts, are useful because they possess pharmacological activity in animals. The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of human neutrophil elastase and homologous serine proteases such as proteinase 3 and pancreatic elastase, and as such are zs predicted to be useful in therapy. The compounds of formula (I) are particularly useful as inhibitors of human neutrophil elastase. They may thus be used in the treatment or prophylaxis of inflammatory diseases and conditions.
Examples of these conditions are: adult respiratory distress syndrome CARDS), cystic 3o fibrosis, pulmonary emphysema, chronic obstructive pulmonary disease (COPD) and ischaemic-reperfusion injury. The compounds of this invention may also be useful in the modulation of endogenous and/or exogenous biological irritants which cause and/or propagate atherosclerosis, diabetes, myocardial infarction; hepatic disorders including but not limited to cirrhosis, systemic lupus erythematous, inflammatory disease of lymphoid origin, including but not limited to T lymphocytes, B lymphocytes, thymocytes;
s autoimmune diseases, bone marrow; inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout); inflammation of the gastro-intestinal tract (especially inflammatory bowel disease, ulcerative colitis, pancreatitis and gastritis);
inflammation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as to osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease);
diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such is as multiple sclerosis); age related illness such as dementia inflammatory diseases of cardiovascular origins; granulomatous diseases; renal diseases including but not limited to nephritis and polyarteritis; cancer; pulmonary hypertension, ingested poisons, skin contacts, stings, bites; asthma; rhinitis; HIV disease progression; for minimising the effects of organ rejection in organ transplantation including but not limited to human organs; and zo replacement therapy of proteinase inhibitors.
Thus, another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of neutrophil elastase as activity is beneficial; and a method of treating, or reducing the risk of, diseases or conditions in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of inflammatory diseases or conditions; and a method of treating, or reducing the risk of, inflammatory diseases or conditions which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
In particular, the compounds of this invention may be used in the treatment of adult respiratory distress syndrome CARDS), cystic fibrosis, pulmonary emphysema, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma, rhinitis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, cancer, atherosclerosis and io gastric mucosal injury.
Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or is condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
For the above mentioned therapeutic indications, the dose of the compound to be 2o administered will depend on the compound employed, the disease being treated, the mode of administration, the age, weight and sex of the patient. Such factors may be determined by the attending physician. However, in general, satisfactory results are obtained when the compounds are administered to a human at a daily dosage of between 0.1 mg/kg to 100 mg/kg (measured as the active ingredient).
The compounds of formula (I) may be used on their own, or in the form of appropriate pharmaceutical formulations comprising the compound of the invention in combination with a pharmaceutically acceptable diluent, adjuvant or carrier. Particularly preferred are compositions not containing material capable of causing an adverse reaction, for example, so an allergic reaction. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals -The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
According to the invention, there is provided a pharmaceutical formulation comprising preferably less than 95% by weight and more preferably less than 50% by weight of a compound of formula (I) in admixture with a pharmaceutically acceptable diluent or Garner.
We also provide a method of preparation of such pharmaceutical formulations that io comprises mixing the ingredients.
The compounds may be administered topically, for example, to the lungs and/or the airways, in the form of solutions, suspensions, HFA aerosols or dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler°~; or systemically, is for example, by oral administration in the form of tablets, pills, capsules, syrups, powders or granules; or by parenteral administration, for example, in the form of sterile parenteral solutions or suspensions; or by rectal administration, for example, in the form of suppositories.
Zo Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation. For inhalation, the compound is desirably finely divided. The finely divided compound preferably has a mass median diameter of less than 10 hum, and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C$-CZO fatty acid or salt thereof, (for example, oleic acid), a bile salt, a as phospholipid, an alkyl saccharide, a perFluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
The compounds of the invention may also be administered by means of a dry powder inhaler. The inhaler may be a single or a mufti dose inhaler, and may be a breath actuated so dry powder inhaler.

One possibility is to mix the finely divided compound with a carrier substance, for example, a mono-, di- or polysaccharide, a sugar alcohol, or an other polyol.
Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. Alternatively the finely divided compound may be coated by another substance. The powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.
Another possibility is to process the finely divided powder into spheres which break up io during the inhalation procedure. This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler~
in which a dosing unit meters the desired dose which is then inhaled by the patient. With this system the active compound, with or without a carrier substance, is delivered to the patient.
is For oral administration the active compound may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into zo tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum, titanium dioxide, and the like. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
zs For the preparation of soft gelatine capsules, the compound may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above mentioned excipients for tablets. Also liquid or semisolid formulations of the drug may be filled into hard gelatine capsules.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
The compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.
io The following Examples are intended to illustrate, but in no way limit the scope of the invention.
General procedures 1H NMR and 13C NMR were recorded on a Varian Inova 400 MHz or a Varian Mercury-is VX 300 MHz instrument. The central peaks of chloroform-d (8H 7.27 ppm), dimethylsulfoxide-d6 (8H 2.50 ppm), acetonitrile-d3 (8H 1.95 ppm) or methanol-d4 (8H 3.31 ppm) where used as internal references. Low-resolution mass spectra were obtained on an Agilent 100 LC-MS system equipped with an APCI ionisation chamber. Column chromatography was carried out using silica gel (0.040-0.063 mm, Merck).
zo Unless stated otherwise, starting materials were commercially available.
All solvents and commercial reagents were of laboratory grade and were used as received. Unless otherwise stated, organic solutions were dried using anhydrous Na~SOq..
Unless otherwise stated, the following methods were used for HPLC and LC/MS
analysis:
zs LClMS-Method A
Instrument Agilent 1100; Column Waters Symmetry 2.1 x 30 mm; Mass APCI; Flow rate 0.7 ml/min; Wavelength 254 nm; Solvent A: Water + 0.1% TFA; B: Acetonitrile +
0.1%
TFA ; Gradient 15-95 %/B 8 min, 95 % B 1 min.
LC-Method B

Instrument Agilent 1100; Column KR100-5C18 150 x 4.6 mm; Flow rate 1.0 ml/min;
Wavelength 220 nm; Solvent A: Water + 0.1% TFA; B: Acetonitrile + 0.1% TFA;
Gradient 20-100%/B 8 min, 100% B 2 min.
s The following abbreviations are used:
HBTU O-(Benzotriazol-1-yI)-N,N,N',N'-tetramethyluronium hexafluorophosphate HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HOBT 1-Hydroxybenzotriazole HOAT 1-Hydroxy-7-azabenzotriazole io DIEA N,N-Diisopropylethylamine NMP 1-N-Methyl-2-pyrrolidinone THF Tetrahydrofuran TFA Trifluoroacetic acid is Example 1 N-(4-Chlorobenz~)-1-(4-chlorophenyl)-6-methyl-2-oxo-1,2-dih~dro~yridine-3-carboxamide a) Eth~l3-f(4-chlorophen~rl)aminol-3-oxopropanoate The title compound was prepared essentially as described by I. V. Ukrainets et al., ao Tetrahedron, 1994, 50, 10331-10338.
b~ Eth~l l-(4-chlorophenyl)-6-meth;rl-2-oxo-1,2-dih~dropYridine-3-carbox A mixture of ethyl 3-[(4-chlorophenyl)amino]-3-oxopropanoate (1 g, 4 mmol), 4-methoxy-3-buten-2-one (0.42 g, 4.2 mmol) and sodium methoxide (0.22 g, 4.1 mmol) in ethanol (10 ml) was heated to reflux for 5 h. After cooling, the solvent was evaporated off. The zs residue was chromatographed on silica using heptane/ethyl acetate (1:1 to 1:5) as eluent, affording the title compound (297 mg, 25%).
1H NMR (CDC13): 8 8.17 (1H, d); 7.49 (2H, d); 7.13 (2H, d); 6.21 (1H, d); 4.34 (2H, q);
2.03 (3H, s); 1.35 (3H, t).
c) 1-f 4-Chloronhenvl)-6-methyl-2-oxo-1,2-dihvdropvridine-3-carboxylic acid so Ethyl 1-(4-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (297 mg, 1.0 mmol) was dissolved in a mixture of 1M sodium hydroxide solution (6 ml) and THF (5 ml). The reaction mixture was stirred for 2.5 h at room temperature, then acidified to pH 2 using 5M hydrochloric acid, and then extracted with dichloromethane. The combined organic phases were washed with water, dried, filtered and evaporated to give the title s compound (268 mg, 100%).
1H NMR (CDC13): 8 8.51 (IH, d); 7.59 (2H, d); 7.18 (2H, d); 6.53 (1H, d); 2.15 (3H, s).
d) N-(4-Chlorobenzyl)-1 ~4-chlorophenyl)-6-methyl-2-oxo-1,2-dih~pyridine-3-carboxamide A mixture of 1-(4-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid io (100 mg, 0.38 mmol), HBTU (59 mg, 0.42 mmol), HOBT (64 mg, 0.42 mmol) and DIEA
(195 p,l, 1.14 mmol) in NMP (1 ml) was added to 4-chlorobenzylamine (108 mg, 0.76 mmol) in NMP (0.5 ml). The reaction mixture was stirred for 18 h. The solvent was evaporated off and the residue was purified using preparative HPLC to give the title compound (60 mg, 41 %).
is 1H NMR (CDC13): ~ 9.91 (1H, brs); 8.54 (1H, d); 7.53 (2H, d); 7.24 (4H, s);
7.13 (2H, d);
6.42 (1H, d); 4.53 (2H, d); 2.07 (3H, s).
Using the general method described in Example 1, the compounds of Examples 1.1 to 1.27 were prepared:
zo Example 1.1 6-Methyl-N-f4-(methylsulfonyl)benzyll-2-oxo-1-f3-~trifluorometh~)phenyll-1,2-dihydropyridine-3-carboxamide 1H NMR (CDC13): 8 9.96 (1H, t); 8.57 (1H, d); 7.85 (2H, d); 7.80 (1H, d); 7.73 (1H, t);
7.50 (3H, brd); 7.42 (1H, d); 6.46 (1H, d); 4.65 (2H, d); 3.00 (3H, s); 2.07 (3H, s).
Example 1.2 6-Methyl-N-(4-morpholin-4-, lbenzyl)-2-oxo-1-f3-(trifluorometh~phe~ll-1,2-dihydropyridine-3-carboxamide rH NMR (DMSO-d~): 8 9.69 (1H, brt); 8.38 (1H, d); 7.89-7.87 (2H, m); 7.79 (1H, t); 7.70 (1H, d); 7.15 (2H, d); 6.87 (2H, d); 6.62 (1H, d); 4.36 (2H, d); 3.72-3.69 (4H, m) 3.05-so 3.03; (4H, m); 2.00 (3H, s).

APCI-MS m/z: 472 [MH+].
Example 1.3 6-Methyl-N-f4-(methylsulfonyl)phenyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1 2-dihydropyridine-3-carboxamide s 1H NMR (CDCl3): 812.00 (1H, s); 8.66 (1H, d); 7.92-7.85 (5H, m); 7.79 (1H, t); 7.56 (1H, s); 7.49 (1H, d); 6.55 (1H, d); 3.04 (3H, s); 2.13 (3H, s).
APCI-MS m/z: 451[MH+].
Example 1.4 N-f4-(Dimethylamino)benzyll-6-methyl-2-oxo-1-f3-io (trifluorometh~phenyll-1,2-dih~rdropyridine-3-carboxamide 1H NMR (CDC13): ~ 9.67 (1H, brs); 8.57 (1H, d); 7.78 (1H, d); 7.71 (1H, t);
7.49 (1H, s);
7.41 (1H, d); 7.21 (2H, brd); 6.72 (2H, brs); 6.43 (1H, d); 4.50 (2H, d); 2.91 (6H, s); 2.05 (3H, s).
is Example 1.5 N-f4-(Aminosulfon 1)~yll-6-methyl-2-oxo-1-f3-,(trifluorometh 1)~phenyll-1,2-dih~p~rridine-3-carboxamide 1H NMR (DMSO-d6): 8 9.89 (1H, brs); 8.37 (1H, d); 7.91 (1H, s); 7.89 (1H, d);
7.80 (1H, t); 7.75 (2H, d); 7.72 (1H, d); 7.45 (2H, d); 7.27 (2H, s); 6.62 (1H, d); 4.54 (2H, s); 2.02 (3H, s).
Example 1.6 N-(4-Methox~Xl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide 1H NMR (CDC13): 8 9.72 (1H, brs); 8.59 (1H, d); 7.79 (1H, d); 7.72 (1H, t);
7.49 (1H, s);
7.42 (1H, d); 7.24 (2H, d); 6.82 (2H, d); 6.44 (1H, d); 4.52 (2H, d); 3.76 (3H, s); 2.05 (3H, 2s s).
Example 1.7 N-Benz-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih.~pyridine-3-carboxamide 1H NMR (CDC13): 8 9.85 (1H, brs); 8.62 (1H, d); 7.81 (1H, d); 7.74 (1H, t);
7.52 (1H, s);
so 7.44 (1H, d); 7.36-7.21 (5H, m); 6.47 (1H, d); 4.61 (2H, d); 2.08 (3H, s).

Example 1.8 N-(4-Chlorobenzyl)-1-(2-fluoro-5-meth~phenyl)-6-methyl-2-oxo-1,2-dih~~yridine-3-carboxamide 1H NMR (CD30D): 8 8.48 (1H, d); 7.40-7.36 (1H, m); 7.30 (4H, s); 7.25 (1H, t);
7.19 (1H, s dd); 6.62 (1H, d); 4.56 (2H, q); 2.39 (3H, s); 2.13 (3H, s).
Example 1.9 N-(3-Chlorobenzyl)-1-(2-fluoro-5-methylphen;rl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1H NMR (CD30D): 8 8.48 (1H, d); 7.40-7.36 (1H, m); 7.33-7.32 (1H, m); 7.29-7.22 (4H, io m); 7.20 (1H, dd); 6.62 (1H, d); 4.57 (2H, q); 2.39 (3H, s); 2.13 (3H, s).
Example 1.10 1-(2-Fluoro-5-methylphenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1H NMR (CD30D): 8 8.48 (1H, d); 7.40-7.36 (1H, m); 7.27-7.21 (3H, m); 7.02 (1H, dd);
is 6.86 (2H, d); 6.62 (1H, d); 4.50 (2H, q); 3.75 (3H, s); 2.39 (3H, s); 2.12 (3H, s).
APCI-MS m/z: 381 [MH+].
Example 1.11 N-(4-Methox~yl)-1-(3-methoxyphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide zo 1H NMR (CDCl3): 8 9.86 (1H, brs); 8.54 (1H, d); 7.45 (1H, t); 7.23 (2H, d);
7.04-7.01 (1H, m); 6.80 (2H, d); 6.78-6.75 (1H, m); 6.70 (1H, t); 6.39 (1H, d); 4.51 (2H, d);
3.82 (3H, s);
3.76 (3H, s); 2.09 (3H, s).
APCI-MS mlz: 379 [MH+].
as Example 1.12 N-(3-Chlorobenz,~l)-1-(3-methoxyphenxl)-6-methyl-2-oxo-1,2-dihxdropyridine-3-carboxamide 1H NMR (CDCl3): 8 10.00 (1H, brs); 8.55 (lH, d); 7.47 (1H, t); 7.30 (1H, brs);
7.19 (3H, brs); 7.05-7.01 (1H, m); 6.80-6.75 (1H, m); 6.72 (1H, t); 6.41 (1H, d); 4.55 (2H, d); 3.83 (3H, s); 2.11 (3H, s).

Example 1.13 N-(4-Chlorobenzyl)-1-(3-methoxy~henyl)-6-methyl-2-oxo-1,2-dihydro~yridine-3-carboxamide 1H NMR (CDC13): 810.00 (1H, brs); 8.56 (1H, d); 7.48 (1H, t); 7.28 (4H, s);
7.07-7.03 (1H, m); 6.81-6.77 (1H, m); 6.73 (1H, t); 6.41 (1H, d); 4.56 (2H, d); 3.85 (3H, s); 2.12 s (3H, s).
Example 1.14 N-f4~Aminosulfonxl)benzyll-1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydro~rridine-3-carboxamide 1H NMR (CDC13): b 9.99 (1H, t); 8.55 (1H, d); 7.84 (2H, d); 7.53-7.49 (2H, m);
7.46 (1H, io d); 7.25-7.24 (1H, m); 7.14-7.10 (1H, m); 6.44 (1H, d); 4.72 (2H, brs);
4.64 (2H, d); 2.10 (3H, s).
Example 1.15 N-(4-Chlorobenzyl)-1-(3-chloro-4-methylphenyl)-6-methyl-2-oxo-1,2-dihydro~yridine-3-carboxamide is 1H NMR (CDCl3): 8 9.93 (1H, brs); 8.56 (1H, d); 7.44 (1H, d); 7.28 (4H, s);
7.24 (1H, d);
7.03 (1H, dd); 6.43 (1H, d); 4.56 (2H, d); 2.46 (3H, s); 2.12 (3H, s).
Example 1.16 1-(3-Chloro-4-methylphenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide ao 1H NMR (CDC13): 8 9.80 (1H, brs); 8.54 (1H, d); 7.40 (1H, d); 7.23 (2H, d);
7.20 (1H, d);
7.00 (1H, dd); 6.81 (2H, d); 6.39 (1H, d); 4.51 (2H, d); 3.76 (3H, s); 2.43 (3H, s); 2.09 (3H, s).
Example 1.17 N-(4-Chlorobenzyl)-1-(2,3-dimethyl~henyl)-6-methyl-2-oxo-1,2-as dih~dropyridine-3-carboxamide 1H NMR (CDC13): 8 10.04 (1H, brs); 8.58 (1H, d); 7.31-7.24 (6H, m); 6.96-6.94 (1H, m);
6.45 (1H, d); 4.63-4.50 (2H, m); 2.38 (3H, s); 2.03 (3H, s); 1.95 (3H, s).
Example 1.18 N-(4-Chlorobenz~l)-1-(3-chloro-4-fluorophenyl)-6-methyl-2-oxo-so 1,2-dihXdropyridine-3-carboxamide 1H NMR (CDC13): 8 9.83 (1H, brs); 8.57 (1H, d); 7.38-7.32 (2H, m); 7.27 (4H, s); 7.15-7.11 (1H, m); 6.45 (1H, d); 4.57 (2H, d); 2.12 (3H, s).
APCI-MS m/z: 405.1, 407 [MH+].
s Example 1.19 1-(3-Chloro-4-fluoro~hen~)-N-(4-methox b',r enzyl)-6-methyl-2-oxo-1,2-dihydro~~rridine-3-carboxamide iH NMR (CDC13): S 9.72 (1H, brs); 8.58 (1H, d); 7.39-7.31 (2H, m); 7.26 (2H, d); 7.14-7.10 (1H, m); 6.84 (2H, d); 6.43 (1H, d); 4.54 (2H, d); 3.79 (3H, s); 2.11 (3H, s).
io Example 1.20 N-(4-Chlorobenzyl)-1-(3-eth~phen~rl)-6-methyl-2-oxo-1,2-dihydrop~rridine-3-carboxamide 1H NMR (CDC13): 810.03 (1H, brs); 8.56 (1H, d); 7.49 (1H, t); 7.36 (1H, d);
7.28 (4H, s);
7.02 (2H, d); 6.42 (1H, d); 4.61-4.50 (2H, m); 2.T5 (2H, q); 2.09 (3H, s);
1.29 (3H, t).
is Example 1.21 1-(3-Bromophenyl)-N-(4-chlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 1H NMR (CDC13): b 9.86 (1H, brs); 8.55 (1H, d); 7.67-7.64 (1H, m); 7.45 (1H, t); 7.39 (1H, t); 7.25 (4H, s); 7.17-7.15 (1H, m); 6.42 (1H, d); 4.54 (2H, d); 2.09 (3H, s).
APCI-MS m/z: 431.1, 433 [MH+].
Example 1.22 1-(3-Bromophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dih~p~ridine-3-carboxamide 1H NMR (CDC13): 8 9.74 (1H, brs); 8.55 (1H, d); 7.65-7.63 (1H, m); 7.44 (1H, t); 7.38 (1H, t); 7.23 (2H, d); 7.16-7.14 (1H, m); 6.81 (2H, d); 6.40 (1H, d); 4.52 (2H, d); 3.76 (3H, 2s s); 2.07 (3H, s).
Example 1.23 N-(2,3-Dihydro-1-benzofuran-5-ylmethyl)-6-methyl-2-oxo-1-f3-~trifluorometh~~henyll-1,2-dih~pyridine-3-carboxamide 1H NMR (CDC13): 8 9.70 (1H, brs); 8.59 (1H, d); 7.79 (1H, d); 7.73 (1H, t);
7.50 (1H, s);
7.43 (1H, d); 7.17 (1H, s); 7.05 (1H, d); 6.69 (1H, d); 6.44 (1H, d); 4.56-4.50 (4H, m); 3.16 (2H, t); 2.06 (3H, s).
APCI-MS m/z: 429 [MH+]
s Example 1.24 6-Methyl-2-oxo-N-f 3-(2-oxopyrrolidin-1-yl)propyll-1-f 3-(trifluorometh 1)~phenyll-12-dihydro~yridine-3-carboxamide iH NMR (CDCl3): 8 9.55 (1H, brs); 8.55 (1H, d); 7.82 (1H, d); 7.75 (1H, t);
7.52 (1H, s);
7.45 (1H, d); 6.45 (1H, d); 3.44-3.33 (6H, m); 2.38 (2H, t); 2.05-1.98 (2H, m); 2.08 (3H, io s); 1.86-1.79 (2H, m).
APCI-MS m/z: 422 [MH+].
Example 1.25 N-(4-Bromobenz~)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen .
1 2-dihydrop~ridine-3-carboxamide is 1H NMR (CDC13): 8 9.84 (1H, brs); 8.58 (1H, d); 7.81 (1H, d); 7.73 (1H, t);
?.51 (1H, s);
7.43 (1H, d); 7.41 (2H, d); 7.20 (2H, d); 6.46 (1H, d); 4.59-4.49 (2H, m);
2.08 (3H, s).
APCI-MS m/z: 465.1, 467 [MH+].
Example 1.26 N-(4-Chloro~henyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)~henyll-zo 12-dihydropyridine-3-carboxamide APCI-MS m/z: 407 [MH+].
Example 1.27 6-Methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide 25 APCI-MS m/z: 297 [MH+].
Example 2 N-(4-Methoxybenzyl)-6-meth-2-oxo-1-phen 1-dihydropyridine-3-carboxamide 3o a) 6-Methyl-2-oxo-1-phenyl-1,2-dih~pyridine-3-carbonitrile A mixture of cyanoacetanilide (0.80 g, 5 mmol), 4-methoxy-3-buten-2-one (1 g, 10 mmol) and 1,4-diazabicyclo[2,2,2]octane (0.55 g, 5 mmol) in diethyleneglycol monomethylether was heated to 125 °C for 5 h. The reaction mixture was partitioned between dichloromethane (100 ml) and 2M hydrochloric acid (100 ml). The organic layer was s separated, washed with water, dried, filtered and evaporated. The residue was chromatographed on silica using heptane/ethyl acetate (1:1) as eluent, affording the title compound (660 mg, 63%).
1H NMR (CDC13): 8 7.78 (1H, d); 7.52 (3H, m); 7.17 (2H, dd); 6.22 (1H, d);
2.06 (3H, s).
b) 6-Methyl-2-oxo-1-phenyl-1,2-dih.~p~ridine-3-carboxylic acid io 6-Methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carbonitrile (300 mg, 1.4 mmol) was dissolved in 2.5M sulphuric acid (10 ml). The mixture was heated to 100 °C for 16 h.
After cooling, the solution was poured into water and made alkaline with 5M
sodium hydroxide solution. The water phase was washed with dichloromethane, then acidified to pH 2-3 using 2M hydrochloric acid. The acidified water phase was extracted with is dichloromethane, dried, filtered and evaporated to give the title compound (300 mg, 92%).
1H NMR (CDC13): 8 13.96 (1H, s); 8.50 (1H, d); 7.59 (3H, m); 7.23 (2H, dd);
6.53 (1H, d); 2.13 (3H, s).
c) N-(4-Methoxybenzyl)-6-methyl-2-oxo-1-phenyl-1,2-dih~pyridine-3-carboxamide zo The title compound was prepared from 6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid and 4-methoxybenzylamine by a method analogous to that described in Example 1 step (d).
1H NMR (CDC13): 8 9.87 (1H, brs); 8.56 (1H, brd); 7.52 (3H, m); 7.23 (2H, d);
7.18 (2H, d); 6.79 (2H, d); 6.40 (1H, d); 4.51 (2H, d); 3.75 (3H, s); 2.04 (3H, s).
zs The compounds of Examples 2.1 to 2.174 were prepared by a method analogous to that described in Example 1 or 2.
Example 2.1 N-(4-Chlorobenzyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-so 3-carboxamide 1H NMR (CDC13): 8 9.96 (1H, s); 8.54 (1H, d); 7.54 (3H, m); 7.23 (4H, s); 7.18 (2H, d);
6.41 (1H, d); 4.54 (2H, d); 2.06 (3H, s).
Example 2.2 N-(4-Chlorobenzyl)-1-(3,5-dimethylphenyl)-6-methyl-2-oxo-1,2-s dihydropyridine-3-carboxamide 1H NMR (CDCl3): 810.01 (1H, brs); 8.52 (1H, d); 7.23 (4H, s); 7.11 (1H, s);
6.78 (2H, s);
6.38 (1H, d); 4.53 (2H, d); 2.36 (6H, s); 2.07 (3H, s).
Example 2.3 N-f4-(Aminosulfonyl)benzyll-1-(3,5-dimethylphenyl)-6-methyl-2-io oxo-1,2-dil~dropyridine-3-carboxamide 1H NMR (CDC13): b 10.14 (1H, brs); 8.51 (1H, d); 7.82 (2H, d); 7.45 (2H, d);
7.12 (1H, s);
6.79 (2H, s); 6.41 (1H, d); 4.72 (2H, s); 4.62 (2H, d); 2.36 (6H, s); 2.09 (3H, s).
Example 2.4 1-~3,5-Dimeth~phenyl)-N-(4-methox~yl)-6-methyl-2-oxo-1,2-is dihydropyridine-3-carboxamide 1H NMR (CDC13): 8 9.90 (1H, brs); 8.54 (1H, d); 7.24 (2H, s); 7.11 (1H, s);
6.81 (2H, d);
6.79 (2H, s); 6.38 (1H, d); 4.52 (2H, d); 3.77 (3H, s); 2.37 (6H, s); 2.07 (3H, s).
Example 2.5 N-Benzyl-1-(3,5-dimeth~phenyl)-6-methyl-2-oxo-1,2-zo dihydropyridine-3-carboxamide 1H NMR (CDC13): 8 9.98 (1H, brs); 8.57 (1H, d); 7.36-7.19 (5H, m); 7.13 (1H, s); 6.82 (2H, s); 6.41 (1H, d); 4.61 (2H, d); 2.39 (6H, s); 2.10 (3H, s).
Example 2.6 N-C4-Chlorobenzyl)-6-methyl-1-(3-methylphenyl)-2-oxo-1,2-zs dihydropyridine-3-carboxamide 1H NMR (CD30D): 8 8.46 (1H, d); 7.47 (1H, t); 7.36 (1H, d); 7.30 (4H, s); 7.10 (1H, s);
7.06 (1H, d); 6.60 (1H, d); 4.56 (2H, s); 2.42 (3H, s); 2.09 (3H, s).
APCI-MS m/z: 367 [MH+].

Example 2.7 N-(4-Methoxybenzyl)-6-methyl-1-(3-rnethylphenyl)-2-oxo-1,2-dihydro~yridine-3-carboxamide 1H NMR (CD30D): 8 8.45 (1H, d); 7.44 (1H, t); 7.33 (1H, d); 7.22 (2H, d); 7.07 (1H, s);
7.03 (1H, d); 6.84 (2H, d); 6.58 (1H, d); 4.49 (2H, s); 3.74 (3H, s); 2.41 (3H, s); 2.07 (3H, s s).
APCI-MS m/z: 363 [MH+].
Example 2.8 N-(3-Chlorobenzyl)-6-methyl-1-(3-meth~phenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide io 1H NMR (CD30D): 8 8.46 (1H, d); 7.46 (1H, t); 7.35 (1H, d); 7.32-7.21 (4H, m); 7.10 (1H, s); 7.06 (1H, d); 6.60 (1H, d); 4.56 (2H, s); 2.42 (3H, s); 2.09 (3H, s).
Example 2.9 N-(4-Chlorobenzyl)-1-(3-chlorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide is 1H NMR (DMSO-d6): S 9.86 (1H, t); 8.35 (1H, d); 7.59-7.58 (3H, m); 7.39-7.29 (5H, m);
6.60 (1H, d); 4.46 (2H, d); 2.04 (3H, s).
APCI-MS m/z: 387.1, 389 [MH+].
Example 2.10 N-~Chlorobenz~rl)-1-(3-chlorophen~)-6-methyl-2-oxo-1,2-ao dihydro~yridine-3-carboxamide 1H NMR (DMSO-d6): 8 9.88 (1H, t); 8.36 (1H, d); 7.59-7.58 (3H, m); 7.39-7.32 (4H, m);
7.25 (1H, d); 6.60 (1H, d); 4.48 (2H, d); 2.04 (3H, s).
APCI-MS m/z: 387.1, 389 [MH+].
as Example 2.11 1-(3-Chlorophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydro~yridine-3-carboxamide 1H NMR (DMSO-d6): 8 9.73 (1H, t); 8.34 (1H, d); 7.56 (2H, d); 7.34-7.31 (1H, m); 7.19 (2H, d); 6.85 (2H, d); 6.58 (1H, d); 6.60 (1H, d); 4.38 (2H, d); 3.69 (3H, s);
2.01 (3H, s).
APCI-MS m/z: 383 [MH+].

Example 2.12 Methyl 4-f (~ f 1-(3-chloro~henyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yllcarbon~rl 1 amino)methyllbenzoate 1H NMR (DMSO-d6): 8 9.92 (1H, t); 8.36 (1H, d); 7.91 (2H, d); 7.60-7.58 (3H, m); 7.41 (2H, d); 7.38-7.35 (1H, m); 6.60 (1H, d); 4.56 (2H, d); 3.83 (3H, s); 2.04 (3H, s).
s APCI-MS m/z: 411 [MH+].
Example 2.13 4-((~ f 1-(3-Chloro~henyl)-6-methyl-2-oxo-1,2-dih~pyridin-3-yllcarbonyllamino)methyllbenzoic acid 1H NMR (DMSO-d6): 8 12.82 (1H, brs); 9.91 (1H, t); 8.36 (1H, d); 7.88 (2H, d);
7.59-7.58 io (3H, m); 7.39 (2H, d); 7.38-7.35 (1H, m); 6.60 (1H, d); 4.55 (2H, d); 2.04 (3H, s).
APCI-MS mlz: 397 [MH+]
Example 2.14 1-(3-Cyanophenyl)-N-(c cl~ylmethyl)-6-methyl-2-oxo-1,2-dihydro~yridine-3-carboxamide is APCI-MS rn/z: 350 [MH+].
Example 2.15 1-(3-Cyanophenyl)-N-(2-furylmethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 334 [MH+].
zo Example 2.16 1-(3-C anophenyl)-6-methyl-2-oxo-N-(~yridin-3- l~yl)-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 345 [MH+].
as Example 2.17 N-Benzyl-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-M5 m/z: 344 fMH+1.

Example 2.18 1-(3-C~ano hens)-N-2,3-dihydro-1H-inden-1-yl-6-methyl-2-oxo-1,2-dihXdropyridine-3-carboxamide APCI-MS m/z: 370 [MH+].
s Example 2.19 1-(3-Cyanophen~)-N-(2-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS mlz: 374 [MH+].
Example 2.20 1-(3-Cyanophenyl)-6-methyl-2-oxo-N-(3,4,5-trimethoxybenzyl)-1,2-io dih,~pyridine-3-carboxamide APCI-MS mlz: 434 [MH+].
Example 2.21 1-(3-Cyanophenyl)-N-(2,5-dimethox .beryl)-6-methyl-2-oxo-1,2-dih~pyridine-3-carboxamide is APCI-MS m/z: 404 [MH+].
Example 2.22 1-(3-Cyanophen~)-N-(3,4-dimethoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS mlz: 404 [MH+].
Example 2.23 1-(3-C~phenyl)-N-f(1-ethylpyrrolidin-2-y~methyll-6-meth oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 365 [MH+].
2s Example 2.24 N-(4-Chlorobenzyl)-1-(3-c~~hen~rl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 378 [MH+].
Example 2.25 1-(3-C~phenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-so dih~dro~~rridine-3-carboxamide APCI-MS m/z: 374 [MH+]
Example 2.26 N-(3-Chlorobenzyl)-1-(3-cyanophenyl)-6-methul-2-oxo-1,2-dih.~pyridine-3-carboxamide s APCI-MS m/z: 378 [MH+].
Example 2.27 1-(3-Cyanophenyl)-6-methyl-2-oxo-N-(thien-2-ylmethyl)-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 350 [MH+].
io Example 2.28 1-(3-Csyano~henxl)-N-(c,~prop ly methyl)-6-methyl-2-oxo-1,2-dih.~pyridine-3-carboxamide APCI-MS m/z: 308 [MH+].
is Example 2.29 1-(3-Cyano~henyl)-N-(3-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropy ridine-3-carboxamide APCI-MS m/z: 374 [MH+].
Example 2.30 1-(3-C,phenyl)-6-methyl-2-oxo-N-(p~ridin-4-ylmethyl)-1,2-ao dih~dropyridine-3-carboxamide APCI-MS m/z: 345 [MH+].
Example 2.31 1-(3-Cyanophenyl)-N-f2-(3,4-dimethoxy~hen l~yll-6-meth oxo-1,2-dih,~pyridine-3-carboxamide zs APCI-MS m/z: 417 [MH+].
Example 2.32 1-(3-Cyanophenyl)-6-methyl-N-f2-(1-methyl~~rrrolidin-2- 1 2-oxo-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 365 [MH+].

Example 2.33 N-f2-(3-Chloro~henyl)ethyll-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dih~~,~ridine-3-carboxamide APCI-MS m/z: 392 [MH+].
s Example 2.34 1-(3-Cyanophenyl)-6-methyl-2-oxo-N-(2-pyridin-2-ylethyl)-1,2-dihydropyridine-3-carboxamide APCI-MS xn/z: 359 [MH+].
Example 2.35 N-f2-(4-Chlorophen l~yll-1-(3-c~phenyl)-6-methyl-2-oxo-io 1,2-dihydropyridine-3-carboxamide APCI-MS mlz: 392 [MH+].
Example 2.36 1-(3-Cyanophenyl)-N-f2-(2-methox~phenyl)ethyll-6-methyl-2-oxo-1,2-dihydro~yridine-3-carboxamide is APCI-MS mlz: 388 [MH+].
Example 2.37 N-f2-(2-Chloro~hen, l~yll-1-(3-c,~phenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 392 [MH+].
Example 2.38 1-(3-C.~phenxl)-N-f2-(3-methoxxphen. l~yll-6-methyl-2-oxo-1,2-dih~dropyridine-3-carboxamide APCI-MS m/z: 388 [MH+].
2s Example 2.39 1-(3-Cyanophenyl)-N-f2-(4-fluoro~henyl)ethyll-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 376 [MH+].
Example 2.40 1-(3-Cyanophenyl)-N-f2-(2,4-dichlorophen l~yll-d-methyl-2-so oxo-1,2-dih dropyridine-3-carboxamide APCI-MS m/z: 426 [MH+]
Example 2.41 1-(3-Cyano henyl)-N-f2-(3-fluorophen l~yll-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide s APCI-MS m/z: 376 [MH+].
Example 2.42 1-(3-Cyanophen~)-N-f2-(2-fluorophen l~yll-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 376 [MH+].
io Example 2.43 1-(3-Cyanophenyl)-N-(2-cyclohex-1-en-1-ylethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 362 [MH+].
is Example 2.44 N-f2-(4-Bromophen l~yll-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 438 [MH+].
Example 2.45 N-(3-Bromobenzyl)-1-(3-c~phenyl)-6-methyl-2-oxo-1,2-ao dihydro~yridine-3-carboxamide APCI-MS mlz: 424 [MH+].
Example 2.46 N-(4-Bromobenzyl)-1-(3-c~phenyl)-6-methyl-2-oxo-1,2-dihydrop~ridine-3-carboxamide as APCI-MS m/z: 424 [MH+].
Example 2.47 N-(2-Bromobenzyl)-1-(3-c~phenyl)-6-methXl-2-oxo-1,2-dih.~o~yridine-3-carboxamide APCI-MS m/z: 424 [MH+].

Example 2.48 1-(3-Cyanophenyl)-N-(3,4-dihydro-2H-pyran-2- lmethyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 350 [MH+].
s Example 2.49 1-(3-Cyanophenyl)-6-methyl-N-(4-methylbenzyl)-2-oxo-1 2-dih dropyridine-3-carboxamide APCI-MS m/z: 358 [MH+].
Example 2.50 1-(3-Cyanophenyl)-6-methyl-N-(1-naphthylmet~l)-2-oxo-1 2-io dihydropyridine-3-carboxamide APCI-MS m/z: 394 [MH+].
Example 2.51 1-(3-C~phenyl)-N-(2-ethox~~l)-6-methyl-2-oxo-1 2-dih~pyridine-3-carboxamide is APCI-MS m/z: 388 [MH+].
Example 2.52 1-(3-Cyanophenyl)-6-methyl-N-f4-(meth lsulfonyl)benzyll-2-oxo-1 2-dihydropyridine-3-carboxamide APCI-MS m/z: 422 [MH+].
Example 2.53 1-(3-Cyanophen~)-6-methyl-N-(3-methylbenzyl)-2-oxo-1 2-dihydropyridine-3-carboxamide APCI-MS m/z: 358 [MH+].
2s Example 2.54 1-(3-Cyanophenyl)-N-(4-fluorobenzyl)-6-methyl-2-oxo-1 2-dih~pyridine-3-carboxamide APCI-MS m/z: 362 [MH+].
Example 2.55 N-(1,3-Benzodioxol-5- l~yl)-1-(3-c ano henyl)-6-meth.
oxo-1,2-dihvdropyridine-3-carboxamide APCI-MS m/z: 388 [MH+].
Example 2.56 1-(3-Cyano~henyl)-N-(2,4-dichlorobenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-c arboxamide s APCI-MS mlz: 412 [MH+].
Example 2.57 1-(3-Cyanophenyl)-6-methyl-N-(2-methylbenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 358 [MH+].
io Example 2.58 1-(3-C~phenxl)-N-(3,4-difluorobenzyl)-6-methyl-2-oxo-1,2-dihydxopyridine-3-carboxamide APCI-MS m/z: 380 [MH+].
is Example 2.59 1-(3-Cyanophenyl)-N-(3,4-dichlorobenzyl)-6-methyl-2-oxo-1,2-dih,~p~rridine-3-carboxamide APCI-MS m/z: 412 [MH+].
Example 2.60 1-(3-C,phenyl)-6-methyl-N-[(5-methyl-2-fur,1)~ rnethyll-2-oxo-zo 1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 348 [MH+].
Example 2.61 1-(3-C,phenyl)-6-methyl-2-oxo-N-1,2,3,4-tetrahydronaphthalen-1-yl-1,2-dihydropyridine-3-carboxamide as APCI-MS m/z: 384 [MH+].
Example 2.62 1-(3-C~phenyl)-N-(2,3-dirnethox beryl)-6-methyl-2-oxo-1,2-dih,~~yridine-3-carboxamide APCI-MS m/z: 404 [MH+].

Example 2.63 1-(3-Cyanophenyl)-N-(3,5-dimethoxybenzyl)-6-methyl-2-oxo-1,2-dih.~pyridine-3-carboxamide APCI-MS m/z: 404 [MH+].
s Example 2.64 1-(3-Cyanophenyl)-N-f 1-(4-fluorophenyl)ethyll-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 376 [MH+].
Example 2.65 N-f 1-(4-Chloro~henyl)ethyll-1-(3-c~phenyl)-6-methyl-2-oxo-io 1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 392 [MH+].
Example 2.66 1-(3-Cyanophenyl)-N-(2,5-difluorobenzyl)-6-methyl-2-oxo-1,2-dihvdropyridine-3-carboxamide is APCI-MS m/z: 380 [MH+].
Example 2.67 1-(3-C~phenyl)-N-(2,3-dihydro-1-benzofuran-5-ylmeth 1 methyl-2-oxo-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 386 [MH+].
zo Example 2.68 Methyl 4-f(~ f 1-(3-c~no~henyl)-6-methyl-2-oxo-1,2-dih~pyridin-3-yllcarbonyl ~ amino)methyllbenzoate APCI-MS m/z: 402 [MH+].
25 Example 2.69 1-(3-Cyano~hen~)-6-methyl-2-oxo-N-(4-phenoxybenzyl)-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 436 [MH+].
Example 2.70 1-(3-Cyanophenyl)-N-f(1S)-2,3-dihydro-1H-inden-1-yll-6-methyl-2-30 oxo-1,2-dihydrop~ridine-3-carboxamide APCI-MS m/z: 370 [MH+]
Example 2.71 1-(3-Cyanophenyl)-6-methyl-2-oxo-N-(thien-3- ly methyl)-1 2-dih~pyridine-3-carboxamide s APCI-MS m/z: 350 [MH+].
Example 2.72 1-(3-Cyanophen 1 -6-methyl-N-f(5-methylisoxazol-3- 1)meth, l oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 349 [MH+].
io °
Example 2.73 1-(3-Cyano henyl)-N-f(2 5-dimeth 1-y 3furyl)methyll-6-meth, oxo-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 362 [MH+].
is Example 2.74 1-(3-C~phenyl)-N-(3-furylmethyl)-6-methyl-2-oxo-1 2-dih~pyridine-3-carboxamide APCI-MS m/z: 334 [MH+].
Example 2.75 1-(3-Cyanophenyl)-6-methyl-2-oxo-N-f4-(1H-pyrazol-1-yl)benz, zo 1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 410 [MH+].
Example 2.76 1-(3-Cyanonhenyl)-6-methyl-2-oxo-N-(4-thien-2-ylbenzyl)-1 2-dihydropyridine-3-carboxamide as APCI-MS m/z: 426 [MH+].
Example 2.77 N-f4-(Aminosulfonyl)benzyll-1-(3-c anophen~)-6-methyl-2-oxo-1,2-dih~~yridine-3-carboxamide APCI-MS m/z: 423 [MH+].

Example 2.78 N-f2-(1,3-Benzodioxol-5-~)eth~ll-1-(3-c ano~henyl)-6-methyl-2-oxo-1,2-dih,~o~yridine-3-carboxamide APCI-MS m/z: 402 [MH+].
s Example 2.79 1-(3-C ano~henyl)-6-methyl-2-oxo-N-(2-thien-2- ly eth,1 dihydropyridine-3-carboxamide APCI-MS m/z: 364 [MH+].
Example 2.80 1-(3-C~~henyl)-N-f2-(2,4-dimethylphenyl)ethyll-6-methyl-2-io oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 386 [MH+].
Example 2.81 1-(3-C~phenyl)-6-methyl-N-f2-(4-methyl~henyl)ethyll-2-oxo-1,2-dihydropyridine-3-carboxamide is APCI-MS m/z: 372 [MH+].
Example 2.82 N-~2-f4-(Aminosulfonyl)phenyllethyl}-1-(3-cyanophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 437 [MH+].
Example 2.83 1-(3-Cyanophenyl)-6-methyl-2-oxo-N-f(1S)-1-phen ly ethyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 358 [MH+].
2s Example 2.84 N-(Cyclohexylmethyl)-6-methyl-2-oxo-1-f 3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 393 [MH+].
Example 2.85 N-(2-Furylmethyl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-so 1,2-dih~dropyridine-3-carboxamide APCI-MS m/z: 377 [MHO].
Example 2.86 6-Meth-2-oxo-N-(pyridin-3-ylmethyl)-1-f 3-(trifluoromethyl)phenyll-1 2-dih;rdro~yridine-3-carboxamide s APCI-MS m/z: 388 [MH+].
Example 2.87 N-2 3-Dihydro-1H-inden-1-yl-6-methyl-2-oxo-1-f3-~trifluoromethyl)~henyll-12-dihydro~yridine-3-carboxamide APCI-MS m/z: 413 [MH+].
io Example 2.88 N-(2-Methox~xl -6-methyl-2-oxo-1-f3-~trifluorometh~phenyll-1 2-dih~pyridine-3-carboxamide APCI-MS m/z: 417 [MH+].
is Example 2.89 6-Methyl-2-oxo-N-(tetrahydrofuran-2-ylmethyl)-1-f3-(trifluoromethyl)~henyll-1 2-dihydropyridine-3-carboxamide APCI-MS mlz: 381 [MH+].
Example 2.90 6-Meth,~-2-oxo-1-f3-(trifluoromethyl)~henyll-N-(3,4,5-zo trimethoxybenzyl)-12-dihydropyridine-3-carboxamide APCI-MS m/z: 477 [MH+].
Example 2.91 N-(3-Fluorobenzyl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1 2-dihydropyridine-3-carboxamide zs APCI-MS miz: 405 [MH+].
Example 2.92 N-(2 5-Dimethoxybenzyl)-6-methyl-2-oxo-1-f3-(trifluorometh~)phen~l-1 2-dihydropyridine-3-carboxamide APCI-MS m/z: 447 [MH+].

Example 2.93 N-f(1-Ethylpyrrolidin-2 yl)methyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1 2-dih~pxridine-3-carboxamide APCI-MS m/z: 408 [MH+].
s Example 2.94 N-(2-Chlorobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1,2-dihydro~yridine-3-carboxamide APCI-MS rn/z: 421 [MH+].
Example 2.95 N-(4-Chlorobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-io 1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 421 [MH+].
Example 2.96 N-(3-Chlorobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide is APCI-MS m/z: 421 [MH+].
Example 2.97 6-Methyl-2-oxo-N-(thien-2-ylmeth~)-1-f 3-(trifluorometh~)phen 1,2-dihydro~,~idine-3-carboxamide APCI-MS m/z: 393 [MH+].
Example 2.98 N-(C~propylmethyl)-6-methyl-2-oxo-1-f3-(trifluoromethxl)phenYll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 351 [MH+].
2s Example 2.99 N-(3-Methoxybenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 417 [MH+].
Example 2.100 6-MethXl-2-oxo-N-(pyridin-4-ylmethyl)-1-f3-so (trifluorometh~phenyll-1,2-dih~~yridine-3-carboxamide APCI-MS m/z: 388 [MH+]
Example 2.101 N-f2-(3,4-Dimethoxy~hen l~yll-6-methyl-2-oxo-1-~3-~trifluoromethyl)phenyll-1,2-dih~dro~yridine-3-carboxamide s APCI-MS m/z: 461 [MH+].
Example 2.102 N-~2-(4-Methoxyphenyl)ethyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)~henyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 431 [MH+].
io Example2.103 6-Methyl-2-oxo-N-(2-phenylethyl)-1-f3-(trifluorometh~phen 1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 401 [MH+].
is Example 2.104 6-Methyl-N-f2-(1-meth~pyrrolidin-2-yl)ethyll-2-oxo-1-f3-Lrifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 408 [MH+].
Example 2.105 N-f2-(3-Chlorophenyl)ethyll-6-methyl-2-oxo-1-f3-ao (trifluorometh~phenyll-1,2-dih~dropyridine-3-carboxamide APCI-MS m/z: 435 [MH+].
Example 2.106 6-Methyl-2-oxo-N-(2-pyridin-2-ylethyl)-1-~3-Lrifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide as APCI-MS m/z: 402 [MH+].
Example 2.107 N-f2-(2-Methoxyphen l~yll-6-methyl-2-oxo-1-f3-trifluorometh~)phenyll-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 431 [MH+].

Example 2.108 N-f2-(2-Chlorophenxl)ethyll-6-methyl-2-oxo-1-f3-(trifluorometh,~~henyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 435 [MH+].
s Example 2.109 N-f2-(3-Methoxyphenxl)ethxll-6-methyl-2-oxo-1-f3-~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 431 [MH+].
Example 2.110 N-f2-(4-Fluorophen~)ethyll-6-methyl-2-oxo-1-f3-io ~trifluorometh~)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 419 [MH+].
Example 2.111 N-f2-(2,4-Dichlorophenyl)ethyll-6-methyl-2-oxo-1-f3-~trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide is APCI-MS m/z: 469 [MH+].
Example 2.112 N-f2-(3-Fluorophenyl)ethyll-6-methyl-2-oxo-1-f3-~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z:419 [MH+].
Example 2.113 N-f2-(2-Fluoro~hen l~yll-6-methyl-2-oxo-1-f3-(trifluoromethyl)~henyll-1,2-dihydropyridine-3-carboxarnide APCI-MS m/z: 418 [MH+].
2s Example 2.114 N-(2-Cyclohex-1-en-1-ylethyl)-6-methyl-2-oxo-1-f3-~trifluoromethvl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 405 [MH+].
Example 2.115 N-f2-(4-Bromophen l~yll-6-methyl-2-oxo-1-(3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 481 [MHO].
Example 2.116 6-Methyl-2-oxo-N-~(1S)-1-phenylethyll-1-f3-~trifluoromethyl)phenxll-1,2-dih~pyridine-3-carboxamide s APCI-MS mlz: 401 [MH+].
Example 2.117 N-(3-Bromobenzyl)-6-methyl-2-oxo-1-f3-(_trifluoromethyl)phenyll-1,2-dihvdrop~ridine-3-carboxamide APCI-MS mlz: 467 [MH+].
io Example 2.118 N-(4-Bromobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih,~opyridine-3-carboxamide APCI-MS m/z: 467 [MH+].
is Example 2.119 N-(2-Bromobenz~)-6-methyl-2-oxo-1-f3-(trifluorometh~phen~ll-1,2-dih~drop~ridine-3-carboxamide APCI-MS mlz: 467 [MH+].
Example 2.120 N-(3,4-Dihydro-2H-p ran-2- lmethyl)-6-methyl-2-oxo-1-f3-zo ~trifluorometh~l)nhenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 393 [MH+].
Example 2.121 6-Meth-N-(4-meth 1~~1)-2-oxo-1-f3-(trifluorometh~phen 1,2-dihydropyridine-3-carboxamide zs APCI-MS m/z: 401 [MH+].
Example 2.122 6-Methyl-N-(1-naphthylrnethyl)-2-oxo-113-(trifluorometl~l)phe~ll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 437 [MHO].

Example 2.123 N-(2-Ethoxybenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1,2-dih.~~yridine-3-carboxamide APCI-MS m/z: 431 [MH+].
s Example 2.124 6-Methyl-N-(3-meth l~yl)-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 401 [MH+].
Example 2.125 N-(4-Fluorobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen io 1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 405 [MH+].
Example 2.126 N-~3-Benzodioxol-5-ylmethyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide is APCI-MS m/z: 431 [MH+].
Example 2.127 N- 2 4-Dichlorobenzyl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydrop~rridine-3-carboxamide APCI-MS m/z: 456 [MH+].
Example 2.128 6-Methyl-N-(2-methylbenzyl)-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 401 [MH+].
2s Example 2.129 N-(3,4-Difluorobenzyl)-6-methyl-2-oxo-1-f 3-(trifluorometh~~henyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 423 [MH+].
Example 2.130 N-(2-Fluorobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-so 1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 405 [MH+]
Example 2.131 N-(2-Chloro-4-fluorobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide s APCI-MS mlz: 439 [MH+].
Example 2.132 N-(3,4-Dichlorobenz~)-6-methyl-2-oxo-1-f3-(trifluorometh~)phenyll-1,2-dihydiopyridine-3-carboxamide APCI-MS m/z: 456 [MH+].
io Example 2.133 6-Methyl-N-f(5-meth 1-~ 1)~yll-2-oxo-1-f3-~rifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 391 [MH+].
is Example2.134 6-Methyl-2-oxo-N-1,2,3,4-tetrahydronaphthalen-1-yl-1-f3-~rifluoromethyl)phenyll-1,2-dih.~ro~yridine-3-carboxamide APCI-MS m/z: 427 [MH+].
Example 2.135 N-(2,3-Dimethoxybenzyl)-6-methyl-2-oxo-1-f3-ao ,~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 447 [MH+].
Example 2.136 N-f 1-(4-Chlorophen l~yll-6-methyl-2-oxo-1-f3-~rifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide as APCI-MS m/z: 434 [MH+].
Example 2.137 N-(2,5-Difluorobenzyl)-6-methyl-2-oxo-1-f3-~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 423 [MH+].

Example 2.138 Meth ly 4-1 f~6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1 dihydropxridin-3-yl lcarbonyl)aminolmethyl lbenzoate APCI-MS m/z: 445 [MH+].
s Example 2.139 6-Meth-2-oxo-N-(4-phenoxybenzyl~-1-f3-(trifluorometh~phenyll-1,2-dih,~yridine-3-carboxamide APCI-MS mlz: 479 [MH+].
Example 2.140 N-f (2,2-Dimethyl-1,3-dioxolan-4-yl)meth~l-6-meth;rl-2-oxo-1-f3-io (trifluorometh~~henyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 411 [MH+].
Example 2.141 6-Methyl-N-f(5-methylisoxazol-3-yl)methyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydro~yridine-3-carboxamide is APCI-MS m/z: 392 [MH+].
Example 2.142 N-f(2,5-Dimethyl-3-furyl)methyll-6-methyl-2-oxo-1-f3-(trifluorometh~~henyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 405 [MH+J.
Example 2.143 N-(3-Fur l~~)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen~l-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 377 [MH+].
2s Example 2.144 6-Methyl-2-oxo-N-f4-(1H-pyrazol-1 ~l)benzyll-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 453 [MH+].
Example 2.145 6-Methyl-2-oxo-N-(4-thien-2- ly benzyl)-1-f3-so (trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 469 [MH+].
Example 2.146 N-f2-(1,3-Benzodioxol-5 ~ 1~)ethyll-6-methyl-2-oxo-1-f3-~trifluorometh~rl)phenyll-1,2-dih~~yridine-3-carboxamide s APCI-MS m/z: 445 [MH+].
Example 2.147 6-Methyl-2-oxo-N-(2-thien-2- ly ethyl)-1-f3-(trifluoromethxl)phen 1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 407 [MH+].
io Example 2.148 N- f 2-(4-Tert-butylphenyl)ethyll-6-methyl-2-oxo-1-f 3-(trifluorometh~)phenyll-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 457 [MH+].
is Example 2.149 6-Methyl-N-f2-(4-methylphen l~yll-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 415 [MH+].
Example 2.150 N-12-f4-(Aminosulfon~phenyllethyl~-6-methyl-2-oxo-1-f3-zo (trifluorometh~~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 480 [MH+].
Example 2.151 6-Methyl-2-oxo-N-f(1R)-1-phen l~yll-1-f3-~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide is APCI-MS m/z: 401 [MH+].
Example2.152 3-~f4-(2-Methoxy~hen~pi~erazin-1-yllcarbonyl~-6-methyl-1-f3-(trifluorometl~l)phenyllpyridin-2(1H)-one APCI-MS m/z: 472 [MH+].

Example 2.153 N-f(4-Cyanocyclohexyl)methyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~~yridine-3-carboxamide APCI-MS m/z: 418 [MH+].
s Example 2.154 3-1 f4-(4-Fluorophenyl)piperazin-1-yllcarbonyll-6-meth~3-(trifluorometh~)phenyllpyridin-2(1H)-one APCI-MS m/z: 460 [MH+].
Example 2.155 N-f2-(4'-Fluoro-1,1'-biphenyl-4-yl)ethyll-6-methyl-2-oxo-1-f3-io (trifluorometh;il)phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 495 [MH+].
Example 2.156 N-(2-H day-1-phenylethyl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide is APCI-MS~m/z: 417 [MH+].
Example 2.157 6-Methyl-2-oxo-N-f(2R)-2-phenylcyclo~ro~yll-1-f3-Orifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 413 [MH+].
Example 2.158 N-fl-(4-Chlorobenz~piperidin-4-yll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 504 [MH+].
2s Example 2.159 6-Methyl-N-(2-morpholin-4-ylethyl)-2-oxo-1-f3-(trifluorometh~ henyll-1,2-dih~pyridine-3-carboxamide APCI-MS mlz: 410 [MH+].
Example 2.160 N-f2-(4-Chlorophenyl)ethyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 435 [MH+]
Example 2.161 N-(2-H drox ~-~2-phen l~yl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide s APCI-MS m/z: 417 [MH+].
Example 2.162 N-Cyclopentyl-6-methyl-2-oxo-1-f3-(trifluoromethyl)~hen,1 dihydropyridine-3-carboxamide APCI-MS m/z: 365 [MH+].
io Example 2.163 N-f2-(1H-Imidazol-4- 1~)ethyll-6-methyl-2-oxo-1-(3-(trifluorometh~)~henyll-1,2-dih~p~rridine-3-carboxamide APCI-MS m/z: 391 [MH+].
is Example 2.164 N-(3,5-Dimethoxybenzyl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 447 [MH+].
Example 2.165 N-(4-H d~ycyclohexyl)-6-methyl-2-oxo-1-f3-ao (trifluorometh~~henyll-1,2-dihydropyridine-3-carboxamide APCI-MS mlz: 395 [MH+].
Example 2.166 6-Methyl-2-oxo-N-(2-~yridin-2-ylethyl)-1-f3-(trifluoromethyl)phenyll-1,2-dihydro~yridine-3-carboxarnide as APCI-MS m/z: 402 [MH+].
Example 2.167 6-Methyl-2-oxo-N-1H-1,2,4-triazol-3-yl-1-f3-(trifluoromethyl)phenyll-1,2-dih~~yridine-3-carboxamide APCI-MS m/z: 364 [MH+].

Example 2.168 N-f 1-(H,~ymethyl)-2-methylpropyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1 2-dihydropyridine-3-carboxamide APCI-MS mlz: 383 [MH+].
s Example 2.169 3~ f 3-(3,4-Dichlorophenoxy)pyrrolidin-1-yllcarbonyll-6-meth f3-(trifluorometh,~l phen r~ll~yridin-2(1H)-one APCI-MS m/z: 512 [MH+].
Example 2.170 6-Methyl-2-oxo-N-(pyridin-3-ylmeth~)-1-f 3-io ~trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS m/z: 388 [MH+].
Example 2.171 N-(2-Methoxyethxl -6-methyl-2-oxo-1-f3-(trifluorometh,~l)~henyll-1,2-dihydropyridine-3-carboxamide is APCI-MS m/z: 355 [MH+].
Example 2.172 N-(2-Hydroxy~ro~yl)-6-methyl-2-oxo-1-f3-[trifluoromet~l)phenyll-1,2-dih~dropyridine-3-carboxamide APCI-MS m/z: 355 [MH+].
Example 2.173 Ethyl 4-f(d6-methyl-2-oxo-1-f3-(trifluoromethyl)~henyll-1,2-dihydropyridin-3-yl ~ carbonyl)aminol~iperidine-1-carboxylate APCI-MS m/z: 452 [MH+].
2s Example 2.174 N-f3-(1H-Imidazol-1-~pro~yll-6-methyl-2-oxo-1-f3-~trifluoromethyl)~henyll-1,2-dihydro~yridine-3-carboxamide APCI-MS m/z: 405 [MH+].
Example 3 N-(4-Chlorobenzyl)-1-(3-methyl~henyl)-2-oxo-1,2-dihydro~ riY 'dine-so 3-carboxamide a) Diethyl f 3-ethoxyprop-2-enylidenelmalonate Diethyl malonate (160 g, 1.0 mole) was added dropwise to a stirred, refluxing solution of 1,1,3,3-tetraethoxypropane (330 g, 1.5 mol), acetic anhydride (306 g, 2.0 moles) and zinc s chloride (10 g, 0.073 mole) over a period of 30 minutes. The mixture was heated for 1 h, and after that a Dean-Stark apparatus was connected and the lower boiling components were distilled off. Additional acetic anhydride (150 ml) was added and refluxing was continued for 1 h. The reaction mixture was distilled to give the title compound as a yellow oil (182 g, 75%), b.p. 139-143 °C at 0.8 mm Hg.
io 1H NMR (CDCl3): 8 7.38 (1H, d, J=12.1 Hz); 7.04 (1H, d, J=12.2 Hz); 6.19 (1H, t, J=12.1 Hz); 4.27 (2H, q); 4.21 (2H, q); 3.96 (2H, q); 1.36-1.24 (9H, m).
b) Diethyl ~3-f(3-meth~phenyl)aminolprop-2-enylidene~malonate Diethyl [3-ethoxyprop-2-enylidene]malonate (9.7 g, 40 mmol) and m-toluidine (4.3 g, 40;
mmol) were dissolved in ethanol (150 ml) and stirred at room temperature for three days.
is The solvents were evaporated off. Column chromatography on silica using heptane/ethyl acetate (4:1) as eluent afforded the title compound as an oil, which solidified after standing for a couple of days (10 g, 83%).
1H NMR (CDCl3): 8 7.65 (1H, d, J=12.4 Hz); 7.39 (2H, brd, J=7.7 Hz); 7.19 (1H, t, J=7.?
Hz); 6.85 (1H, d, J=7.7 Hz); 6.75 (1H, s); 6.73 (1H, d, J=6.5 Hz); 6.46 (1H, m, J=12.4, 6.5 ao Hz); 4.32 (2H, q); 4.25 (2H, q); 2.35 (3H, s); 1.36 (3H, t) 1.33 (3H, t).
APCI-MS m/z: 304 [MH+].
c) 1-(3-Methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid Diethyl {3-[(3-methylphenyl)amino]prop-2-enylidene}malonate (10 g, 33 rnmol) was mixed with 2M sodium hydroxide solution (100 ml) and stirred at room temperature for 30 as minutes. The reaction mixture was extracted (washed) with ethyl acetate and the water phases were acidified with hydrochloric acid to pH 3-4. An orange coloured precipitate appeared and was filtered off, washed with water and dried to afford the title compound (7.3 g, 97%).

1H NMR (CDC13): 814.08 (1H, s); 8.64 (1H, dd, J=7.2, 2.2 Hz); 7.72 (1H, dd, J=6.7, 2.2 Hz); 7.47 (1H, t, J=7.7 Hz); 7.37 (1H, d, J=7.7 Hz); 7.23 (1H, s); 7.21 (1H, brd); 6.67 (1H, t, J=7.2, 6.7 Hz); 2.47 (3H, s).
APCI-MS m/z: 230 [MH+].
s d) N-(4-Chlorobenz~l)-1-(3-meth~phenyl)-2-oxo-1,2-dih~pyridine-3-carboxamide To a mixture of 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (115 mg, 0.5 mmol), HATU (209 mg, 0.55 mmol), HOAT (75 mg, 0.55 mmol) and DIEA (275 ~,1, 1.6 mmol) in dichloromethane (2.5 ml) was added 4-chlorobenzylamine (71 mg, 0.5 mmol) in dichloromethane (1 ml). The reaction was stirred for 1 h at room temperature. More to dichloromethane was added and the crude product was washed twice with aqueous sodium hydrogencarbonate, 0.5M aqueous citric acid and water. The solvent was removed in vacuo and the residue was purified by column chromatography on silica using dichloromethane/ethyl acetate (4:1) as eluent to afford the title compound in almost quantitative yield.
is 1H NMR (CDC13): 810.10 (1H, brt); 8.68 (1H, dd); 7.58 (1H, dd); 7.43 (1H, t); T.33-7.25 (5H, m); 7.20-7.14 (2H, m); 6.53 (1H, t); 4.59 (2H, d); 2.45 (3H, s).
APCI-MS m/z: 353 [MH+].
Example 4 N-(4-Chlorobenzyl)-6'-methyl-2-oxo-2H-1,2'-bipyridine-3-ao carboxamide a Diethyl d3-f(6-methylp~rridin-2-Yl)aminolprop-2-enylidene~malonate Diethyl [3-ethoxyprop-2-enylidene]malonate (1.7 g, 7 mmol) and 2-amino-6-methylpyridine (1.08 g, 10 mmol) were heated (without solvent) at 140 °C for 6 h. The as reaction mixture was worked-up as described in Example 3 (b) to afford the title compound.
APCI-MS m/z: 305 [MH+].
b) 6'-Methyl-2-oxo-2H-1,2'-bipyridine-3-carboxylic acid The title compound was prepared from diethyl { 3-[(6-methylpyridin-2-yl)amino]prop-2-so enylidene}malonate using the method described in Example 3 (c).

1H NMR (CDC13): 814.02 (1H, brs); 8.65 (1H, dd); 8.20 (1H, dd); 7.84 (1H, t);
7.68 (1H, d); 7.33 (1H, d); 6.72 (1H, t); 2.64 (3H, s).
APCI-MS mlz: 231 [MH+].
c) N-(4-Chlorobenzyl)-6'-methyl-2-oxo-2H-1,2'-bipyridine-3-carboxamide s The title compound was prepared from 6'-methyl-2-oxo-2H-1,2'-bipyridine-3-carboxylic acid and 4-chlorobenzylamine using the method described in Example 3 (d).
1H NMR (CDC13): 810.04 (1H, brt); 8.68 (1H, dd); 7.95 (1H, dd); 7.79 (1H, t);
7.55 (2H, d); 7.29 (5H, brd); 6.58 (1H, t); 4.61 (2H, d); 2.62 (3H, s).
APCI-MS m/z: 354 [MH+].
io The compounds of Examples 4.1 to 4.18 were prepared by a method analogous to that described for Example 4.
Example 4.1 N-(4-Methox, benzyl)-1-(3-meth~phen,~l)-2-oxo-1,2-is dihydropyridine-3-carboxamide 1H NMR (CDCl3): 8 9.98 (1H, brt); 8.68 (1H, dd); 7.56 (1H, dd); 7.42 (1H, t);
7.32-7.25 (3H, m); 7.18-7.13 (2H, m); 6.84 (2H, d); 6.52 (1H, t); 4.56 (2H, d); 3.79 (3H, s); 2.43 (3H, s).
APCI-MS m/z: 349 [MH+]
Example 4.2 Methyl 4-f(d f 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridin-3-yllcarbonyl l amino)methyllbenzoate 1H NMR (CDC13): S 10.17 (1H, brt); 8.69 (1H, dd); 7.98 (2H, d); 7.59 (1H, dd);
7.46-7.40 (3H, m); 7.32 (1H, d); 7.20-7.16 (2H, m); 6.54 (1H, t); 4.69 (2H, d); 3.92 (3H, s); 2.45 (3H, S).
APCI-MS mlz: 377 [MH+]
Example 4.3 4-f(( f 1-(3-Methylphenyl)-2-oxo-1,2-dih~pyridin-3-yllcarbonyl~amino)methyll benzoic acid A suspension of methyl 4-[({ [1-(3-methylphenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl}amino)methyl] benzoate (120 mg, 0.32 mmol) and 2M sodium hydroxide solution (0.5 ml) in methanol (20 ml) and water (10 ml) was stirred at 40 °C overnight. The methanol was evaporated off and the aqueous solution was acidified with 1M
hydrochloric acid (1 ml). A beige coloured precipitate appeared which was filtered off, washed twice with water and dried to afford the title compound (110 mg, 95%).
1H NMR (DMSO-db): S 12.84 (1H, s); 10.05 (1H, t); 8.45 (1H, dd); 7.99 (1H, dd); 7.88 (2H, d); 7.43-7.38 (3H, m); 7.30 (1H, d); 7.27 (1H, s); 7.24 (1H, d); 6.61 (1H, t); 4.57 (2H, d); 2.35 (3H, s).
io APCI-MS m/z: 363 [MH+]
Example 4.4 N-(4-Chlorobenzyl)-1-(2-fluoro-5-meth~phenyl)-2-oxo-1,2-dih~pyridine-3-carboxamide 1H NMR (CDC13): 8 9.97 (1H, brt); 8.69 (1H, dd); 7.51 (1H, dd); 7.31-7.26 (5H, m); 7.21-is 7.15 (2H, m); 6.56 (1H, t); 4.59 (2H, brs); 2.40 (3H, s).
APCI-MS m/z: 371 [MH+].
Example 4.5 1-(2-Fluoro-5-meth~phenyl)-N-(4-methox, benzyl)-2-oxo-1,2- o dih~pyridine-3-carboxamide zo 1H NMR (CDC13): 8 9.86 (1H, brt); 8.69 (1H, dd); 7.49 (1H, dd); 7.30-7.25 (3H, m); 7.20-7.14 (2H, m); 6.84 (2H, d); 6.54 (1H, t); 4.56 (2H, brd); 3.79 (3H, s); 2.39 (3H, s).
APCI-MS m/z: 367 [MH+].
Example 4.6 N-f4-(Dimethylamino)benzyll-1-(2-fluoro-5-meth~phenyl)-2-oxo-as 1,2-dih~pyridine-3-carboxamide 1H NMR (CDC13): 8 9.78 (1H, brt); 8.69 (1H, dd); 7.47 (1H, dd); 7.27 (1H, dd);
7.22 (2H, d); 7.19-7.13 (2H, m); 6.68 (2H, d); 6.53 (1H, t); 4.53 (2H, brd); 2.92 (6H, s); 2.39 (3H, s).
APCI-MS mlz: 380 [MH+].

Example 4.7 N-f4-(Aminosulfonyl)ben~ll-1-(2-fluoro-5-meth~lphenyl)-2-oxo-1,2-dihvdropyridine-3-carboxamide 1H NMR (CDC13): 810.11 (1H, brt); 8.69 (1H, dd); 7.86 (2H, d); 7.54 (1H, dd);
7.48 (2H, d); 7.30 (1H, dd); 7.20 (2H, d); 7.17 (2H, brd); 6.58 (1H, t); 4.68 (2H, brd);
2.41 (3H, s).
s APCI-MS m/z: 416 [MH+]
Example 4.8 N-.(4-Chlorobenzyl)-4'-methyl-2-oxo-2H-1,2'-bipyridine-3-carboxamide 1H NMR (CDCl3): S 10.02 (1H, brt); 8.68 (1H, dd); 8.48 (1H, d); 7.94 (1H, dd);
7.58 (1H, io s); 7.30-7.28 (4H, m); 7.23 (1H, d); 6.58 (1H, t); 4.61 (2H, d); 2.48 (3H, s).
APCI-MS m/z: 354 [MH+].
Example 4.9 N-(4-Chlorobenzyl)-1-(2,5-dimethylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is 1H NMR (CDCl3): 810.11 (1H, brt); 8.69 (1H, dd); 7.47 (1H, dd); 7.29-7.20 (6H, m); 7.02 (1H, s); 6.54 (1H, t); 4.59 (2H, m); 2.38 (3H, s); 2.09 (3H, s).
APCI-MS mlz: 367 [MH+].
Example 4.10 1-(2,5-Dimethylphenyl)-N-(4-methoxybenz~rl)-2-oxo-1,2-zo dihydro~yridine-3-carboxamide 1H NMR (CDC13): 8 9.97 (1H, brt); 8.67 (1H, dd); 7.43 (1H, dd); 7.27-7.16 (4H, m); 6.99 (1H, s); 6.81 (2H, d); 6.50 (1H, t); 4.53 (2H, m); 3.77 (3H, s); 2.35 (3H, s);
2.07 (3H, s).
APCI-MS m/z: 363 [MH+].
zs Example 4.11 N-f4-(Dimethylamino)benzyll-1-(2,5-dimeth~phenyl)-2-oxo-1,2-dih~pyridine-3-carboxamide 1H NMR (CDCl3): 8 9.91 (1H, brt); 8.69 (1H, dd); 7.43 (1H, dd); 7.26-7.19 (4H, m); 7.01 (1H, s); 6.68 (2H, d); 6.52 (1H, t); 4.52 (2H, m); 2.92 (6H, s); 2.37 (3H, s);
2.08 (3H, s).
APCI-MS m/z: 376 [MH+].

Example 4.12 N-(4-Chlorobenzyl)-1-f2-methyl-5-(trifluoromethyl)phenyll-2-oxo-1,2-dihydropyridine-3-carboxamide 1H NMR (CDC13): b 9.94 (1H, brt); 8.72 (1H, dd); 7.69 (1H, dd); 7.53 (1H, d);
7.50 (1H, s); 7.46 (1H, dd); 7.28 (4H, s); 6.60 (1H, t); 4.59 (2H, m); 2.23 (3H, s).
s APCI-MS m/z: 421 [MH+].
Example 4.13 N-(4-Methoxybenzyl)-1-f2-methyl-5-(trifluoromethyl)phen 1 oxo-1,2-dihydro~~rridine-3-carboxamide 1H NMR (CDCl3): 8 9.80 (1H, brt); 8.71 (1H, dd); 7.65 (1H, dd); 7.50 (1H, d);
7.47 (1H, io . s); 7.42 (1H, dd); 7.2?-7.24 (4H, m); 6.82 (2H, d); 6.56 (1H, t); 4.54 (2H, m); 3.76 (3H, s);
2.19 (3H, s).
APCI-MS m/z: 417 [MH+]
Example 4.14 N-f4-(Dimeth~amino)benzyll-1-f2-methyl-5-is (trifluorometh~phenyll-2-oxo-1,2-dih .~pyridine-3-carboxamide 1H NMR (CDC13): 8 9.75 (1H, brt); 8.73 (1H, dd); 7.67 (1H, dd); 7.52 (1H, d);
7.49 (1H;
s); 7.42 (1H, dd); 7.23 (2H, d); 6.69 (2H, d); 6.57 (1H, t); 4.53 (2H, m);
2.92 (6H, s); 2.21 (3H, s).
APCI-MS m/z: 430 [MH+]
Example 4.15 N-Benzyl-5-methyl-2-oxo-1-f3-(trifluorometh~phen ly 1-1 2-dihydropyridine-3-carboxamide APCI-MS m/z: 387 [MH+].
2s Example 4.16 N-(2-Chlorobenzyl)-5-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS mlz: 421 [MH+].
Example 4.17 5-Methyl-2-oxo-N-(2-phen~yl)-1-f 3-(trifluorometh~~he~ll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 401 [MH+].
Example 4.18 N-(4-Chlorophenyl)-5-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 407 [MH+].
Example 5 6-Ethyl-N-f4-(methylsulfon 1)~yll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~dropyridine-3-carboxamide io a) 6-Ethyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxylic acid The title compound was prepared from ethyl 3-oxo-3-{ [3-(trifluoromethyl)phenyl]
amino}propanoate and 1-methoxypent-1-en-3-one using the method described in Example 1 steps (a) and (b).
1H NMR (CDC13): 8 13.75 (1H, brs); 8.59 (1H, d); 7.87 (1H, d); 7.79 (1H, t);
7.55 (1H, s);
is 7.49 (1H, d); 6.61 (1H, d); 2.37 (2H, q); 1.20 (3H, t).
APCI-MS m/z: 312 [MH+].
bl 6-Ethyl-N-f4-(methvlsulfonvl)benzvll-2-oxo-1-f3-(trifluoromethvl)phenvll-1,2-dihydropyridine-3-carboxamide The title compound was prepared from 6-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-ao dihydropyridine-3-carboxylic acid and 4-(methylsulfonyl) benzylamine hydrochloride using the method described in Example 3 (d).
iH NMR (CDC13): ~ 10.00 (1H, brt); 8.64 (1H, d); 7.88 (2H, d); 7.82 (1H, d);
7.75 (1H, t);
7.53 (2H, d); 7.52 (1H, s); 7.45 (1H, d); 6.51 (1H, d); 4.68 (2H, m); 3.02 (3H, s); 2.31 (2H, q); 1.17 (3H, t).
as APCI-MS rn/z: 479 [MH+]
The compounds of Examples 5.1 and 5.2 were prepared by a method analogous to that described for Example 5.

Example 5.1 N-f4-Meth ls~xl)benzyll-2-oxo-6-propyl-1-f3-~trifluorometh~)phenyll-1,2-dihydropyridine-3-carboxamide 1H NMR (CDC13): b 10.00 (1H, brt); 8.62 (1H, d); 7.88 (2H, d); 7.83 (1H, d);
7.75 (1H, t);
7.53 (2H, d); 7.52 (1H, s); 7.45 (1H, d); 6.49 (1H, d); 4.68 (2H, m); 3.02 (3H, s); 2.26 (2H, t); 1.55 (2H, sxt); 0.87 (3H, t).
APCI-MS m/z: 493 [MH+].
Example 5.2 6-Butyl-N-f4-(methylsulfonyl)benzyll-2-oxo-1-f3-~trifluorometl~l)phenyll-1,2-dih d~ropyridine-3-carboxamide io 1H NMR (CDC13): 8 10.00 (1H, brt); 8.62 (1H, d); 7.88 (2H, d); 7.83 (1H, d); 7.75 (1H, t);
7.54 (2H, d); 7.52 (1H, s); 7.45 (1H, d); 6.49 (1H, d); 4.68 (2H, m); 3.03 (3H, s); 2.29 (2H, t); 1.49 (2H, qv); 1.24 (2H, sxt); 0.80 (3H, t).
APCI-MS m/z: 507 [MH+].
is Example 6 6-(Methox~xl_)-N-f4-(methylsulfonyl)benzyll-2-oxo-1-f3-~trifluoromethxl)phenyll-1,2-dihydropyridine-3-carboxamide a) 6-(Bromometh~)-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxylic acid zo The title compound was prepared by refluxing 6-methyl-2-oxo-1-[3-(trifluoromethyl) phenyl]-1,2-dihydropyridine-3-carboxylic acid (297 mg, 1 mmol), N-bromosuccinimide (240 mg, 1.3 mmol) and 2,2'-azobis-2-methylpropionitrile (AIBN) (15 mg) in carbon tetrachloride/chloroform (2:1, 5 ml) overnight. The solvent was evaporated to give the title compound.
as APCI-MS m/z: 376/378 [MH+]
b) 6-(Methoxymeth~)-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxylic acid The title compound was prepared by heating crude 6-(bromomethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid with an excess of sodium 3o methoxide in methanol at 40 °C for 15 minutes. The organic solvents were removed, water was added and the reaction mixture was washed with ethyl acetate. The water phases were acidified with hydrochloric acid to pH 3-4. A yellowish precipitate appeared which was filtered off, washed (water and water/methanol, 1:1) and dried to give the title compound.
1H NMR (CDCl3): S 13.66 (1H, brs); 8.63 (1H, d); 7.87 (1H, d); 7.77 (1H, t);
7.58 (1H, s);
7.50 (1H, d); 6.84 (1H, d); 3.96 (2H, d); 3.27 (3H, s).
APCI-MS m/z: 328 [MH+].
c) 6-(Methoxymethyl)-N-f4-(meth.lsulfonyl)benzyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide The title compound was prepared from 6-(methoxymethyl)-2-oxo-1-[3-io (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid and 4-(methylsulfonyl) benzylamine hydrochloride using the method described in Example 3 (d).
1H NMR (CDC13): 8 9.98 (1H, brt); 8.67 (1H, d); 7.87 (2H, d); 7.82 (1H, d);
7.73 (1H, t);
7.53 (3H, m); 7.47 (1H, d); 6.72 (1H, d); 4.67 (2H, m); 3.92 (2H, d); 3.23 (3H, s); 3.01 (3H, s).
is APCI-MS m/z: 495 [MH+].
Example 7 6-(H dy rox~rmethyl)-N-f4-(methylsulfonyl)benzyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~o~yridine-3-carboxamide ao a) 6-(Hydroxyl)-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxylic acid The title compound was prepared by heating 6-(bromomethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid and dilute sodium hydroxide in methanol for a few minutes. The reaction mixture was washed with ethyl as acetate. The water phases were acidified with hydrochloric acid. A
precipitate appeared which was recrystallised several times from ethyl acetate/methanol to give the title compound.
1H NMR (DMSO-d~): 8 13.99 (1H, brs); 8.53 (1H, d); 8.00 (1H, s); 7.94 (1H, d);
7.83 (1H, t); 7.81 (1H, d); 6.94 (1H, d); 5.85 (1H, t); 3.99 (2H, d).
3o APCI-MS m/z: 314 [MH+].

b) 6-(Hydroxymethyl)-N-f4-(methylsulfon 1)benzyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihy~yridine-3-carboxamide The title compound was prepared from 6-(hydroxymethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid and 4-(methylsulfonyl) benzylamine hydrochloride using the method described in Example 3 (d).
1H NMR (DMSO-d6): 8 9.92 (1H, brt); 8.49 (1H, d); 7.92-7.81 (4H, m); 7.78 (1H, t); 7.71 (1H, d); 7.53 (2H, d); 6.78 (1H, d); 5.71 (1H, t); 4.57 (2H, brd); 3.95 (2H, brd); 3.16 (3H, s).
APCI-MS m/z: 481 [MH+].
io Example 8 N-f4-(Aminosulfonyl)benzyll-2,4-dioxo-3-f3-(trifluoromethxl)phenyll-1,2,3,4-tetrahydt'opyrimidine-5-carboxamide a) 2,4-Dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carbox is acid 3-(Trifluoromethyl)phenyl isocyanate (3.52 g, 22 mmol) was added quickly to a vigorously stirred ice-cooled solution of aqueous ammonia (10 ml, 33%) in acetonitrile (40 ml). The mixture was heated at 40 °C for 10 minutes and then the solvent was evaporated. The resulting urea was redissolved in dry ethanol (15 ml) and diethyl ethoxymethylene-ao malonate (5 ml, 24.7 mmol) and finally sodium ethoxide solution (50 mmol in ethanol) was added, and the mixture was refluxed for 2 h. Water (10 ml) was added and the mixture was allowed to cool, then washed with ethyl acetate, acidified to pH~3 with conc.
hydrochloric acid and extracted with ethyl acetate. The organic extracts were dried and evaporated to give a solid material. Recrystallisation from heptanelethyl acetate afforded as the title compound (0.5 g, 7%).
1H NMR (CDC13): 812.41 (1H, brd, J=6.4Hz); 8.15 (1H, d, J=6.4Hz); 7.46 (1H, d, J=7.6Hz); 7.40 (1H, t, J=7.6Hz); 7.30 (brs, 1H); 7.22 (1H, d, J=7.6Hz).
APCI-MS m/z: 300 [MH+].
b) N-f4-(Aminosulfon 1)benzXll-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-so tetrahydropyrimidine-5-carboxamide The title compound was prepared from 2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and N-[4-(aminosulfonyl)-benzylamine hydrochloride using the method described in Example 1 (d).
1H NMR (DMSO-d6): 8 12.21 (1H, brd); 9.11 (1H, t); 8.29 (1H, s); 7.81 (2H, d);
7.77-7.70 s (3H, m); 7.65 (1H, d); 7.44 (1H, d); 7.28 (2H, s); 4.46 (2H, d).
The compounds of Examples 8.1 to 8.8 were prepared using the general method described for Example 8.
io Example 8.1 N-f4-(Dimethylamino)benzyll-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide trifluoroacetate 1H NMR (CD3CN): 8 9.73 (1H, brd); 8.96 (1H, brt); 8.35 (1H, d); 7.79 (1H, d);
7.72 (1H, t); 7.63 (1H, s); 7.55 (1H, d); 7.36 (2H, d); 7.23 (2H, d); 4.49 (2H, d); 3.04 (6H, s).
is Example 8.2 N-(4-Chlorobenzyl)-2 4-dioxo-3-f3-(trifluoromethyl)phen 1 2,3,4-tetrah~pyrimidine-5-carboxamide iH NMR (CD3CN): 8 9.65 (1H, brd); 8.96 (1H, brt); 8.39 (1H, d); 7.80 (1H, d);
7.72 (1H, t); 7.63 (1H, s); 7.56 (1H, d); 7.33 (2H, d); 7.25 (2H, d); 4.49 (2H, d).
2o Example 8.3 N-(2,3-Dihydro-1-benzofuran-5-ylmethyl)-2 4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide 1H NMR (CDCl3): 8 8.53 (1H, d); 7.76 (1H, m); 7.67 (1H, m); 7.53 (1H, m); 7.44 (1H, m), 7.13 (1H, m); 7.04 (1H, m); 6.68 (1H, d); 5.28 (2H, d); 4.57 (2H, t); 3.19 (2H, t).
APCI-MS m/z: 432 [MH+].
Example 8.4 N-f4-(Methylsulfon 1)~yll-2 4-dioxo-3-f3-trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1H NMR (CDC13): 8 9.05 (1H, m); 8.52 (1H, d); 8.40 (1H, m); 7.88 (2H, d); 7.75 (1H, d);
7.66 (1H, t); 7.53 (1H, m); 7.49 (2H, d); 7.44 (1H, d); 4.65 (2H, d); 3.01 (3H, s).
so APCI-MS m/z: 468 [MH+].

Example 8.5 N-(4-Bromobenzyl)-2 4-dioxo-3-f 3-(trifluorometh~~henyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide 1H NMR (CDC13): S 8.90 (1H, m); 8.50 (1H, d); 8.32 (1H, m); 7.74 (1H, d); 7.65 (1H, m);
s 7.52 (1H, m); 7.42 (3H, m); 7.16 (2H, d); 4.50 (2H, d).
APCI-MS m/z: 467[MH+].
Example 8.6 N-(4-Methoxybenzyl)-2 4-dioxo-3-f3-(trifluorometh~phen 1,2,3,4-tetrahydropyrimidine-5-carboxamide io 1H NMR (CDC13): 8 8.86 (1H, m); 8.62- 8.53 (2H, m); 7.77 (1H, m); 7.69 (1H, m); 7.55 (1H, m), 7.47 (1H, m), 7.24 (2H, m); 6.86 (1H, m); 4.52 (2H, d); 3.80 (3H, s).
APCI-MS m/z: 420 [MH+].
Example 8.7 N-(1,3-Benzodioxol-5-ylmethyl)-2 4-dioxo-3-f3-is (trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide iH NMR (CDCl3): 8 8.93 (1H, m); 8.71 (1H, m); 8.54 (1H, t); 7.76 (1H, d); 7.68 (1H, t);
7.54 (1H, m); 7.46 (1H, d); 7.27 (1H, s); 6.85 (1H, d); 6.76 (1H, d); 5.95 (2H, d); 4.56 (1H, d); 4.48 (1H, d).
APCI-MS m/z: 434 [MH+].
Example 8.8 N-(3-Chlorobenzyl)-2,4-dioxo-3-f3-(trifluorometh 1) henyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1H NMR (CDC13): b 10.07 (1H, d); 9.11 (1H, t); 8.54 (1H, d); 7.78 (1H, d);
7.69 (1H, t);
7.55 (1H, m); 7.47 (1H, d); 7.29 (1H, m); 7.26 (2H, m); 7.19 (1H, m); 4.58 (2H, d).
2s APCI-MS m/z: 424 [MH+].
Example 9 1-Butyl-N-f4-(methylsulfonyl)benzyll-2 4-dioxo-3-f3-(trifluorometh~~henyll-1,2,3,4-tetrah~pyrimidine-_ 5-carboxamide so a~ N-Butyl-N'-f3-(trifluoromethyl)phen llurea 1-Isocyanato-3-(trifluoromethyl)benzene (0.74 ml, 5.34 mmol) was added to an ice cooled solution of n-butylamine (1.06 ml, 10.68 mmol) in acetonitrile (10 ml). The mixture was stirred for 10 minutes and then the solvent was evaporated to give the title compound as a white solid (1.37 g, 99%).
s APCI-MS m/z: 261 [MH+].
b) Ethyll-butyl-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxylate To a solution of N-butyl-N'-[3-(trifluoromethyl)phenyl]urea (1.37 g, 5.26 mmol) and diethyl (ethoxymethylene)malonate (2.13 ml, 10.68 mmol) in NMP (6 ml) at 100 °C was io added potassium tent-butoxide (0.10 g, 0.89 mmol) and the mixture was stirred for 1 h.
Ethyl acetate was added and the mixture was washed with 1M hydrochloric acid, brine and water. The solvent was evaporated and the resulting oil was purified by HPLC
to give the title compound (667 mg, 33%).
1HNMR (CDC13): &8.33 (1H, s); 7.70 (1H, d); 7.62 (1H, t); 7.51 (1H, s); 7.41 (1H, d);
is 4.35 (2H, q); 3.89 (2H, t); 1.81-1.74 (2H, m); 1.45-1.33 (5H, m); 0.99 (3H, t).
APCI-MS m/z: 385 [MH+].
c) 1-Butyl-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidine-carboxylic acid A solution of ethyl 1-butyl-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-ao tetrahydropyrimidine-5-carboxylate (101 mg, 0.26 mmol) and 0.5M sodium hydroxide solution (700 ~,1, 0.35 mmol) in THF was stirred for 2 h. Water was added and the mixture was washed with ethyl acetate. Acidification of the aqueous phase, extraction with ethyl acetate and removal of the solvent yielded the title compound (65 mg, 70%).
1H NMR (CDC13): S 8.57 (1H, s); 7.79 (1H, d); 7.70 (1H, t); 7.55 (1H, s); 7.46 (1H, d);
as 3.96 (2H, t); 1.85-1.75 (2H, m); 1.50-1.37 (2H, m); 1.00 (3H, t).
APCI-MS m/z: 357 [MH+].
d) 1-Butyl-N-f4-(methylsulfonyl)benzyll-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide A solution of 4-methylsulphonylbenzylamine hydrochloride (30 mg, 0.14 mmol) and so DIEA (24 ~,1, 0.14 mmol) in dichloromethane (1 ml) was added to a stirred mixture of 1-butyl-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (44 mg, 0.12 mmol), HATU (52 mg, 0.14 mmol), HOAT (19 mg, 0.14 mmol) and DIEA (63 ~,1, 0.37 mmol) in dichloromethane (1 ml). The resulting mixture was stirred for 2 h. The solvent was evaporated and the product was purified by HPLC and by flash chromatography to give the title compound (22 mg, 35°Io).
1H NMR (CDC13): 8 9.14 (1H, t); 8.55 (1H, s); 7.89 (2H, d); 7.75 (1H, d); 7.67 (1H, t);
7.53 (1H, s); 7.50 (2H, d); 7.44 (1H, d); 4.66 (2H, d); 3.93 (2H, t); 3.03 (3H, s); 1.83-1.75 (2H, m); 1.47-1.38 (2H, m); 0.99 (3H, t).
APCI-MS m/z: 524 [MH+].
io The compounds of Examples 9.1 to 9.4 were prepared using the general method described for Example 9:
Example 9.1 1-(2-Methox~yl)-N-f4-(methylsulfonyl)benzyll-2,4-dioxo-3-f3-is (trifluorometh~phenyl~-1,2,3,4-tetrah~dropyrimidine-5-carboxamide 1H NMR (CDC13): 8 9.13 (1H, t); 8.61 (1H, s); 7.90 (2H, d); 7.75 (1H, d); 7.67 (1H~ t);
7.54 (1H, s); 7.51 (2H, d); 7.45 (1H, d); 4.66 (2H, d); 4.12 (2H, t); 3.68 (2H, t); 3.40 (3H, s); 3.03 (3H, s).
APCI-MS m/z: 526 [MH+].
Example 9.2 1-Methyl-N-f4-(methylsulfon 1)~yll-2,4-dioxo-3-f3-(trifluorometh~)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1H NMR (CDC13): 8 9.10 (1H, t); 8.57 (1H, s); 7.90 (2H, d); 7.76 (1H, d); 7.67 (1H, t);
7.52 (1H, s); 7.50 (2H, d); 7.43 (1H, d); 4.66 (2H, d); 3.61 (3H, s); 3.03 (3H, s).
2s APCI-MS m/z: 482 [MH+].
Example 9.3 1-Ethyl-N-f4-(methylsulfon 1)~yll-2,4-dioxo-3-f3-(trifluoromethyl)phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1H NMR (CDC13): 8 9.13 (1H, t); 8.58 (1H, s); 7.90 (2H, d); 7.75 (1H, d); 7.67 (1H, t);
7.53 (1H, s); 7.50 (2H, d); 7.44 (1H, d); 4.66 (2H, d); 4.01 (2H, q); 3.03 (3H, s); 1.45 (3H, t).
APCI-MS m/z: 496 [MH+].
Example 9.4 N-(4-Chlorobenzyl)-1-(2-methoxyeth~)-2,4-dioxo-3-f3-(trifluoromethXl phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide 1H NMR (CDC13): 8 8.99 (1H, t); 8.60 (1H, s); 7.74 (1H, d); 7.66 (1H, t); 7.53 (1H, s); 7.44 (1H, d); 7.30-7.22 (4H, m); 4.54 (2H, d); 4.11 (2H, t); 3.67 (2H, t); 3.40 (3H, s).
io APCI-MS m/z: 482 [MH+].
Example 10 5-Iodo-6-methyl-N-f4-(methylsulfonyl)benzyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide N-Iodosuccinimide (9.7mg, 0.043 mmol) was added to a stirred solution of 6-methyl-N-is [4-(methyls~lfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (20 mg, 0.043 mmol) in trifluoromethanesulfonic acid (0.5 ml). The mixture was stirred for 10 minutes. Dichloromethane (10 ml) was added and the organic phase was washed with aqueous sodium hydrogencarbonate, aqueous sodium thiosulfate and water.
The extracts were dried and evaporated to give the title compound (100%).
ao 1H NMR (CDC13): 8 9.81 (1H, brt); 8.86 (1H, s,); 7.88 (2H, d); 7.82-7.69 (3H, m); 7.48 (2H, d); 7.40 (1H, d); 4.65 (2H, m); 3.01 (3H, s); 2.28 (3H, s).
The following Intermediates were prepared using the procedure described in Example 9(c):
as 1-(2-Methoxyethyl)-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydro~yrimidine-5-carboxylic acid APCI-MS m/z: 359 [MH+].
3-(3-Chlorophenyl)-1-(2-methox~ethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-so carboxylic acid APCI-MS m/z: 325 [MH+].
1-Butyl-3-(3-methox p~ henyl)-2,4-dioxo-1,2,3,4-tetrahydrop~rimidine-5-carboxylic acid 1H NMR (DMSO-d6): 8 12.09 (1H, br s); 8.79 (1H, s); 7.39 (1H, t); 7.01 (1H, dd); 9.91 (1H, t); 6.85(lH,d); 3.89 (2H, t); 3.74 (3H, s); 1.61 (2H, pentet); 1.30 (2H, hextet); 0.89 (3H, t).
1-Butyl-3-(3-(trifluorometh~phenyl)-2,4-dioxo-1,2,3,4-tetrah~~yrimidine-5-carboxylic acid io 1H NMR (DMSO-d6): 8 12.55 (1H, br s); 8.76 (1H, s); 7.84-7.60 (4H, m); 3.89 (2H, t);
1.63 (2H, pentet); 1.30 (2H, hextet); 0.89 (3H, t).
1-Butyl-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid APCI-MS m/z 323 [MH+].
is 1-Butyl-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydxopyrimidine-5-carboxylic acid 1H NMR (DMSO-d6): S 12.30 (1H, br s); 8.74 (1H, s); 7.94-7.85 (2H, m); 7.75-7.69 (2H, m); 3.89 (2H, t); 1.63 (2H, pentet); 1.30 (2H, hextet); 0.89 (3H, t).
zo Example 11 N-(4-Chlorobenz~)-1-(2-methoxyethyl)-2,4-dioxo-3-~3-~trifluoromethyl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide 1-(2-Methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (0.016 mmol, 0.2M in NMP) was added to PS-Carbodiimide resin (60 mg), HOBT (0.032 mmol, 0.3M in NMP) and NMP (200 ~.1). The mixture was stirred for as 15 minutes and 4-chlorobenzylamine (0.019 mmol, 0.3M in NMP) was added.
After shaking overnight the excess HOBT was scavenged using PS-Trisamine resin (45 mg), shaking for 2 h before the resin reagents were filtered off. The title compound was obtained after purification using preparative HPLC.
APCI-MS m/z: 482.4 [MH+]

Examples 11.1 to 11.13 were prepared from 1-(2-methoxyethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and the appropriate amine using the general procedure described in Example 11:
s Example 11.1 N-(4-Methoxyben~l)-1-(2-methox~yl)-2,4-dioxo-3-f3-~trifluorometh~)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 478.5 [MH+].
Example 11.2 1-(2-Methoxyethyl)-2,4-dioxo-N-(pyridin-4-ylmethyl)-3-f3-io (trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 449.4 [MH+].
Example 11.3 N-f2-(3,4-Dimethoxyphen~tl)ethyll-1-(2-methox,~yl)-2,4-dioxo-3-f 3-(trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide is APCI-MS m/z: 522.5 [MH+].
Example 11.4 1-(2-Methoxyethyl)-N-f2-(3-methoxyphen l~yll-2;4-dioxo-3-f3-~trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 492.5 [MH+].
Example 11.5 1-(2-Methoxyethyl)-N-(4-meth, l~yl)-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 462.5 [MH+].
2s Example 11.6 1-(2-Methoxyethyl)-N-f4-(methylsulfonyl)benzyll-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 526.5 [MH+].
Example 11.7 N-(4-Fluorobenz~)-1-(2-methoxyethyl)-2,4-dioxo-3-f3-so (trifluoromethyl)phenyll-1,2,3,4-tetrah~dropyrimidine-5-carboxamide APCI-MS m/z: 466.4 [MH+].
Example 11.8 N-(1,3-Benzodioxol-5-Xlmethyl)-1-(2-methoxyethyl)-2 4-dioxo-3-j3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS mlz: 492.5 [MH+].
Example 11.9 N-(2-Chloro-4-fluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrah~dropyrimidine-5-carboxamide APCI-MS m/z: 500.4 [MH+].
io Example 11.10 N-(3,4-Dichlorobenzyl)-1-(2-methox~yl)-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 516.4, 518.4 [MH+].
is Example 11.11 Methyl 4-~ f(~ 1-(2-methoxyethyl)-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidin-5-yl ~carbonyl)aminolmethyl benzoate APCI-MS m/z: 506.5 [MH+].
ao Example 11.12 1-(2-Methox~yl)-N-f (5-methylisoxazol-3-yl)methyll-2 4-dioxo-f 3-(trifluorometh~phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS mlz: 453.4 [MH+].
Example 11.13 1-(2-Methoxyethyl)-2,4-dioxo-N-f4-(1H-pyrazol-1-yl)benz 11-zs (trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 514.5 [MH+]
Examples 11.14 to 11.29 were prepared from 3-(3-chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and the appropriate amine using the so general procedure described in Example 11:

Example 11.14 N-(4-Chlorobenz~)-3-(3-chlorophenyl)-1-(2-methox~yl)-2,4-dioxo-1,2,3,4-tetrah',rdropyrimidine-5-carboxamide APCI-MS m/z: 448.4, 450.4 [MH+].
s Example 11.15 3-(3-Chlorophenyl)-N-(4-methox b~yl)-1-(2-methox~ l dioxo-1,2,3,4-tetrah.~~yrimidine-5-carboxamide APCI-MS m/z: 444.4 [MH+].
io Example 11.16 3-(3-Chlorophenyl)-1-(2-methoxyethyl)-2,4-dioxo-N-(Pyridin-4-l~yl)-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 415.4 [MH+].
Example 11.17 3-~Chlorophenyl)-N-f2-(3,4-dimethoxxphen .l~yll-1-(2-is methox~yl)-2,4-dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 488.5 [MH+].
Example 11.18 3-(3-Chlorophenyl)-1-(2-methoxyethyl)-N-f2-(3-methoxy~henyl)ethyll-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 2o APCI-MS m/z: 458.5 [MH+].
Example 11.19 N-(3-Bromobenzyl)-3-(3-chlorophenyl)-1-(2-methox~yl)-2,4-dioxo-1,2,3,4-tetrah~dropyrimidine-5-carboxamide APCI-MS m/z: 492.4, 494.3 [MH+].
Example 11.20 3-(3-Chlorophenyl)-1-(2-methoxyethyl)-N-(4-meth lbenz l dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS rn/z: 428.4 [MH+].

Example 11.21 3-(3-Chloro~henyl)-1-(2-methoxyethyl)-N-f4-~methylsulfonXl)benzyll-2,4-dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 492.4 [MH+].
Example 11.22 3-(3-Chlorophenyl)-N-(4-fluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 432.4 [MH+].
Example 11.23 N-(1,3-Benzodioxol-5- ly methyl)-3-(3-chlorophenyl)-1-(2-io methoxyethyl)-2,4-dioxo-1,2,3,4-tetrahYdropyrimidine-5-carboxamide APCI-MS m/z: 458.4 [MHt]
Example 11.24 3-(3-Chlorophenyl)-N-(3,4-difluorobenzyl)-1-(2-methoxyethyl)-2,4-dioxo-1,2,3,4-tetrah~pyrimidine-5-carboxamide is APCI-MS mlz: 450.3 [MH+]
Example 11.25 N-(2-Chloro-4-fluorobenzyl)-3-(3-chlorophenyl)-1-(2-methox~yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 466.4, 468.4 [MH+].
Example 11.26 3-(3-Chlorophenyl)-N-(3,4-dichlorobenzyl)-1-(2-methoxyethyl)-2 4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 482.3, 484.3 [MH+].
2s Example 11.27 Methyl 4-f(d f3-(3-chloro~henXl)-1-(2-methoxyeth~)-2 4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yllcarbonyll amino)methyllbenzoate APCI-MS m/z: 472.4 [MH+].
Example 11.28 3-(3-Chlorophenyl)-1-(2-methox~yl)-N-f (5-methylisoxazol-3-so yl)methyll-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 419.4 [MH+]
Example 11.29 3-(3-Chlorophenyl)-1-(2-methox~yl)-2,4-dioxo-N-f4-(1H-pyrazol-1- 1)~yll-1,2,3,4-tetrahydropyrimidine-5-carboxamide s APCI-MS m/z: 480.5 [MH+].
Examples 11.30 to 11.38 were prepared from 1-butyl-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and the appropriate amine using the general procedure described in Example 11:
io Example 11.30 1-Butyl-N-(4-chlorobenzyl)-3-(3-methoxyphenyl)-2 4-dioxo-1 2 3 4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 442.4 [MH+].
is Example 11.31 1-Butyl-3-(3-methox~phenyl)-N-f2-(3-methoxyphenyl)eth 1 dioxo-1.2,3,4-tetrah~~rimidine-5-carboxamide APCI-MS m/z: 452.3 [MH+].
Example 11.32 N-(3-Bromobenzyl)-1-butyl-3-(3-methoxxphenyl)-2 4-dioxo-1 2 3 4-zo tetrahydropyrimidine-5-carboxamide APCI-MS mlz: 486.4, 488.4 [MH+].
Example 11.33 1-Butyl-N-(4-fluorobenzyl)-3-(3-methoxyphenyl)-2 4-dioxo-1 2 3 4-tetrahydropyrimidine-5-carboxamide zs APCI-MS m/z: 426.3 [MH+].
Example 11.34 N-(1,3-Benzodioxol-5-ylmeth l~tyl-3-(3-methox henyl)-2 4-dioxo-1,2, 3 ,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 452.4 [MH+].

Example 11.35 1-Butyl-N-(2,4-dichlorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrah~dropyrimidine-5-carboxamide APCI-MS m/z: 476.4, 478.4 [MH+].
s Example 11.36 1-Butyl-N-(3,4-difluorobenzyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrah,~pyrimidine-5-carboxamide APCI-MS m/z: 444.3 [MH+].
Example 11.37 1-Butyl-N-(2-chloro-4-fluorobenzyl)-3-(3-methoxyphenyl)-2,4-io dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 460.3 [MH+].
Example 11.38 1-Butyl-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-3-(3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide is APCI-MS m/z: 450.5 [MH+].
Examples 11.39 to 11.58 were prepared from 1-butyl-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and the appropriate amine using the general procedure described in Example 11:
ao Example 11.39 1-Butyl-N-(4-chlorobenzyl)-3-(3-chlorophenyl)-2,4-dioxo-1 2 3 4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 446.4, 448.4 [MH+].
as Example 11.40 1-Butyl-3-(3-chlorophenyl)-N-(4-methox benzyl)-2,4-dioxo-1 2 tetrahYdropyrimidine-5-carboxamide APCI-MS m/z: 442.4 [MH+].
Example 11.41 1-Butyl-3-(3-chlorophenyl)-2,4-dioxo-N-(pyridin-4-ylmethyl)-so 1,2,3,4-tetrahydrop~rimidine-5-carboxamide APCI-MS m/z: 413.3 [MH+]
Example 11.42 1-Butyl-3-(3-chlorophenyl)-N-f 2-(3,4-dimethoxyphenyl)ethyll-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide s APCI-MS m/z: 486.4 [MH+].
Example 11.43 1-Butyl-3-(3-chlorophenyl)-N-f2-(3-methoxyphenyl)ethyll-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 456.4 [MH+].
io Example 11.44 N-(3-Bromobenzyl)-1-butyl-3-(3-chlorophenxl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 490.3, 492.3 [MH+].
is Example 11.45 N-(4-Bromobenzyl)-1-butyl-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 490.3, 492.3 [MH+].
Example 11.46 1-Butt-3-(3-chlorophenyl)-N-(4-methylbenzyl)-2,4-dioxo-1,2,3,4-ao tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 426.4 [MH+].
Example 11.47 1-Butyl-3-(3-chlorophenyl)-N-f4-(methylsulfon 1)~yll-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as APCI-MS m/z: 490.4 [MH+].
Example 11.48 1-Butyl-3-(3-chloro~henyl)-N-(4-fluorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydroQyrimidine-5-carboxamide APCI-MS m/z: 430.4 [MIi+].

Example 11.49 N-(1,3-Benzodioxol-5-ylmethyl)-1-butyl-3-(3-chlorophenyl)-2 4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 456.4 [MH+].
s Example 11.50 1-Butyl-3-(3-chlorophenyl)-N-(2,4-dichlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 480.3, 482.3 [MH+].
Example 11.51 1-Butyl-3-(3-chlorophenyl)-N-(3,4-difluorobenzyl)-2,4-dioxo-io 1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 448.4 [MH+].
Example 11.52 1-Butyl-N-(2-chloro-4-fluorobenzyl)-3-(3-chlorophenyl)-2,4-dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide is APCI-MS m/z: 464.4, 466.4 [MH+].
Example 11.53 1-Butyl-3-(3-chlorophenyl)-N-(3,4-dichlorobenzyl)-2,4-dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 480.3, 482.4 [MH+].
ao Example 11.54 1-Butyl-3-(3-chlorophenyl)-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 452.4 [MH+].
zs Example 11.55 1-Butyl-3-(3-chlorophenyl)-N-f (4-c anoc c~x 1)y meth l dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 443.3 [MH+].
Example 11.56 1-Butyl-3-(3-chlorophenyl)-N-f(5-methylisoxazol-3- 1)meth,1 so dioxo-1,2,3,4-tetrah~dropyrimidine-5-carboxamide APCI-MS m/z: 417.3 [MH+].
Example 11.57 1-Butyl-3-(3-chlorophenyl)-2,4-dioxo-N-f4-(1H-~yrazol-1-1)benzyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide s APCI-MS m/z: 478.4 [MH+].
Example 11.58 1-Butyl-3-(3-chlorophenyl)-2,4-dioxo-N-f3-(2-oxopyrrolidin-1-~propyll-1,2,3,4-tetrah~~yrimidine-5-carboxamide APCI-MS m/z: 447.3 [MH+].
io Examples 11.59 to 11.77 were prepared from 1-butyl-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and the appropriate amine using the general procedure described in Example 11:
is Example 11.59 1-Butyl-N-(4-chlorobenzyl)-3- 3-c~phenyl)-2 4-dioxo-1 2 3 4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 437.4 [MH+].
Example 11.60 1-Butyl-3-(3-cyanophen~)-N-(4-methoxybenzyl)-2 4-dioxo-1 2 3 4-zo tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 433.5 [MH+].
Example 11.61 1-Butyl-3-(3-cyanophenyl)-2,4-dioxo-N-(pyridin-4- lmeth 1,2,3,4-tetrahydropyrimidine-5-carboxamide zs APCI-MS m/z: 404.3 [MH+].
Example 11.62 1-Butyl-3-(3-cyanophenyl)-N-f2-(3,4-dimethoxyphenyl)ethyll-2 4-dioxo-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 477.4 [MH+].

Example 11.63 1-Butyl-3-(3-c~phen~)-N-f2-(3-methoxxphenyl)ethyll-2,4-dioxo-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 447.3 [MH+].
s Example 11.64 N-(3-Bromobenz~)-1-butyl-3-(3-c~phenyl)-2,4-dioxo-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 481.4, 483.4 [MH+].
Example 11.65 N-(4-Bromobenzyl)-1-butyl-3-(3-cXanophenyl)-2,4-dioxo-1,2,3,4-io tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 481.4, 483.4 [MH+].
Example 11.66 1-Butyl-3-(3-c~~henyl)-N-(4-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide is APCI-MS m/z: 417.4 [MH+].
Example 11.67 1-Butyl-3-(3-c~phenyl)-N-f4-(methylsulfon 1)~yll-2,4-dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS mlz: 481.4 [MH+].
Example 11.68 1-Butyl-3-(3-cyanophenyl)-N-(4-fluorobenzyl)-2,4-dioxo-1,2,3 4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 421.3 [MH+].
2s Example 11.69 N-(1,3-Benzodioxol-5-ylmethyl)-1-butyl-3-(3-c anophen.1 dioxo-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 447.4 [MH+].
Example 11.70 1-Butyl-3-(3-cyanophenyl)-N-(2,4-dichlorobenzyl)-2 4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 471.4, 473.4 [MH+].
Example 11.71 1-Butyl-3-(3-cyanophenyl)-N-(3,4-difluorobenzyl)-2,4-dioxo-1,2,3,4-tetrah~pyrimidine-5-carboxamide s APCI-MS m/z: 439.4 [MH+].
Example 11.72 1-Butyl-N-(2-chloro-4-fluorobenzyl)-3-(3-cyanophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 455.4 [MH+].
io Example 11.73 1-Butyl-3-(3-cyanophen;rl)-N-(3,4-dichlorobenzyl)-2,4-dioxo-1,2,3,4-tetrah,~~yrimidine-5-carboxamide APCI-MS mlz: 471.4, 473.5 [MH+].
is Example 11.74 1-Butyl-N-f (4-cyanocyclohex 1)~yll-3-(3-c~phenyl)-2,4=
dioxo-1,2,3,4-tetrah.%~pyrimidine-5-carboxamide APCI-MS mlz: 434.5 [MH+].
Example 11.75 1-Butyl-3-(3-c~anophenyl)-N-f (5-methylisoxazol-3-yl)methyll-2,4-zo dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 408.4 [MH+].
Example 11.76 1-Butyl-3-(3-cyanophenyl)-2,4-dioxo-N-f4-(1H-pyrazol-1-yl)benzyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide as APCI-MS m/z: 469.5 [MH+].
Example 11.77 1-Butyl-3-(3-cyanophenyl)-2,4-dioxo-N-f3-(2-oxop~rrolidin-1-yl)propyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 438.4 [MH+].

Examples 11.78 to 11.97 were prepared from 1-butyl-3-(3-(trifluoromethyl)phenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid and the appropriate amine using the general procedure described in Example 11:
Example 11.78 1-Butyl-N-(4-chlorobenzyl)-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide y APCI-MS m/z: 480.4, 482.4 [MH+]
Example 11.79 1-Butyl-N-(4-methox, b~~)-2,4-dioxo-3-f3-io (trifluorometh~)phenyll-1,2,3,4-tetrah~~yrimidine-5-carboxamide APCI-MS m/z: 476.5 [MH+].
Example 11.80 1-Butyl-2,4-dioxo-N-(~yridin-4-ylmethyl)-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydro~yrimidine-5-carboxamide is APCI-MS m/z: 447.4 [MH+].
Example 11.81 1-Butyl-N-f2-(3,4-dimethoxyphen. l~)ethyll-2,4-dioxo-3-f3-~trifluoromethyl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 520.4 [MH+].
Example 11.82 1-Butyl-N-f2-(3-methoxxphen, l~yll-2,4-dioxo-3-f3-~trifluoromethxl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 490.4 [MH+].
zs Example 11.83 N-(3-Bromobenzyl)-1-butyl-2,4-dioxo-3-f3-(trifluoromethXl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 524.4, 526.5 [MH+].
Example 11.84 N-(4-Bromobenzyl)-1-butyl-2,4-dioxo-3-f3-so (trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 524.4, 526.5 [MH+]
Example 11.85 1-Butyl-N-(4-methylbenzyl)-2,4-dioxo-3-~3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide s APCI-MS m/z: 460.4 [MH+].
Example 11.86 1-Butyl-N-f4-(methylsulfonyl)benzyll-2,4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 524.5 [MH+].
io Example 11.87 1-Butyl-N-(4-fluorobenzyl)-2,4-dioxo-3-f3-(trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 464.4 [MH+].
is Example 11.88 N-(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2 4-dioxo-3-~3-(trifluoromethyl)phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 490.5 [MH+].
Example 11.89 1-Butyl-N-(2,4-dichlorobenzyl)-2 4-dioxo-3- f 3-ao (trifluorometh~phenyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS m/z: 514.4, 516.4 [MH+].
Example 11.90 1-Butyl-N-(3,4-difluorobenzyl)-2,4-dioxo-3-f3-trifluorometh~phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide as APCI-MS m/z: 482.5 [MH+].
Example 11.91 1-Butyl-N-(2-chloro-4-fluorobenzyl)-2 4-dioxo-3-f3-(trifluorometh~phenyll-1,2 3 4-tetra~dropyrimidine-5-carboxamide APCI-MS m/z: 498.4, 500.4 [MH+].

Example 11.92 1-Butyl-N-(3,4-dichlorobenzyl)-2 4-dioxo-3-f3-trifluoromethyl)phenyll-1,2,3,4-tetrah~o~pyrimidine-5-carboxamide APCI-MS m/z: 514.4, 516.4 [MH+].
Example 11.93 1-Butyl-N-(2,3-dihydro-1-benzofuran-5-ylmethyl)-2 4-dioxo-3-f3-(trifluoromethyl)phenyll-1,2,3,4-tetrah~vrimidine-5-carboxamide APCI-MS mlz: 486.5 [MH+].
Example 11.94 1-Butyl-N-f(4-cyanoc clohex 1)methyll-2 4-dioxo-3-f3-io (trifluorometh~phenyll-1,2,3,4-tetrah~pyrimidine-5-carboxamide APCI-MS m/z: 477.5 [MH+].
Example 11.95 1-Butyl-N-f(5-methylisoxazol-3-yl)methyll-2,4-dioxo-3-f3-(trifluorometh~ henyll-1,2,3,4-tetrah~dropyrimidine-5-carboxamide is APCI-MS m/z: 451.3 [MIi+]
Example 11.96 1-Butyl-2,4-dioxo-N-f4-(1H-pyrazol-1- 1)benz 1~3-~rifluoromethyl) henyll-1,2,3,4-tetrahydro~yrimidine-5-carboxamide APCI-MS m/z: 512.5 [MH+].
ao Example 11.97 1-Butyl-2,4-dioxo-N-(3-(2-oxopyrrolidin-l~l~ro~yll-3-f3-(trifluoromethyl~ henyll-1,2,3,4-tetrahydropyrimidine-5-carboxamide APCI-MS mlz: 481.4 [MH+].
zs Example 12 6-(Chloromethyl)-N-f4-(meth~sulfonyl)benzyll-2-oxo-1-f3-(trifluoromethyl) henyll-1,2-dihydropyridine-3-carboxamide The title compound was prepared by heating 6-(hydroxymethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (48 mg, 0.1 mmol) and an excess of thionyl chloride (1 ml) in CH2C12 (10 ml) for 1 h. Removal of the solvents afforded the product (50 mg, 100%) as a white solid after trituration from diethyl ether.
1H-NMR (DMSO-d6): 8 9.93 (1H, brt); 8.67 (1H, d); 7.88 (2H, d); 7.86 (1H, d);
7.76 (1H, t); 7.61 (1H, s); 7.54 (1H, d); 7.52 (2H, d); 6.75 (1H, d); 4.68 (2H, m); 4.12 (2H, s); 3.02 s (3H, s).
APCI-MS m/z: 499 [MH+].
Example 13 N-f4-(Methulsulfonyl)benzyll-6-f(methylthio)methyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide io The title compound was prepared by stirring 6-(chloromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (40 mg, 0.08 mmol) with an excess of sodium methylthiolate (28 mg, 0.4 mmol) in NMP (10 ml) at room temperature overnight. Water was added and the reaction mixture was extracted with EtOAc. The crude product was purified by column is chromatography on silica using EtOAc/heptane (4:1) as eluent to afford 15 mg (37%) of .
the title compound.
1H-NMR (CDC13): 8 9.97 (1H, brt); 8.63 (1H, d); 7.88 (2H, d); 7.81 (1H, d);
7.73 (1H, t);
7.62 (1H, s); 7.53 (3H, m); 6.51 (1H, d); 4.67 (2H, m); 3.26 (2H, d); 3.02 (3H, s); 2.03 (3H, s).
ao APCI-MS m/z: 511 [MH+]
Example 14 N-f4-(Meth lsy ulfonyl)benzyll-6-(~ f4-(methylsulfonyl)benzyllaminolmethyl)-2-oxo-1-f3-(trifluorometh~)phen 1 dih~pyridine-3-carboxamide as The title compound was prepared by stirring 6-(chloromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide with an excess of 4-(methylsulfonyl) benzylamine hydrochloride and DIEA
in NMP at room temperature overnight. The crude product was purified by preparative HPLC.
so APCI-MS m/z: 648 [MH+].

Example 15 N-f4-(Meth,~lsulfon 1)~~rll-6-(morpholin-4-ylmethyl)-2-oxo-1-f 3-(trifluorometh~)phenyll-1,2-dihXdro~yridine-3-carboxamide The title compound was prepared by stirring 6-(chloromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide with an excess of morpholine in THF at 50 °C overnight. The crude product was purified by preparative HPLC.
APCI-MS m/z: 550 [MH+].
io Example 16 6-(Cyanomethyl)-N-f4-(methylsulfonyl)benzyll-2-oxo-1-~3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide The title compound was prepared by stirring 6-(chloromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide with an excess of sodium cyanide in THF at 50 °C overnight.
The crude is product was purified by preparative HPLC.
APCI-MS m/z: 490 [MH+].
Example 17 6-Isopropyl-N-f4-(methylsulfon 1)benzyll-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~opyridine-3-carboxamide ao a) 6-Isopropyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxylic acid A mixture of ethyl 3-oxo-3-{ [3-(trifluoromethyl)phenyl]amino }propanoate (5.5 g, 20 mmol), 1-methoxy-4-methylpent-1-en-3-one (prepared using the method of S.M.
as Bromidge et al, Synth. Conamun., 23(4), 487-494 (1993) (2.7 g, 21 mmol) and sodium methoxide (2 g, 40 mmol) in ethanol (50 ml) was heated to reflux for 5 h and then cooled.
Water (50 ml) and 2M NaOH were added and the mixture stirred at room temperature overnight. The organic solvents were removed and the reaction mixture extracted with EtOAc. The aqueous phases were acidified with 0.5M citric acid to pH 3-4, the precipitate formed was filtered off, washed with water and dried to afford 0.4 g (6%) of the title compound as a brownish powder.
1H-NMR (CDCl3): 8 13.74 (1H, s); 8.59 (1H, d); 7.87 (1H, d); 7.78 (1H, t);
7.54 (1H, brs); 7.48 (1H, d); 6.64 (1H, d); 2.54 (1H, m); 1.20 (6H, t).
s APCI-MS mlz: 326 [MH+].
b) 6-Isopropyl-N-f4-(methylsulfon 1)~yll-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydro~yridine-3-carboxamide To a mixture of 6-isopropyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (98 mg, 0.3 mmol), HATU (126 mg, 0,33 mmol), HOAT (45 mg, 0,33 io mmol) and DIEA (162 ~.1, 0.95 mmol) in NMP (3 ml) was added 4-(methylsulfonyl) benzylamine hydrochloride (69 mg, 0.31 mmol), the pH was adjusted to approx.
pH 8-9 with DIEA.
The mixture was stirred for 1 h at room temperature. EtOAc was added and the organic phase washed twice with aqueous sodium hydrogen carbonate, 0.5M citric acid and water is The solvent was removed in vacuo and the residue was purified by column chromatography on silica using CHZCl2/EtOAc (4:1) as eluent to afford the title compound in quantitative yield.
1H-NMR (CDC13): S 9.99 (1H, brt); 8.65 (1H, d); 7.87 (2H, d); 7.82 (1H, d);
7.74 (1H, t);
7.51 (3H, m); 7.44 (1H, d); 6.54 (1H, d); 4.67 (2H, m); 3.01 (3H, s); 2.49 (1H, m); 1.17 ao (6H, t).
APCI-MS m/z: 493 [MH+].
Example 18 N-f4-(Ethylsulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~opyridine-3-carboxamide is a) tent-Butyl f4-(methylsulfonxl)benzyllcarbamate To a solution of [4-(methylsulfonyl)benzyl]amine (600 mg, 2.7 mmol) in THF (9 ml), di-tert-butyldicarbonate (590 mg, 2.7 mmol) and DIEA (926 ~,1, 5.4 mmol) were added and the mixture was stirred overnight. After removal of the solvent the crude product was 3o purified by flash chromatography to give the subtitle compound (650 mg, 84 %).

1H-NMR (CDC13): 8 7.91 (2H, d); 7.49 (2H, d); 5.00 (1H, bs); 4.42 (2H, d);
3.05 (3H, s);
1.48 (9H, s).
APCI-MS m/z: 169.1, 186.1 [MH+].
b) tert-Butyl f4-(ethylsulfon,~l)benz~rllcarbamate s To a solution of tert-butyl [4-(methylsulfonyl)benzyl]carbamate (400 mg, 1.4 mmol) in THF (5 ml) at -72 °C, n-butyl lithium (1750 p,l, 2.8 mmol) was added dropwise while maintaining the temperature at -70 °C. After addition the temperature was allowed to rise to -40 °C and methyl iodide (105 ~,1, 1.7 mmol) added. The mixture was stirred for 1 h, an aqueous solution of NH4Cl was added and then the mixture was extracted with EtOAc.
io The organic layer was washed with NH4C1 solution and evaporated. The crude product was purified by preparative HPLC to give the subtitle compound (148 mg, 35%).
1H-NMR (CDC13): 8 7.88 (2H, d); 7.49 (2H, d); 4.98 (1H, bs); 4.43 (2H, bs);
3.11 (2H, q);
1.48 (9H, s); 1.28 (3H, t).
APCI-MS m/z: 183.2, 200.2 [MH+].
is c) f4-(Ethylsulfon,1)~yllamine trifluoroacetate Tert-butyl [4-(ethylsulfonyl)benzyl]carbamate (148 mg, 0.5 mmol) was stirred in 10%
TFA in CH2Cl2 for 3 h. The solvent was evaporated leaving the title compound (191 mg).
APCI-MS m/z: 200.1 [MH+].
d) N-f4-CEthylsulfon 1)~;rll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1 ao dih~pyridine-3-carboxamide The title compound was obtained from 4-(ethylsulfonyl)benzylamine trifluoroacetate and 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid using a procedure analogous to that described in Example 17.
1H-NMR (CDC13): 8 9.98 (1H, t); 8.59 (1H, d); 7.84-7.81 (3H, m); 7.74 (1H, t);
7.52-7.50 zs (3H, m); 7.45 (1H, d); 6.48 (1H, d); 4.74-4.63 (2H, m); 3.08 (2H, q); 2.09 (3H, t); 1.26 (3H, t).
APCI-MS m/z: 479.3 [MH+].
Example 19 N-f3-Chloro-4-(meth~sulfon,1)~yll-6-methyl-2-oxo-1-f3-30 (trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide a) 3-Chloro-4-(methylthio)benzaldehyde To a stirred solution of 2-chlorothioanisole (1.25 ml, 9.5 mmol) in CH2C12 at -5 °C, titanium(IV) chloride (2076 ~,1, 18.9 mmol) was added dropwise over 10 min, while s ~ maintaining the temperature below 0 °C . After addition the mixture was stirred for 10 min before a,a-dichloromethyl methyl ether (0.94 ml, 10.4 mmol) was added dropwise maintaining the temperature below 0 °C. After addition, the mixture was allowed to reach ambient temperature and poured onto a saturated aqueous solution of sodium bicarbonate (70 ml). The mixture was filtered through a plug of celite, washing with CHZClz. The io phases were separated and the aqueous phase was extracted with CH2C12. The combined organic phases were washed with brine and the solvent removed in vacuo. The crude product was purified by flash chromatography to yield the subtitle product (535 mg, 30%).
1H-NMR (CDC13): 8 9.91 (1H, s); 7.84 (1H, d); 7.75 (1H, dd); 7.27 (1H, d);
2.56 (3H, s).
is APCI-MS m/z: 187.1 [MH+].
b) f3-Chloro-4-(meth. lt~phenyllmethanol To a solution of 3-chloro-4-(methylthio)benzaldehyde (332 mg, 1.8 mmol) in THF
(6 ml) and water (0.6 ml), NaBH4 (269 mg, 7.1 mmol) was added . The mixture was stirred for 2 h. The reaction was quenched with 1M aqueous HCl and EtOAc was added. After ao separating the phases, the organic layer was washed with water, dried and evaporated to afford the subtitle compound (350 mg, 91%).
1H-NMR (CDC13): 8 7.39 (1H, d); 7.26 (1H, dd); 7.17 (1H, d); 4.66 (2H, s);
2.49 (3H, s).
APCI-MS m/z: 170.9 [MH+].
c) f3-Chloro-4-(methylsulfon~phenyllmethanol zs [3-Chloro-4-(methylthio)phenyl]methanol (350 mg, 1.9 mmol) was dissolved in aqueous sodium hydroxide (0.5M, 4.44 ml) and stirred for 20 min, sodium bicarbonate (1.23 g) and acetone (1.5 ml) were added followed by addition of Oxone~ (1.85 g, 3.0 mmol) in EDTA (6.5 ml, 0.4 mM). After stirnng for 2 h the reaction was quenched by addition of sodium bisulphite (0.9 g) in water. EtOAc was added and the solution was acidified with so aqueous 2M HCI. Sodium chloride was added to the aqueous which was then extracted with EtOAc. The organic layers were combined and washed with water, brine and dried.
Evaporation afforded the subtitle compound as a white solid (359 mg, 88%).
1H-NMR (CDCl3): 8 8.12 (1H, d); 7.60 (1H, d); 7.44 (1H, dd); 4.81 (2H, s);
3.27 (3H, s).
d) 4-(Bromomethyl)-2-chloro-1-(methylsulfonyl)benzene s [3-Chloro-4-(methylsulfonyl)phenyl]methanol (239 mg, 1.1 mmol) was added to dioxane.
The slurry was stirred and heated to 40 °C before addition of PBr3 (71 ~ul, 0.8 mmol). The reaction was heated to 100 °C for 1 h and then allowed to cool. Water was added and the mixture extracted with EtOAc. The organic layer was washed with water followed by brine and dried. Evaporation afforded the subtitle compound (310 mg, 100%).
io 1H-NMR (CDCl3): ~ 8.14 (1H, d); 7.61 (1H, d); 7.49 (1H, dd); 4.46 (2H, s);
3.28 (3H, s).
e) f3-Chloro-4-(methylsulfonyl)benzyllamine 4-(Bromomethyl)-2-chloro-1-(methylsulfonyl)benzene (160 mg, 0.56 mmol) was dissolved in methanol (3 ml) and added to an equal mixture of ammonia (28%) and methanol (10 ml). The reaction was stirred at 40 °C for 1 h and evaporated. The crude is product was dissolved in EtOAc and aqueous 6M sulphuric acid. The aqueous phase was separated, adjusted to pH 14 using sodium hydroxide and extracted with CH2C12.
The CH2Cl2 phase was dried and evaporated to afford the title compound (65 mg, 53%).
APCI-MS m/z: 219.9 [MH+].
f) N-f3-Chloro-4-(meth~sulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluorometh~)phenyll-ao 1,2-dih,~~yridine-3-carboxamide The title compound was prepared as described in Example 17. ' 1H-NMR (CDC13): 8 10.03 (1H, t); 8.58 (1H, d); 8.07 (1H, d); 7.82 (1H, d);
7.75 (1H, t);
7.52 (2H, d); 7.45 (1H, d); 7.41 (1H, d); 6.49 (1H, d); 4.69-4.57 (2H, m);
3.23 (3H, s);
2.10 (3H, s).
as APCI-MS m/z: 499.0 [MH+].
Example 20 6-Methyl-2-oxo-1-(3-trifluoromethyl-phenyl)-1,2-dihydro-pyridine-3-carboxylic acid 4-~clopropanesulfon.1-Benz, lamide so a) 4-C~clopropanesulfonyl-benzylamine 1-Cyclopropanesulfonyl-4-methyl-benzene, prepared by the method of W. E.
Truce, et al, J. Org. Chern., 1961, 26, 1463-1467, (190 mg, 0.969 mmol), N-bromosuccinimide (190 mg, 1.07 mmol) and benzoyl peroxide (12 mg) in carbon tetrachloride (4 ml) were heated under reflux for 24 h, cooled, filtered and concentrated. The residue in methanol (1 ml) s was added in portions during 10 min to a solution of ammonium hydroxide (28 %, 2 ml) in methanol (2 ml). After 2 h the solution was partitioned between EtOAc (10 ml) and sulphuric acid (0.4M, 10 ml), the pH of the aqueous layer was adjusted to 14 using 2M
aqueous KOH and then extracted three times with dichloromethane. The organic phase was dried and concentrated to give the subtitle compound (83 mg).
l0 1H-NMR (CDC13): 8 7.78 (2H, bd); 7.35 (2H, bd); 2.46 (3H, s); 2.46 (1H, m);
1.34 (2H, m); 1.02 (2H, m).
APCI-MS m/z: 212 [MH+].
The corresponding dibenzyl amine (12%) is also present.
b) 6-Methyl-2-oxo-1-(3-trifluoromethyl-phenyl)-1,2-dihydro-p~rridine-3-carboxylic acid is 4-cyclopropanesulfonyl-Benz l The title compound was obtained from 4-cyclopropanesulfonyl-benzylamine and 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid by a method analogous to that described in Example 17.
1H-NMR (CDC13): 8 9.93 (1H, brt); 8.38 (1H, d); 7.89 (2H, bd); 7.84-7.80 (3H, m); 7.73 zo (1H, bd); 7.53 (2H, d); 6.26 (1H, d); 4.58 (2H, d); 2.80 (1H, m); 2.02 (3H, s); 1.08 (2H, m); 1.01 (2H, m).
APCI-MS m/z: 491.1 [MH+].
Example 21 N-f3-Methoxy-4-(methylsulfonyl)benzyll-6-methyl-2-oxo-1-f3-zs (trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide a) f3-Methoxy-4-(methylsulfonyl)phenyllmethanol [3-Methoxy-4-(methylthio)phenyl]methanol, prepared as described by Garcia et al.
Suprarnolecular Chemistry, 1992, 1, 31-45, (75 mg, 0.4 mmol) was dissolved in aqueous so sodium hydroxide (0.5M, 1.22 ml) and stirred for 30 min. Further reaction as in Example 19 (c) gave, after trituation with toluene, the subtitle compound as white crystals (47 mg, 54%).
1H-NMR (CDCl3): ~ 7.97 (d, J 8.0 Hz, 1H); 7.15 (s, 1H); 7.08 (d, J 8.0 Hz, 1H); 4.81 (d, J
5.4 Hz, 2H); 4.04 (s, 3H); 3.32 (s, 3H).
s APCI-MS m/z: 217 [MH+].
b) 4-(Bromometh~)-2-methoxy-1-(methylsulfonyl)benzene To a slurry of [3-methoxy-4-(methylsulfonyl)phenyl]methanol (69 mg, 0.32 mmol) and toluene at 40 °C was added PBr3 (30 ~,1, 0.32 mmol). The reaction was heated to 100 °C
for 1 h, cooled and water added. The reaction mixture was diluted with EtOAc, washed io with water and brine and dried. Evaporation afforded the subtitle compound as a pale yellow oil (62 mg, 69%).
1H-NMR (CDCl3): 8 7.97 (d, J 8.0 Hz, 1H); 7.14 (dd, J 8.0, 1.4 Hz, 1H); 7.10 (d, J 1.2 Hz, 1H); 4.50 (s, 2H); 4.05 (s, 3H); 3.24 (s, 3H).
APCI-MS m/z: 280 [MH+].
is c) 3-Methoxy-4-(methylsulfonyl)benz,1 4-(Bromomethyl)-2-methoxy-1-(methylsulfonyl)benzene (62 mg, 0.22 mmol) in methanol was slowly added to an equal mixture of ammonia (28%) and methanol.
The reaction was stirred at room temperature for 2 h and evaporated. The reaction mixture was partitioned was between EtOAc and aqueous 6M sulphuric acid. The aqueous phase was ao made alkaline with sodium hydroxide and extracted with CHZCl2. The CH2C12 phase was dried and evaporated to afford the title compound (36 mg, 76%).
APCI-MS m/z: 216 [MH+].
d) N-f3-Methoxy-4-(methylsulfon 1)~yll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide as The title compound was obtained from 3-methoxy-4-(methylsulfonyl)benzylamine and 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid by a method analogous to that described in Example 17.
1H-NMR (CDC13): 8 10.03 (s, 1H); 8.60 (d, J 7.5 Hz, 1H); 7.91 (d, J 8.1 Hz, 1H); 7.83 (d, J 8.3 Hz, 1H); 7.76 (t, J 7.8 Hz, 1H); 7.54 (d, J 4.7 Hz, 1H); 7.46 (d, J 7.2 Hz, 1H); 6.50 (d, J 7.2 Hz, 1H); 7.05 (td, J 7.9, 5.3 Hz, 2H); 4.64 (t, J 6.3 Hz, 2H); 3.98 (s, 3H); 3.19 (s, 3H); 2.11 (s, 3H).
APCI-MS m/z: 495 [MH+].
Example 22 N-f3-Bromo-4-(methylsulfon.1)b~enzfyll-6-methyl-2-oxo-1-f3-~trifluorometh~phenyll-1,2-dih~dropyridine-3-carboxamide a) 3-Bromo-4-(methylthio)benzaldehyde To a solution of 3-bromo-4-fluorobenzaldehyde (0.5 g, 2.5 mmol) in NMP (10 ml), io potassium carbonate (0.68 g, 4.92 mmol) and sodium metanethiolate (0.26 g, 3.69 mmol) were added. The mixture was heated to 70 °C for 7 h, cooled, and partitioned between EtOAc and water. The organic phase was dried, filtered, evaporated and purified by column chromatography on silica using heptane/EtOAc (4:1) as eluent to afford the title compound (0.25 g, 44%).
is 1H-NMR (CDCl3): b 9.89 (1H, s); 8.00 (1H, d); 7.79 (1H, dd); 7.23 (1H, d);
2.54 (3H; s).
APCI-MS mlz: 465.3 [MHO].
b) f 3-Bromo-4-(meth lt~phenyllmethanol To a solution of 3-bromo-4-(methylthio)benzaldehyde (0.25 g, 1.08 mmol) in methanol (15 ml) was added sodium borohydride (0.2 g, 5.4 mmol). The solution was stirred at ao room temperature for 4 h, water was added, and the mixture was extracted with CH2C12.
The organic layer was dried, filtered and evaporated to give 0.24 g (95%) of the title compound.
1H-NMR (CDC13): 8 7.55 (1H, d); 7.29 (1H, dd); 7.12 (1H, d); 4.64 (2H, s);
2.48 (3H, s).
c) L3-Bromo-4-(methylsulfon~phenyllmethanol as A suspension of sodium hydroxide (2.5 ml, 1.25 mmol) and [3-bromo-4-(methylthio)phenyl]methanol (0.24 g, 1.03 mmol) was stirred at ambient temperature for 20 min, then sodium bicarbonate (0.69 g, 8.2 mmol) and acetone (1 ml) were added, followed by a Oxone~ solution (1.6 g in 6 ml of 0.4 mM EDTA) added over 10 min. The suspension was stirred overnight at room temperature. EtOAc was added and the solution so was acidified with 5M HCl. The organic phase was washed several times with water and then dried, filtered and evaporated to give the title compound 0.19 g (70%).
APCI-MS m/z: 249.1, 251 [MH+].
d) 2-Bromo-4-(bromomethyl)-1-(methylsulfonyl)benzene [3-Bromo-4-(methylsulfonyl)phenyl]methanol (0.19 g, 0.72 mmol) was mixed with s toluene (5 ml) and phosphorus tribromide (30 ~,1, 0.32 mmol) at 40 °C, and the mixture was stirred at 100 °C for 20 min. EtOAc (100 ml) was added to the cooled solution and then washed with water. The organic phase was dried, filtered and evaporated to give 0.23 g (97%) of the title compound.
1H-NMR (DMSO-d4): 8 8.06 (1H, d); 8.02 (1H, d); 7.73 (1H, dd); 4.76 (2H, s);
3.38 (3H, io s).
e) f3-Bromo-4-(methylsulfonyl)benzyllamine A solution of 2-bromo-4-(bromomethyl)-1-(methylsulfonyl)benzene (230 mg, 0.70 mmol) in methanol (3 ml) and THF (1 ml) was added to NH40H (7 ml, 28%) during 30 min.
After 4 h the solution was acidified with 0.5M HCI, washed twice with CH2Clz and then is basified to pH 14 with 5M sodium hydroxide. The water phase was extracted with ' CHzCIz, and the organic layer was dried, filtered and evaporated to give 80 mg (43%) of the title compound.
1H-NMR (DMSO-d6): 8 7.99 (1H, d); 7.89 (1H, d); 7.58 (1H, dd); 3.79 (2H, s);
3.31 (3H, s). a zo APCI-MS m/z: 264, 266 [MH+].
f) N-f3-Bromo-4-(methylsulfon l)~yll-6-methyl-2-oxo-1-f3-(trifluorometh~phen 1,2-dihydropyridine-3-carboxamide The title compound was obtained from [3-bromo-4-(methylsulfonyl)benzyl]amine and 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid by a method zs analogous to that described in Example 17.
1H-NMR (DMSO-d6): b 9.94 (1H, t); 8.37 (1H, d); 8.02 (1H, d); 7.93-7.68 (5H, m); 7.54 (1H, d); 6.61 (1H, d); 4.55 (2H, d); 3.33 (3H, s).
APCI-MS m/z: 543.2, 545.2 [MH+].

Example 23 N-f 3-Cyano-4-(methylsulfon 1)benzyll-6-methyl-2-oxo-1- f 3-(trifluoromethyl)-phenyll-1,2-dihydrop~ridine-3-carboxarnide a) 5-Formyl-2-~meth~thio)benzonitrile s The subtitle compound was prepared analogously to Example 22a but at room temperature for 1 h instead of heating the reaction mixture.
1H-NMR (400 MHz, CDC13): 8 9.94 (1H, s); 8.07 (1H, d, J 1.7 Hz); 8.01 (1H, dd, J 8.3, 1.8 Hz); 7.40 (1H, d, J 8.3 Hz); 2.64 (3H, s).
GC-MS m/z: 177 [M+].
io b~ 5-(H~drox methyl)-2-(methylthio)benzonitrile The subtitle compound was prepared analogously to Example 22b.
1H-NMR (400 MHz, CDC13): 8 7.62 (1H, s); 7.53 (1H, d, J 8.3 Hz); 7.32 (1H; d, J 8.3 Hz); 4.70 (2H, s); 2.57 (3H, s).
c2 5-(H droxymeth~)-2-(methylsulfon~)benzonitrile is The subtitle compound was prepared analogously to Example 22c.
1H-NMR (400 MHz, CDC13): ~ 8.17 (1H, d, J 8.1 Hz); 7.93 (1H, s); 7.79 (1H, d, J 8.2 Hz); 4.88 (2H, s); 3.27 (3H, s).
d) 5-(Bromomethyl)-2-(methylsulfonyl)benzonitrile The subtitle compound was prepared analogously to Example 22d.
ao 1H-NMR (400 MHz, CDCl3): 8 8.18 (1H, d, J 8.1 Hz); 7.93 (1H, d, J 1.7 Hz);
7.82 (1H, dd, J 8.2, 1.6 Hz); 4.51 (2H, s); 3.29 (3H, s).
e) 5-(Aminomethyl)-2-(methylsulfonyl)benzonitrile The subtitle compound was prepared analogously to Example 22e.
1H-NMR (400 MHz, CD30D): b 8.14 (1H, d, J 8.2 Hz); 8.04 (1H, s); 7.88 (1H, d, J 8.1 as Hz); 3.97 (2H, s); 3.29 (3H, s) APCI-MS m/z: 211 [MH+].
f) N-f3-Cyano-4-(methylsulfon 1)benzyll-6-metal-2-oxo-1-f3-(trifluoromethyl)phen 1,2-dihydropyridine-3-carboxamide The title compound was prepared analogously to Example 17.

1H-NMR (400 MHz, CDC13): 8 10.19 (1H, t, J 5.7 Hz); 8.56 (1H, d, J7.4 Hz);
8.11 (1H, d, J 8.1 Hz); 7.85 - 7.71 (4H, m); 7.53 (1H, s); 7.46 (1H, d, J B.OHz); 6.51 (1H, d, J 7.5 Hz); 4.71 (1H, dd, J 15.9, 6.2 Hz); 4.65 (1H, dd, J 15.9, 6.0 Hz); 3.23 (3H, s); 2.11 (3H, s).
s APCI-MS m/z: 490 [MH+].
Example 24 6-Methyl-N-f3-methyl-4-(rnethylsulfonyl)benzyll-2-oxo-1-f3-(trifluoromethyl)-phenyll-1,2-dih~~~rridine-3-carboxamide io a) 3-Methyl-4-(methylthio)benzaldehyde The subtitle compound was prepared analogously to Example 22a.
GC-MS m/z: 166 [M+].
b) f3-Methyl-4-(meth, lt~phenyllmethanol The subtitle compound was prepared analogously to Example 22b.
is 1H-NMR (300 MHz, CDCl3): 8 7.18 - 7.09 (3H, m); 4.57 (2H, s); 2.44 (3H, s);
2.32 (3H, s).
c) f 3-Methyl-4-(methylsulfonyl)phenyllmethanol The subtitle compound was prepared analogously to Example 22c.
1H-NMR (300 MHz, CDCl3): 8 7.92 (1H, d, J 18.7 Hz); 7.35 - 7.29 (2H, m); 4.73 (2H, s);
ao 3.05 (3H, s); 2.66 (3H, s).
d) 4-(Bromomethyl)-2-methyl-1-(meth ls~yl)benzene The subtitle compound was prepared analogously to Example 22d.
1H-NMR (300 MHz, CDC13): 8 8.00 (1H, d, J 8.1 Hz); 7.42 - 7.28 (2H, m); 4.46 (2H, s);
3.07 (3H, s); 2.70 (3H, s).
is e) f3-Methyl-4-(methylsulfon 1)benzyllamine The subtitle compound was prepared analogously to Example 22e.
1H-NMR (400 MHz, CDC13): 8 7.98 (1H, d, J 8.2 Hz); 7.35 - 7.29 (2H, m); 3.93 (2H, s);
3.06 (3H, s); 2.70 (3H, s).
APCI-MS m/z: 200 [MH+].

f~ 6-Methyl-N-f3-methyl-4-(methylsulfonyl)benzyll-2-oxo-1-f3-(trifluoromethyl) phenyll-1,2-dihydro~yridine-3-carboxamide The title compound was prepared analogously to Example 17.
1H-NMR (300 MHz, CDCl3): 8 9.91 (1H, bt, J 5.7Hz); 8.58 (1H, d, J 7.5 Hz);
7.95 (1H, d, J 8.lHz); 7.83 - 7.27 (6H, m); 6.47 (1H, dd, J 7.5, 0.5 Hz); 4.68 - 4.53 (2H, m); 3.03 (3H, s); 2.66 (3H, s); 2.08 (3H, s).
APCI-MS m/z: 479 [MH+].
Example 25 6-Methyl-N-f4-(methylthio)benzyll-2-oxo-1-f3-io (trifluoromethyl)phenyll-12-dih~pyridine-3-carboxamide 6-Methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (1.29 g, 4.35 mmol) and [4-(methylthio)benzyl]amine (0.66 g, 4.35 mmol) were dissolved in NMP (18 ml). HBTU (1.81 g, 4.79 mmol) and DIEA (1.86 ml, 10.9 mmol) were added neat at room temperature and the mixture was stirred overnight. The reaction mixture was is poured into EtOAc. The organic phase was washed with 2.5% aqueous sodium carbonate, then three times with water and dried. Purification by flash-chromatography (EtOAc:
cyclohexane 9:1) gave the title compound (1.3 g, 69%).
1H-NMR (400 MHz, DMSO-d6) 8 9.78 (1H, t, J 5.8 Hz); 8.38 (1H, d, J 7.4 Hz);
7.91 7.69 (4H, m,); 7.22 (4H, m); 6.62 (1H, d, J 7.6 Hz); 4.42 (2H, d, J 5.9 Hz);
2.43 (3H, s,);
zo 2.01 (3H, s).
APCI-MS m/z: 433.1 [MH+]
Example 26 6-Methyl-N-f4-(meth lsulfinyl)benzyll-2-oxo-1-f3-(trifluoromethyl)phenyll-1_ 2-dih~pyridine-3-carboxamide zs 6-Methyl-N-[4-(methylthio)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (1.26 g, 2.93 mmol) was dissolved in CH2Clz (12 ml).
The solution was cooled to -15 °C. To the stirred solution 3-chloroperoxybenzoic acid (672 mg, 2.93 mmol) was added portion wise. The reaction was stirred for 1 h.
The cooling bath was removed and the reaction was allowed to reach room temperature. After 30 2 h, CHzClz and diluted sodium thiosulphate solution were added. The mixture was shaken and the water phase was separated. The organic layer was washed twice with saturated NaHC03, once with brine and finally dried. Purification by flash-chromatography (EtOAc: MeOH 9:1) gave the title compound (1.1 g, 80%).
1H-NMR (400 MHz, DMSO-d6) 8 9.88 (1H, t, J 5.9 Hz); 8.38 (1H, d, J7.5 Hz);
7.93 -7.69 (4H, m,); 7.62 (2H, d, J 8.2 Hz); 7.47 (2H, d, J 8.2 Hz); 6.62 (1H, d, J
7.7 Hz); 4.54 (2H, d, J 6.0 Hz); 2.70 (3H, s,); 2.02 (3H, s,).
APCI-MS m/z: 449.1 [MH+].
Example 27 N-f4-(Benzylsulfon.1)~benzyll-6-methyl-2-oxo-1-f3-io (trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide a) N-(4-Mercaptobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen l dih,~pyridine-3-carboxamide 6-Methyl-N-[4-(methylsulfinyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-is dihydropyridine-3-carboxamide (0.30 g, 0.67 mmol) was dissolved in dry acetonitrile (3 ml) and 2,6-lutidine (0.24 ml, 2.08 mmol) was added. The solution was cooled to -20 °C
and trifluoroacetic anhydride (0.28 ml, 2.0 mmol) was added . The reaction was kept between -10 °C and 0 °C for 1 h, and then allowed to reach room temperature. All volatile materials were evaporated at 30 °C. The crude residue was cooled to 0 °C. A
ao degassed, dry 1:1 mixture of triethylaxnine (1.1 ml) and methanol (1.1 ml), cooled to 0 °C, was added. The reaction was stirred at room temperature for 30 min and then evaporated.
The residue was dissolved in a l:l mixture of methanol and 6M hydrochloric acid and stirred at 50 °C for 20 min. The major part of the solvent was evaporated. Ethyl acetate and water were added. The water phase was separated and washed again with ethyl as acetate. The combined organic phase was washed with brine, dried, evaporated and used as crude product in the next step.
LC-MS; method B RT: 8.19 min, APCI-MS m/z: 419.3 [MH+].
b) N-f4-(Ben~lsulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen l 3o dih~pyridine-3-carboxamide In an argon filled vial N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) was dissolved in dried, degassed ethanol (0.1 ml) and cooled to 0 °C. A
solution of potassium tert-butoxide (7.8 mg, 0.7 mmol) in ethanol (0.2 ml) was added. The reaction was stirred s for 45 rnin. (Bromomethyl)benzene (12 ~,1, 0.105 mmol) in ethanol (0.1 ml) was added.
The ice bath was removed and the reaction was stirred overnight. A mixture of ethyl acetate and 1M aqueous NH4C1 was added. The organic layer was separated, dried and evaporated. The residue was dissolved in CH2Cl2 (240 p,l) and cooled with stirnng to -15 °C. 3-Chloroperoxybenzoic acid (35 mg, 0.154 mmol) in CH2Cl2 (200 p,l) was added. The io cooling bath was removed and the reaction was stirred overnight. EtOAc and 5% aqueous sodium thiosulfate were added. The organic layer was separated, washed with 5%
aqueous sodium carbonate, brine and dried. Purification by preparative HPLC
gave the title compound (11 mg, 30%).
1H-NMR (400 MHz, DMSO-d6) b 9.91 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.5 Hz);
7.81 (4H, is m); 7.66 (2H, d, J 8.4 Hz); 7.46 (2H, d, J 8.2 Hz); 7.31 - 7.11 (5H, m,);
6.63 (1H, d, J 7.6 Hz); 4.62 (2H, s,); 4.57 (2H, d, J 6.1 Hz); 2.03 (3H, s,).
APCI-MS mlz: 541.4 [MH+].
Following the general method of Example 27 (b), the compounds of Examples 28 to 33 ao were prepared:
Example 28 6-Methyl-2-oxo-N-f4-(propylsulfon 1)~benzyll-1-~3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-zs dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 1-bromopropane (10 p,l, 0.105 mmol). Yield: 12 mg (35%).
1H-NMR (400 MHz, DMSO-d6) 8 9.93 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.5 Hz);
7.94 -7.70 (6H, m); 7.53 (2H, d, J 8.2 Hz); 6.63 (1H, d, J 7.6 Hz); 4.58 (2H, d, J
6.1 Hz); 3.22 (2H, m); 2.02 (3H, s,); 1.52 (2H, q, J 7.6 Hz); 0.89 (3H, t, J 7.4 Hz).
so APCI-MS m/z: 493.3 [MH+].

Example 29 N-f4-(But lsulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2- , s dihydropyridine-3-carboxamide (29 mg, 0.07 mrnol) and 1-bromobutane (11 pl, 0.105 mmol). Yield: 14 mg, 0.028 mmol (39%).
1H-NMR (400 MHz, DMSO-d6) 8 9.93 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.4 Hz);
7.93 -7.70 (6H, m); 7.53 (2H, d, J 8.3 Hz); 6.63 (1H, d, J 7.7 Hz); 4.59 (2H, d, J
6.1 Hz); 3.24 (2H, m); 2.02 (3H, s,); 1.48 (2H, m); 1.31 (2H, m); 0.81 (3H, t, J 7.3 Hz).
io APCI-MS m/z: 507.3 [MH+]
Example 30 N-f4-(Isobutylsulfon 1)benzyll-6-methyl-2-oxo-1-f3-(trifluorometh,~l)phenyll-1,2-dil~drop~ridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-is dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 1-bromo-2-methylpropane (11 p,l, 0.105 mmol). Yield: 10 mg, 0.020 mmol (28%).
1H-NMR (400 MHz, DMSO-d6) b 9.93 (1H, t, J 6.0 Hz); 8.38 (1H, d, J 7.5 Hz);
7.94 -7.69 (6H, m,); 7.53 (2H, d, J 8.3 Hz); 6.63 (1H, d, J7.7 Hz); 4.58 (2H, d, J
6.2 Hz); 3.16 (2H, d, J 6.5 Hz); 2.02 (3H, s,); 1.96 (1H, quintet, J 6.6 Hz); 0.95 (6H, d, J
6.7 Hz).
zo APCI-MS m/z: 507.3 [MH+]
Example 31 N-f4-(sec-Butylsulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-zs dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-brombutane (11 p,l, 0.105 mmol). Yield: l2 mg, 0.024 mmol (35%).
1H-NMR (400 MHz, DMSO-d~) 8 9.94 (1H, t, J 6.0 Hz); 8.38 (1H, d, J 7.5 Hz);
7.93 -7.69 (6H, m,); 7.53 (2H, d, J 8.2 Hz); 6.63 (1H, d, J 7.8 Hz); 4.59 (2H, d, J
6.1 Hz); 3.17 (1H, dq, J 13.4, 6.7 Hz); 2.02 (3H, s,); 1.77 (1H, m); 1.29 (1H, m); 1.11 (3H, d, J 6.9 Hz);
30 0.89 (3H, t, J 7.5 Hz).

APCI-MS mlz: 507.4 [MH+].
Example 32 N-f4-(Isopropylsulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~~yridine-3-carboxamide s From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-bromopropane (10 ~,1, 0.105 mmol). Yield:ll mg, 0.022 mmol (33%).
1H-NMR (400 MHz, DMSO-d6) 8 9.94 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.4 Hz);
7.94 -7.69 (6H, m,); 7.54 (2H, d, J 8.3 Hz); 6.63 (1H, d, J 7.7 Hz); 4.60 (2H, d, J
6.1 Hz); 3.36 io (1H, septet, J 6.2 Hz); 2.03 (3H, s,); 1.13 (6H, d, J 6.8 Hz).
APCI-MS m/z: 493.3 [MH+]
Example 33 6-Methyl-N-14-f(3-methylbutyl)sulfonyllbenzyl~-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide is From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 1-bromo-3-methylbutane (13 pl, 0.105 mmol). Yield:l l mg, 0.021 mmol (31 %).
1H-NMR (400 MHz, DMSO-d6) 8 9.93 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.4 Hz);
7.94 -7.69 (6H, m,); 7.53 (2H, d, J 8.3 Hz); 6.63 (1H, d, J 7.5 Hz); 4.59 (2H, d, J
6.1 Hz); 3.23 20 (2H, m); 2.02 (3H, s,); 1.57 (1H, septet, J 6.8 Hz); 1.39 (2H, m); 0.80 (6H, d, J 6.6 Hz).
APCI-MS m/z: 521.4 [MH+].
Following the general method of Example 27, the compounds of Examples 34 to 52 were prepared:
Example 34 N-(4-f(C~propylmeth~)sulfonyllbenzyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and (bromomethyl)cyclopropane (10 ~.1, 0.105 mmol). Yield: 13 mg, 0.027 mmol (38%).

1H-NMR (400 MHz, DMSO-ds) 8 9.93 (1H, t, J 6.2 Hz); 8.38 (1H, d, J7.5 Hz);
7.93 -7.70 (6H, m,); 7.53 (2H, d, J 8.3 Hz); 6.63 (1H, d, J 7.6 Hz); 4.59 (2H, d, J
6.1 Hz); 3.21 (2H, d, J 7.2 Hz); 2.02 (3H, s,); 0.80 (1H, m); 0.43 (2H, m); 0.09 (2H, m).
APCI-MS mlz: 505.3 [MH+].
Example 35 6-Methyl-2-oxo-N-f4-f(tetrahydrofuran-2-ylmethyl)sulfonyll-benz~~-1-f 3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-(bromomethyl)tetrahydrofuran io (12 ~.1, 0.105 mmol). Yield: 8 mg, 0.015 mmol (22%).
1H-NMR (400 MHz, DMSO-d6) 8 9.93 (1H, t, J 6.0 Hz); 8.38 (1H, d, J7.5 Hz);
7.93 -7.70 (6H, m,); 7.51 (2H, d, J 8.2 Hz); 6.63 (1H, d, J 7.6 Hz); 4.58 (2H, d, J
6.1 Hz); 4.05 (1H, quintet, J 6.5 Hz); 3.59 (1H, q, J 7.4 Hz); 3.5.0 (3H, m); 2.02 (3H, s,);
1.94 (1H, m);
1.75 (2H, m); 1.54 (1H, m).
is APCI-MS m/z: 535.4 [MH+].
Example 36 N-14-f(2-H~yethyl)sulfon ll~yl~-6-methyl-2-oxo-1-f3-(trifluorometh~)phenyll-1,2-dihydropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-ao dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-bromoethanol (7 ~,1, 0.105 mmol). Yield: 12 mg, 0.025 mmol (36%).
1H-NMR (400 MHz, DMSO-ds) b 9.93 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.4 Hz);
7.93 -7.70 (6H, m,); 7.52 (2H, d, J 8.3 Hz); 6.63 (1H, d, J 7.6 Hz); 4.58 (2H, d, J
6.1 Hz); 3.65 (2H, t, J 6.4 Hz); 3.40 (2H, t, J 6.5 Hz); 2.02 (3H, s,).
zs APCI-MS m/z: 495.3 [MH+]
Example 37 N-~4-f(Cyanomethyl)sulfonyllbenzyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~ropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and chloroacetonitrile (7 ~l, 0.105 mmol). Yield: 8 mg, 0.017 mmol (24%).
1H-NMR (400 MHz, DMSO-d~) 8 9.96 (1H, t, J 6.1 Hz); 8.37 (1H, d, J 7.5 Hz);
7.95 -7.69 (6H, m,); 7.62 (2H, d, J 8.3 Hz); 6.63 (1H, d, J 7.6 Hz); 5.20 (2H, s,);
4.61 (2H, d, J
6.2 Hz); 2.03 (3H, s,).
APCI-MS m/z: 490.3 [MH+].
Example 38 N-14-1(2-Amino-2-oxoethyl)sulfonyllbenzyll-6-methyl-2-oxo-1-io f3-(trifluoromethy~phenyll-1,2-dihydro~yridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-bromoacetamide (14 mg, 0.105 mmol). Yield: 15 mg, 0.029 mmol (41 %).
1H-NMR (400 MHz, DMSO-d6) 8 9.94 (1H, t, J 6.1 Hz); 8.38 (1H, d, J 7.4 Hz);
7.95 -is 7.46 (lOH, m,); 6.62 (1H, d, J 7.6 Hz); 4.58 (2H, d, J 6.0 Hz); 4.18 (2H, s,); 2.02 (3H, s,).
APCI-MS m/z: 508.3 [MH+].
Example 39 N-d4-f(4-Cyanobenzyl)sulfon ll~yll-6-methyl-2-oxo-1-(3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide zo From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 4-(bromomethyl)benzonitrile (21 mg, 0.105 mmol). Yield: 3 mg, 0.004 mmol (6%).
LC-MS; method B RT: 7.80 min, APCI-MS m/z: 566.4 [MH+].
as Example 40 N-(4-f(2-Cyanoethyl)sulfonyllbenzXll-6-methyl-2-oxo-1-f3-(trifluorometh,~l)phenyll-1,2-dihydropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 3-chloropropanenitrile (8 ~1, 0.105 mmol). Yield: 1 mg, 0.002 mrnol (3%).
so LC-MS; method B RT: 7.16 min, APCI-MS m/z: 504.3 [MH+].

Example 41 N-d4-f(3-HydroxyproRyl)sulfonyllbenzyl~-6-methyl-2-oxo-1-(3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide From N-(4-mercaptobenzyl) -6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 3-bromopropan-1-of (9 ~,1, 0.105 mrnol). Yield: 6 mg, 0.012 mmol (18%).
LC-MS; method B RT: 6.40 min, APCI-MS m/z: 509.3 [MH+].
Example42 N-(4-lf2-(Dimethylamino)-2-oxoethyllsulfonyl~benzyl)-6-methyl-l0 2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-chloro-N,N-dimethylacetamide (11 ~,1, 0.105 mmol). Yield: 10 mg, 0.019 mmol (27%).
LC-MS; method B RT: 6.61 min, APCI-MS m/z: 536.4 [MH+].
Example43 Ethyl3-f(4-~((~6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1 dihydropyridin-3-yl 1 carbonyl)aminolmeth~phenyl)sulfonyllpropanoate From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluorome'thyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and ethyl 3-bromopropanoate (13 ~,1, ao 0.105 mmol). Yield: 5 mg, 0.009 mmol (13%).
LC-MS; method B RT: 7.64 min, APCI-MS m/z: 551.4 [MH+].
Example44 2-f(4-~f(d6-Methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridin-3-yllcarbonyl)aminolmeth~phenyl)sulfon l~yl acetate as From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-bromoethyl acetate (12 ~,1, 0.105 mmol). Yield: 7 mg, 0.014 mmol (20%).
LC-MS; method B RT: 7.19 min, APCI-MS m/z: 537.3 [MH+].

Example 45 N-~4-f(3-Cyanobenzyl)sulfonyllbenzyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 3-(bromomethyl)benzonitrile (21 mg, 0.105 mmol). Yield: 2 mg, 0.004 mmol (6%).
LC-MS; method B RT: 7.77 min, APCI-MS ~mlz: 566.3 [MH+].
Example46 Methyl3-f(4-lf((6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1,2-dih',rdropyridin-3-yl 1 carbonyl)aminolmethyl 1 phenyl)sulfonyllpropanoate io From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and methyl 3-bromopropanoate (11 ~,1, 0.105 mmol). Yield: 2 mg, 0.005 mmol (7%).
LC-MS; method B RT: 7.28 min, APCI-MS m/z: 537.3 [MH+]
is Example47 6-Methyl-N-(4-~f(2-methyl-1,3-thiazol-4-yl)methyllsulfon .l~~benzyl)-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxamide trifluoroacetate From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 4-(chlorornethyl)-2-methyl-1,3-zo thiazole hydrochloride (19 mg, 0.105 mmol). Yield: 11 mg, 0.017 mmol (24%).
LC-MS; method B RT: 7.21 min, APCI-MS m/z: 562.3 [MH+].
Example 48 6-Methyl-2-oxo-N-~4-~(pyridin-4- l~yl)sulfonyllbenzyl~-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carboxamide trifluoroacetate as From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 4-(chloromethyl)pyridine hydrochloride (17 mg, 0.105 mmol). Yield: 5 mg, 0.008 mmol (11%).
LC-MS; method B RT: 5.79 min, APCI-MS m/z: 542.3 [MH+].

Example 49 N-14-f~3-Cyanopropyl)sulfon lly benz~l-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1 2-dih~pyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 rnmol) and 4-bromobutanenitrile (10 ~,1, 0.105 mmol). Yield: 11 mg, 0.022 mmol (31 %).
LC-MS; method B RT: 7.19 min, APCI-MS m/z: 518.3 [MH+].
Example 50 N-(4-1~~(3 5-Dimethylisoxazol-4- 1)~thyllsulfon l~~ 1 methyl-2-oxo-1-f 3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide to trifluoroacetate From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 4-(chloromethyl)-3,5-dimethylisoxazole (13 ~,1, 0.105 mmol). Yield: 9 mg, 0.013 mmol (19%).
LC-MS; method B RT: 7.50 min, APCI-MS m/z: 560.4 [MH+].
Example 51 N-(4-~f4-(Acetylamino)benzyllsulfonyl~benzyl)-6-methyl-2-oxo-1-f 3-(trifluoromethyl)phenyll-1,2-dih~dropyridine-3-carboxamide From N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and N-[4-(chloromethyl)phenyl]-ao acetamide (19 mg, 0.105 mrnol). Yield: 7 mg, 0.013 mmol (18%).
LC-MS; method B RT: 6.98 min, APCI-MS m/z: 598.4 [MH+].
Example 52 6-Meth-N-f4-(d2-f(5-methyl-1,3,4-thiadiazol-2-yl)aminol-2-oxoethyl ~ sulfo ~1)benzyll-2-oxo-1-f 3-(trifluorometh~phenyll-1,2-dihydropyridine-3-as carboxamide Frorn N-(4-mercaptobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (29 mg, 0.07 mmol) and 2-bromo-N-(5-methyl-1,3,4-thiadiazol-2-yl)acetamide (25 mg, 0.105 mmol). Yield: 4 mg, 0.006 mmol (9%).
LC-MS; method B RT: 6.62 min, APCI-MS m/z: 606.2 [MH+].

Example 53 6-Meth~L4-(methylsulfonyl)phenoxyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide To a mixture of 6-methyl-2-oxo-1-[3-~(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (67 mg, 0.22 mmol), HATU (93.7 mg, 0.25 mmol), HOAT (34 mg, 0.25 s mmol), DIEA (150 ,ul, .87 mmol) and NMP (2 ml) was added O-[4-(methylsulfonyl)phenyl]hydroxylamine, prepared according to the procedure in J.
Med. Claem., 1967, 512 (41 mg, 0.22 mmol). After stirring at room temperature for 3 h the mixture was partitioned between EtOAc and water. The organic extract was washed with brine, dried, filtered and evaporated to dryness. The crude product was further purified by io preparative HPLC to give the title compound as a white solid (41 mg, 40°70).
1H-NMR (CDC13): b 12.19 (1H, s); 8.58 (1H, d, J 7.4 Hz); 7.92 - 7.86 (3H, m);
7.80 (1H, t, J 7.9 Hz); 7.57 (1H, s); 7.50 (1H, d, J 7.9 Hz); 7.30 - 7.26 (5H, m); 6.56 (1H, d, J7.5 Hz); 3.03 (3H, s); 2.16 (3H, s).
APCI-MS m/z: 567 [MH+].
is Example 54 6-Methyl-2-oxo-1-(3-trifluorometh ~~l-phenyl)-1,2-dih~pyridine-3-carboxylic acid (4-bromo-phenoxy)-amide A solution of 6-methyl-2-oxo-1-(3-trifluoromethyl-phenyl)-1,2-dihydro-pyridine-carboxylic acid (0.060 g, 0.20 mmol) in CH2C12 (5 ml) and SOCl2 (5 ml) was stirred for 3 ao h at room temperature and then concentrated to give the crude intermediate acid chloride as a solid. The solid was dissolved in 1,4-dioxane and O-(4-bromo-phenyl)-hydroxylamine, prepared according to the procedure in J. Med. Chem., 1967, 512, (0.10 g, 0.53 rnmol) was added and the mixture was stirred at room temperature for 10 min. The volatiles were removed and the residue was purified on preparative HPLC, giving 0.055 g is (58%) of the title compound as an off-white solid.
1H-NMR (CDCl3): 8 12.08 (1H, s); 8.57 (1H, d, J 7.42 Hz); 7.84 (1H, d, J 8.01 Hz); 7.77 (1H, t, J 8.01 Hz); 7.55 (1H, s); 7.47 (1H, d, J 8.01 Hz); 7.38 (2H, d, J 8.87 Hz); 7.00 (2H, 8.90 Hz); 6.52 (1H, d, J 7.48 Hz); 2.13 (3H, s) APCI-MS m/z: 467.1 and 469.0 [MH+].

Example 55 6-Methyl-2-oxo-N-phenoxy-1-f3-(trifluorometh,~phenyll-1,2-dihy-dr~yridine-3-carboxamide The title compound was prepared as described in Example 53 starting form O-phenyl hydroxylamine.
1H-NMR (CDC13): 8 12.04 (lH,s); 8.58 (lH,d); 7.85-7.74 (2H,m); 7.55 (lH,brs);
7.48 (lH,d); 7.32-7.26 (2H,m); 7.12 (2H,d); 7.02 (lH,t); 6.51 (lH,d); 2.12 (3H;s).
APCI-MS m/z: 389[MH+].
Example 56 N-(4-Aminobenz~)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-io 1,2-dihydroproline-3-carboxamide To a mixture of 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (212 mg, 0.7 mmol), HATU (272 mg, 0.7 mmol), HOAT (97 mg, 0.7 mmol) and DIEA (275 mg, 2.13 mmol) in NMP (3 ml) was added (4-aminobenzyl)amine (87 mg, 0.7 mmol) in NMP (1 ml). The reaction was stirred for 12 h at room temperature. The reaction mixture is was diluted with water (1.0 ml) and purified on a Xterra@Prep MS CS column (19 x 50 mm) using a gradient of CH3CN/water at a flow rate of 20 ml/min. Freeze drying of the mixture afforded the title compound (140 mg, 49%).
1H-NMR (400 MHz, CDCl3), 8 9.74 (1H, t, J 5.4 Hz ), 8.56 (1H, d, J7.5 Hz. ), 7.78 (1H, m),7.50(lH,s),7.43(lH,d,J7.8Hz),7.27(lH,s),7.15(2H,d,J8.lHz),6.81(2H, zo d, J 8.2 Hz ), 6.43 (1H, d, J7.4 Hz), 4.49 (2H, m), 2.06 (3H, s, J 9.1 Hz) APCI-MS m/z: 402.2 [MH+].
Example 57 6-Meth-N-d4-f (methylsulfon~)aminolbenzyl l-2-oxo-1-f 3-(trifluoromethyl)phenyl-1,2-dih~dropyridine-3-carboxamide zs To a mixture of N-(4-aminobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydroproline-3-carboxamide (80 mg, 0.2 mrnol) in CH2Clz, methanesulfonyl chloride (23 mg, 0.2 mmol) and DIEA (26 mg, 0.2 mmol) were added . The reaction mixture was stirred for 0.5 h at room temperature. The CH2Clz was evaporated off and the residue dissolved in CH3CN/water and purified on a Xterra@Prep MS C8 column (19 x 50 mm) using a gradient of CH3CN/water at a flow rate of 20 ml/min. Freeze drying of the mixture afforded the title compound (67 mg, 70%).
1H-NMR (400 MHz, CDC13) 8 9.83 (1H, s ), 8.59 (1H, d, J 7.4 Hz ), 7.80 (1H, d, J 7.9 Hz), 7.73 (1H, t, J 7.8 Hz), 7.51 (1H, s), 7.43 (1H, d, J 7.9 Hz), 7.31 (2H, d, J 8.4 Hz), 7.14 (2H, d, J 8.4 Hz), 6.46 (1H, d, J7.4 Hz), 6.38 (1H, s), 4.57 (m, 1H), 2.97 (3H, s, J
3.9 Hz), 2.08 (3H, s, J 4.3 Hz ).
APCI-MS m/z: 480.1 [MH+].
Example 58 N-14-fBis(meth~rlsulfonyl)aminolbenzyll-6-methyl-2-oxo-1-f3-io (trifluorometh,~l)phenyll-1,2-dihydropyridine-3-carboxamide The title compound was isolated as a by-product using the method described in Example 57.
1H-NMR (400 MHz, CDC13): 8 9.94 (t, J 5.6 Hz, 1H), 8.59 (d, J 7.4 Hz, 1H), 7.82 (d, J
7.9 Hz, 1H), 7.75 (t, J 7.8 Hz, 2H), 7.53 (s, 1H), 7.45 (t, J 5.6 Hz, 3H), 7.29 (d, J 9.7 Hz, is 2H); 6.47 (d, J 7.5 Hz, 1H), 4.64 (t, J 5.1 Hz, 2H), 3.39 (s, 6H), 2.09 (s, 3H).
APCI-MS m/z: 558.4 [MH+]
Example59 N-ff4-ff(Dimethylamino)sulfonyllaminolphen ll~yll-1,2-dihydro-6-methyl-2-oxo-1-f 3-(trifluorometh~phen l~pyridinecarboxamide ao The title compound was prepared from N-(4-aminobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydroproline-3-carboxamide and dimethylsulfamoyl chloride (2 mg, 10%) following the method outlined in Example 57.
1H-NMR (400 MHz, CD30D) 8 8.48 (1H, d, J 7.5 Hz); 7.86 (1H, d, J 7.4 Hz); 7.79 (2H, t, J 7.9 Hz); 7.73 (1H, s, ); 7.59 (1H, d, J 8.5 Hz); 7.25 (2H, d, J 8.6 Hz);
7.17 (2H, d, J
as 8.5 Hz); 6.63 (1H, d, J 7.6 Hz); 4.52 (2H, s, ); 2.74 (6H, s, ); 2.09 (3H, s).
APCI-MS m/z: 509.3 [MH+]
Example 60 6-Methyl-N-~4-fmeth 1(m~ethylsulfonyl)aminolbenzyl~-2-oxo-1-~3-(trifluoromethyl~phenyll-1,2-dih~~yridine-3-carboxamide To a mixture of 6-methyl-N-{4-[(methylsulfonyl)amino]benzyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (10 mg, 0.02 mmol) in dichloromethane, iodomethane (4 mg, 0.03 mmol) and DIEA (3.9 mg, 0.03 mmol) were added . The reaction was stirred for 10 min at 60 °C in a microwave oven. After s evaporation of the solvent, the residue was dissolved in CH3CN/water and purified on a Xterra@Prep MS C8 column (19 x 50 mm) using a gradient of CH3CN/water at a flow rate of 20 ml/min. Freeze drying of the mixture afforded the title compound (6 mg, 60%).
1H-NMR (400 MHz, DMSO-ds) 8 9.83 (1H, t, J 5.9 Hz), 8.38 (1H, d, J 7.5 Hz), 7.89 (2H, d, J 8.7 Hz), 7.80 (1H, t, J7.7 Hz), 7.71 (1H, d, J 8.0 Hz), 7.32 (4H, m), 6.62 (1H, d, J7.5 io Hz), 4.48 (2H, d, J 5.9 Hz), 3.20 (3H, s), 2.91 (3H, s), 2.01 (3H, s) APCI-MS m/z: 494.1 [MH+].
Following the general method of Example 60, the compounds of Examples 60.1 to 60.7 were prepared:
is Example 60.1 N-ff4-fBut 1(y methylsulfonyl)aminolphen ll~thyll-1,2-dih~rdro-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-3-pyridinecarboxamide Using 1-iodobutane. Yield (7 mg, 43%).
20 1H-NMR (400 MHz, DMSO-d6) ~ 9.86 (1H, s, ); 8.38 (1H, d, J 7.3 Hz); 7.89 (2H, d, J 9.5 Hz); 7.80 (1H, t, J7.4 Hz); 7.72 (1H, d, J 8.2 Hz); 7.32 (4H, s, ); 6.63 (1H, d, J 7.2 Hz);
4.49 (2H, d, J 5.8 Hz); 3.58 (2H, s, ); 2.91 (3H, s, ); 2.02 (3H, s, ); 1.27 (4H, s, ); 0.81 (3H, t, J 6.2 Hz).
APCI-MS m/z: 536.4 [MH+].
Example 60.2 1,2-Dihydro-6-methyl-N-ff4-f(1-methylethyl)(meth is amino].phenyllmethyll-2-oxo-1-f3-(trifluoromethyl)phen l~pyridinecarboxamide Using 2-iodopropane. Yield (10 mg, 38%).
1H-NMR (400 MHz, DMSO-d6) 8 9.88 (2H, t, J 6.0 Hz); 8.39 (2H, d, J 7.4 Hz);
7.89 (4H, 3o d, J 11.6 Hz); 7.80 (3H, t, J 7.8 Hz); 7.72 (2H, d, J 8.1 Hz); 7.33 (4H, d, J 8.3 Hz); 7.22 (4H, d, J 8.3 Hz); 6.63 (2H, d, J 7.6 Hz); 4.52 (4H, d, J 6.1 Hz); 4.30 (2H, quintet, J 6.7 Hz); 3.02 (7H, s, ); 2.02 (6H, s, ); 1.04 (12H, d, J 6.8 Hz).
APCI-MS m/z: 522.4 [MH+].
s Example 60.3 N-,(4-f(2-MethoxXeth~)(methylsulfonyl)aminolbenzyl~-6-meth ~~l-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide Using 2-bromoethyl methyl ether. Yield (15 mg, 33%).
1H-NMR (400 MHz, DMSO-d6) 8 9.86 (1H, t, J 5.9 Hz); 8.38 (1H, d, J 7.4 Hz);
7.89 (2H, d,J9.3Hz);7.80(lH,t,J7.8Hz);7.72(lH,d,J7.9Hz);7.32(4H,d,);6.62(lH,d,J
io 7.5 Hz); 4.49 (2H, d, J 6.0 Hz); 3.73 (2H, t, J 5.8 Hz); 3.29 (2H, t, J 5.7 Hz); 3.17 (3H, s, ); 2.98 (3H, s, ); 2.02 (3H, s).
APCI-MS mlz: 538.4 [MH+].
Example 60.4 N-(4-f(2-C amyl)(methylsulfonyl)aminolbenz~~-6-methyl-2-is oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide Using 3-bromopropionitrile. Yield (3 mg, 19%).
1H-NMR (400 MHz, DMSO-d6) 8 9.86 (1H, t, ); 8.39 (1H, d, J 7.4 Hz); 7.89 (2H, d, J 9.3 Hz); 7.80 (1H, t, J 0.0 Hz); 7.72 (1H, d, J 7.5 Hz); 7.36 (4H, s, ); 6.63 (1H, d, J 7.5 Hz);
4.50 (2H, d, J 6.2 Hz); 3.86 (2H, t, J 6.4 Hz); 3.00 (3H, s, ); 2.60 (2H, t, J
6.3 Hz); 2.02 zo (3H, s).
APCI-MS m/z: 533.1 [MH+].
Example 60.5 N-~4-Ethyl(methylsulfonyl)aminolbenzyl~-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide zs Using iodoethane. Yield: (6 mg, 59%).
1H-NMR (400 MHz, DMSO-d6) 8 9.86 (1H, t, J 5.9 Hz); 8.38 (1H, d, J 7.4 Hz);
7.89 (2H, d, J 9.3 Hz); 7.80 (1H, t, J 7.8 Hz); 7.72 (1H, d, J 8.1 Hz); 7.32 (4H, dd, J
11.6, 8.7 Hz);
6.62 (1H, d, J 7.5 Hz); 4.49 (2H, d, J 6.0 Hz); 3.62 (2H, q, J 7.1 Hz); 2.93 (3H, s, ); 2.02 (3H, s, ); 0.96 (3H, t, J 7.1 Hz);
so APCI-MS m/z: 508.4 [MH+].

Example 60.6 1,2-Dihydro-6-methyl-N-ff4-f(methylsulfonyl)propylaminol-phen, ll~yll-2-oxo-1-f 3-(trifluorometh~)phen ly 1-3-pyridinecarboxamide Using 1-iodopropane. Yield (6 mg, 57%).
1H-NMR (400 MHz, DMSO-d6) 8 9.86 (1H, t, J 6.0 Hz); 8.38 (1H, d, J 7.5 Hz);
7.89 (2H, d, J 8.8 Hz); 7.80 (1H, t, J 7.8 H~); 7.72 (1H, d, J 8.2 Hz); 7.32 (4H, s, );
6.62 (1H, d, J
7.7 Hz); 4.49 (2H, d, J 6.0 Hz); 3.54 (2H, t, J 7.1 Hz); 2.92 (3H, s, ); 2.01 (3H, s, ); 1.31 (2H, q, J 7.2 Hz); 0.80 (3H, t, J 7.3 Hz).
APCI-MS m/z: 522.4 [MH+].
io Example 60.7 N-ff4-f(3-Amino-3-oxopropyl)(methylsulfonyl)aminolphenyll-methyll-1 2-dih~dro-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen ly l-3-pyridinecarboxamide Using 3-bromopropionamide. Yield (7 mg, 30°l0).
is 1H-NMR (400 MHz, DMSO-d6) 8 9.86 (1H, t,"J 6.0 Hz); 8.39 (1H, d, J 7.5.
Hz); x7.89 (2H, d, J 10.5 Hz); 7.80 (1H, t, J7.7 Hz); 7.72 (1H, d, J7.8 Hz); 7.32 (5H, dd, J 11.0, 8.8 Hz); 6.81 (1H, s, ); 6.63 (1H, d, J 7.6 Hz); 4.50 (2H, d, J 6.0 Hz); 3.80 (2H, t, J 7.5 Hz);
2.96 (3H, s, ); 2.17 (2H, t, J 7.6 Hz); 2.02 (3H, s).
APCI-MS m/z: 551.4 [MH+].
Example6l 1,2-Dihydro-6-methyl-N-ff4-f(methylsulfonyl)oxylphen ll~yll-2-oxo-1-f 3-(trifluoromethxl)phenyll-3-pyridinecarboxamide a) N-(4-Hydroxybenz~l -6-methyl-2-oxo-1-f3-(trifluoromethyl)phen 1 2s dihydropyridine-3-carboxamide To a mixture of 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (1 g, 3.36 mmol), HATU (1.28 g, 3.36 mmol), HOAT (457 mg, 3.36 mmol) and DIEA (1.7 g, 13.36 mmol) in NMP (10 ml) was added (4-hydroxybenzyl)amine hydrobromide (686 mg, 3.36 mmol) in NMP (5 ml). The reaction was stirred for 12 h at room temperature.
so The reaction mixture was diluted with water (75.0 ml) and extracted with EtOAc. The organic phase was dried (MgSOq.), filtered and evaporated affording the title compound (1.2 g, 89°70).
1H-NMR (400 MHz, DMSO-d6) 8 9.66 (1H, t, J 5.7 Hz); 9.27 (1H, s, ); 8.36 (1H, d, J 7.4 Hz); 7.86 (2H, d, J 4.5 Hz); 7.78 (1H, t, J 8.0 Hz); 7.68 (1H, d, J 7.9 Hz);
7.06 (2H, d, J
s 8.3 Hz); 6.67 (2H, d, J 8.5 Hz); 6.60 (1H, d, J 7.4 Hz); 4.33 (2H, d, J 5.8 Hz); 1.99 (3H, s).
APCI-MS m/z: 403.3 [MH+].
b) 1,2-Dihydro-6-methyl-N-ff4-f(methylsulfon,rl)oxylphenyllmethyll-2-oxo-1-f3-(trifluorometh~phenyll-3-pyridinecarboxamide io The title compound was prepared from N-(4-hydroxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide and methansulfonyl chloride as in Example 57 (200 mg, 84%).
1H-NMR (400 MHz, DMSO-d6) 8 9.87 (1H, t, J 6.0 Hz); 8.38 (1H, d, J 7.5 Hz);
7.89 (2H, d, J 8.9 Hz); 7.80 (1H, t, J 7.8 Hz); 7.72 (1H, d, J 7.9 Hz); 7.39 (2H, d, J
8.6 Hz); ?.29 is (2H, d, J 8.6 Hz); 6.62 (1H, d, J 7.5 Hz); 4.50 (2H, d, J 6.0 Hz); 3.35.
(3H, s)2.02 (3H, s).
APCI-MS m/z: 481.3 [MH+].
Example 62 2-Propanesulfonic acid, 4-~f~fl,2-dihydro-6-methyl-2-oxo-1-f3-ao (trifluoromethyl)phenyll-3-pyridinyllcarbonyllaminolmethyllphen,1 The title compound was prepared from N-(4-hydroxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide and isopropylsulfonyl chloride as in Example 57.
1H-NMR (400 MHz, DMSO-d6) 8 9.83 (1H, t, ); 8.35 (1H, d, J7.5 Hz); 7.86 (2H, d, J 8.7 25 Hz); 7.78 (1H, t, J 7.7 Hz); 7.69 (1H, d, J 7.3 Hz); 7.35 (2H, d, J 8.5 Hz); 7.22 (2H, d, J
8.6 Hz); 6.60 (1H, d, J 7.3 Hz); 4.46 (2H, d, J 6.2 Hz); 3.66 (1H, m); 1.99 (3H, s); 1.38 (6H, d, J 6.9 Hz).
APCI-MS m/z 509.4 [MH+].

Example 63 N-f(l,l-Dioxido-2,3-dihydro-1-benzothien-5-yl)methyll-6-methvl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide a~ 2,3-Dihydro-1-benzothiophene-5-carbaldehyde and 2,3-Dihydro-1-benzothiophene-7-s carbaldeh,~
The subtitle compounds were prepared according to the procedure described in WO
01/12602.
b) 2,3-Dihydro-1-benzothien-5-ylmethanol and 2,3-Dihydro-1-benzothien-7-ylmethanol The title compounds were prepared by stirring a mixture of 2,3-dihydro-1-io benzothiophene-5-carbaldehyde and 2,3-dihydro-1-benzothiophene-7-carbaldehyde (4.3 g, 26 mmol) with sodium borohydride (3.78 g, 100 mmol) in THF (100 ml) and water (10 ml) at room temperature overnight. 1M Hydrochloric acid was added slowly to quench the excess of borohydride. The mixture was extracted with EtOAc and washed with water. The solvents were removed in vacuo and the residue purified by column is chromatography on silica using heptane/EtOAc (4:1) as eluent to afford 2,3-dihydro-1-benzothien-5-ylmethanol (1.84 g):
1H-NMR (CDCl3): 8 7.22 (1H, brs); 7.20 (1H, d, J 8.3 Hz); 7.11 (1H, brd, J 8.3 Hz); 4.61 (2H, s); 3.41-3.25 (4H, m);
and 2,3-dihydro-1-benzothien-7-ylmethanol (1.18 g) (total yield 70%):
ao 1H-NMR (CDC13): ~ 7.18 (1H, d, J 7.5 Hz); 7.15 (1H, d, J 7.5 Hz); 7.05 (1H, t, J 7.5 Hz);
4.63 (2H, s); 3.41-3.28 (4H, m).
c) 1,1-Dioxido-2,3-dihydro-1-benzothien-5-yl)methanol The title compound was prepared by stirring 2,3-dihydro-1-benzothien-5-ylmethanol (1.08 g, 6.38 mmol), oxone (5.8 g, 9.4 mmol), aqueous EDTA (22 ml, 0.4 mM), and as sodium hydrogen carbonate (4.8 g) in a mixture of acetone and water at pH
7.5 at room temperature overnight. The reaction mixture was extracted with EtOAc and washed with water. The solvents were removed in vacuo and the residue purified by column chromatography on silica using heptane/EtOAc (4:1) as eluent to afford the subtitle compound (1.0 g, 79%).

1H-NMR (CDC13): 8 7.70 (1H, d, J 7.9 Hz); 7.43 (1H, d, J 7.9 Hz); 7.42 (1H, s); 4.79 (2H, s); 3.53-3.36 (4H, m).
d) 5-(Bromomethyl)-2,3-dih~dro-1-benzothiophene 1,1-dioxide The title compound was prepared by refluxing (1,1-dioxido-2,3-dihydro-1-benzothien-5-s yl)methanol (1.0 g, 5 mmol) with phosphorus tribromide (0.524 g, 0.188 ml, 2 mmol) in dry toluene (20 ml) for 1 h. Water was added and the crude mixture was extracted with EtOAc, washed with water and brine and dried. The solvents were removed in vacuo to afford the subtitle compound (1.15 g, 88%).
1H-NMR (CDCl3): 8 7.73 (1H, d, J 8.0 Hz); 7.51 (1H, d, J 8.0 Hz); 7.43 (1H, s); 4.51 to (2H, s); 3.53 (2H, t, J 6.8 Hz); 3.43 (2H, t, J 6.8 Hz).
e~(1,1-Dioxido-2,3-dihydro-1-benzothien-5-yl)meth l~ ne The title compound was prepared by stirring 5-(bromomethyl)-2,3-dihydro-1-benzothiophene l,l-dioxide (1.14 g, 4.36 mmol) with aqueous ammonia (43 ml) in methanol/THF 1:1 (30 ml) overnight. The solvents were removed in vacuo to afford the is subtitle compound (700 mg, 81%).
1H-NMR (CDCl3): 8 8.05 (2H, brs); 7.82 (1H, d, J 8.3 Hz); 7.63 (1H, s); 7.61 (1H, d, J
8.3 Hz); 4.15 (2H, s); 3.62 (2H, t, J 6.9 Hz); 3.36 (2H, t, J 6.9 Hz).
APCI-MS m/z: 198 [MH+].
f) N~1,1-Dioxido-~,3-dihydro-1-benzothien-5- l~met~I~-6-methyl-2-oxo-1-f3-Zo (trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide Starting from 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-carboxylic acid (743 mg, 2.5 mmol) and (1,1-dioxido-2,3-dihydro-1-benzothien-5-yI)methylamine (500 mg, 2.5 mmol) using the method described in Example 17, the title compound (1.05 g, 88%) was obtained.
zs 1H-NMR (CDC13): 8 9.94 (1H, brt, J 6.0 Hz); 8.39 (1H, d, J 7.5 Hz); 7.93 (1H, s);
7.91(lH,d,J7.7Hz);7.83(lH,t,J7.7Hz);7.74(lH,d,J7.7Hz);7.70(lH,d,J8.0 Hz); 7.45(1H, d, J 8.0 Hz); 7.43 (1H, s); 6.64 (1H, d, J7.5 Hz); 4.58 (2H, d, J6.0 Hz);
3.57 (2H, t, J 6.9 Hz); 3.34 (2H, t, J 6.9 Hz); 2.04 (3H, s).
APCI-MS m/z: 477 [MHO].

Example 64 N-f(1,1-Dioxido-2 3-dihydro-1-benzothien-5- 1)meth~ll-5-iodo-6-methyl-2-oxo-1-f 3-(trifluoromethyl)phenyll-1 2-dih~dro~yridine-3-carboxamide To a solution of N-[(1,1-dioxido-2,3-dihydro-1-benzothien-5-yl)methyl]-6-methyl-2-oxo 1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (102 mg, 0.21 mmol), s dichloromethane (1.8 ml) and TFA (0.9 ml) was added N-iodosuccinimide (47 mg, 0.21 mmol). The mixture was stirred at room temperature for 4 h and the solvent was then removed in vacuo. The residue was partitioned between EtOAc and aqueous NaHC03 and the organic extract was washed with water, dried, filtered and evaporated. The crude product was purified by preparative HPLC to give the title compound as a white solid (87 mg, 69%).
1H-NMR (CDC13): 8 9.85 (1H, t, J 5.7 Hz); 8.91 (IH, s); 7.83 (1H, d, J 8.1 Hz); 7.76 (IH, t, J 8.0 Hz); ?.68 (IH, d, J 8.0 Hz); 7.49 (1H, s); 7.41 (2H, d, J 8.0 Hz);
7.34 (1H, s); 4.64 (2H, t, J 6.5 Hz); 3.48 (2H, t, J 6.9 Hz); 3.35 (2H, t, J 7.0 Hz); 2.32 (3H, s).
APCI-MS m/z: 603 [MH+].
~s Example 65 5-Todo-N-14-f isopropyl(methylsulfonyl)aminolbenz~ }-6-methyl-2-oxo-1-f 3-(trifluorometh~phenyll-1 2-di~dropyridine-3-carboxamide The title product was prepared as described for Example 64 but starting from N-{4-[isopropyl(methylsulfonyl)-amino]benzyl }-6-methyl-2-oxo-1-[3-ao (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide. White powder (4 mg, 68%).
1H-NMR (400 MHz, DMSO-d6) d 9.77 (1H, t, J 6.1 Hz); 8.6I (1H, s); 7.90 (2H, t, J 8.2 H2); 7.81 (1H, t, J 7.9 Hz); 7.72 (IH, d, J 7.9 Hz); 7.33 (2H, d, J 8.2 Hz);
7.21 (2H, d, J
8.3 Hz); 4.51 (2H, d, J 6.0 Hz); 4.30 (1H, quintet, J 6.7 Hz); 3.02 (3H, s);
2.20 (3H, s);
zs 1.04 (6H; d, J 6.7 Hz).
APCI-MS mlz: 648 [MH+].
Example 66 1 2-Dihydro-6-methyl-N-ff4-f(methylsulfon 1 methyllphen~ll-methyll-2-oxo-1-f3-(trifluoromethyl)phen l~~l-3-~yridinecarboxamide a) 6-Methyl-N-d4-f(meth~thio)meth llbenzyll-2-oxo-1-L3-(trifluoromethyl)phenyl]-1 2-dihydrOU~ridine-3-carboxamide To a mixture of 1-(3-methylphenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (412 mg, 1.39 mmol), TBTU (527 mg, 1.39 mmol) and DIEA (719 mg, 5.56 mmol) in NMP
s was added [(methylthio)methyl]benzene (232 mg, 1.39 mmol) in NMP (1 ml). The reaction was stirred for 1 h at room temperature, then diluted with water (15 ml) and extracted with EtOAc. The organic phase was dried (MgSOq.), filtered and evaporated affording the crude title compound (620 mg), which was used directly in the next step.
b) 1,2-Dihydro-6-methyl-N-ff4-((methylsulfon~l)meth ~~llphe~llmethyll-2-oxo-1-f3-(trifluorometh~phenyli-3-~~dinecarboxamide.
To crude 6-methyl-N-{4-[(methylthio)methyl]benzyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (620 mg 1.39 mmol ) in CH2C12 (10 ml) cooled to -150 °C was added m-chloroperoxybenzoic acid (483 mg; 2.8 mmol). The mixture was stirred for 30 min and then overnight at room temperature. The is reaction mixture was diluted with more CH~Cl2 and water, washed with sodium thiosulfate, sodium bicarbonate and brine. The solvent was removed in vacuum and 25 mg of the residue was dissolved in CH3CN/water (2.0 ml) and purified on a XterraC~Prep MS C8 column (19 x 50 mm) using a gradient of CH3CNlwater at a flow rate of 20 ml/min. Freeze drying of the mixture afforded the title compound (15 mg).
IH-NMR (400 MHz, DMSO-dg) 8 9.66 (1H, t, J 5.7 Hz); 9.27 (1H, s, ); 8.36 (1H, d, J 7.4 Hz); 7.86 (2H, d, J 4.5 Hz); 7.78 (1H, t, J 8.0 Hz); 7.68 (1H, d, J7.9 Hz);
7.06 (2H, d, J
8.3 Hz); 6.67 (2H, d, J 8.5 Hz); 6.60 (1H, d, J 7.4 Hz); 4.33 (2H, d, J 5.8 Hz); 1.99 (3H, s).
APCI-MS m/z: 479.3 [MH+].
as Example 67 6-Chloro-5-methyl-4-(3-meth~phenyl-N-f4-(meth lsy uIfon. I)~benzyll-3-oxo-3,4-dih~~rrazine-2-carboxamide a) 6-Chloro-5-methyl-4-(3-methylphenyl)-3-oxo-3,4-dih~pyrazine-2-carbonitrile The title compound was prepared essentially as described by Gibson. et al. J.
Org. Chefn.
1994, 59, 1072-1077 and Hoornaert et al. Tetrahedrofa,1990, 46, 5715-5732.
b) 6-Chloro-5-methyl-4-(3-methylphenyl)-3-oxo-3 4-dihydrop~razine-2-carbox~
acid A solution of 6-chloro-5-methyl-4-(3-methylphenyl)-3-oxo-3,4-dihydropyrazine-2-s carbonitrile (100 mg, 0.38 mmol) in 11M sulphuric acid (10 ml) was heated at 90 °C for 16 h. Water (200 ml) was added. The water phase was extracted with dichloromethane.
The organic layer was dried, filtered and evaporated to give the subtitle compound (20 mg, i9%).
APCI-MS m/z: 279.2 [MH+], HPLC Ghrornolith speedROD RP 18e 50-4.6 mm, flow 2.5 io ml/min, wavelength 254 nm, time 1.93 min.
c) 6-Chloro-5-methyl-4-(3-meth~phenyl-N-f4-(meth ls~ ulfonyl)benzyli-3-oxo-3 4-dih~dropyrazine-2-carboxamide The title compound was prepared starting from 6-chloro-5-methyl-4-(3-methylphenyl)-3-oxo-3,4-dihydropyrazine-2-carboxylic acid and (4-methylsulfonyl)benzyl amine as 1s described in Example 17.
1H NMR (DMSO-d~): ~ 9.68 (1H, t); 7.87 (2H, d); 7.57 (2H, d); 7.49 (1H, t);
7.36 (1H, d); 7.19 (2H, d); 4.59 (2H, d); 3.18 (3H, s); 2.36 (3H, s); 2.11 (3H, s).
APCI-MS m/z: 446.3 [MH+].
zo Example 6S 5-Bromo-6-(difluorometh 1~-N-~4-(rnet~lsulfonyl)benzyll-2-oxo-1-T3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide a? Ethyl 6-methyl-2-oxo-I-(3-(trifluorometh~phen 1-12-dihydro~yridine-3-carboxylate The title compound was prepared by stirring a mixture of 6-methyl-2-oxo-1-[3-25 (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (20.8 g, 70 mmol) with sodium carbonate (8.16 g, 77 mmol) in NMP (150 ml). Ethyl iodide (15.6 g, I00 mmol) was added slowly (about 10-15 minutes) and the mixture stirred at room temperature for 4 h. Water was added and the crude product was extracted with EtOAc, washed with water and dried and filtered. The solvent was removed in vacuo and the residue triturated with diethyl ether (100 mI), filtered, washed with diethyl ether and dried to afford the subtitle compound (18 g, 79%) as a white solid.
1H-NMR (CDC13): 8 8.21 (1H, d, J 7.4 Hz); 7.75 (1H, d, J 7.9 Hz); 7.68 (1H, t, J 7.9 Hz);
7.49 (1H, s); 7.42 (1H, d, J7.9 Hz); 6.25 (IH, d, J7.4 Hz); 4.36 (2H, q, J7.2 Hz); 2.03 s (3H, s); 1.37 (3H, t, J 7.2 Hz).
APCI-MS m/z: 326 [MH+].
b) Ethyl 5-bromo-6-(bromomethyl)-2-oxo-1-f3-(trifluoromethy~phenyll-1 2-dihydrop~ridine-3-carbox, The subtitle compound (3.25 g, 98%) was prepared by stirring ethyl 6-methyl-2-oxo-1-[3-~o (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylate (2.25 g, 6.9 mmol) with N-bromosuccinimide (2.45 g, 13.8 mmol) and benzoyl peroxide (35 mg, 0.14 mmol) in carbon tetrachloride (40 ml) at 70 °C for 4 h.
IH-NMR (CDCl3): S 8.33 (IH, s); 7.82 (1H, d, J7.9 Hz); 7.72 (1H, t, J 7.9 Hz);
7.62 (1H;
s); 7.56 (1H, d, J 7.9 Hz); 4.38 (2H, q, J 7.1 Hz); 4.16-4.08 (2H, m); 1.37 (3H, t, J 7.1 is Hz).
APCI-MS m/z: 482/484/486 [MHO].
Ethyl 5-bromo-6-(h~droxymethyl)-2-oxo-1-f 3-(trifluoromethyl)phenvll-1 2-dih~ opyridine-3-carboxylate The subtitle compound was prepared in quantitative yield by stirring ethyl 5-bromo-6-ao (bromomethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylate with aqueous sodium bicarbonate in aqueous THF at 60 °C overnight.
1H-NMR (CDC13): 8 8.35 (1H, s); 7.78 (1H, d, J 7.9 Hz); 7.68 (1H, t, J7.9 Hz);
7.57 (1H, s); 7.50 (IH, d, J 7.9 Hz); 4.45-4.33 (4H, m); I.37 (3H, t, J 7.1 Hz).
APCI-MS m/z: 420/422 [MH+].
as d) Ethyl 5-bromo-6-formyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1 2-dihydr~ridine-3-carbox.~e Dimethyl sulphoxide (1.14 g, 1.036 ml, 14.6 mmol) was added dropwise to a solution of oxalyl chloride (0.93 g, 0.64 ml, 7.3 mmol) in dry CH2Cla (40 ml) at -70 °C under an argon atmosphere. After 10 minutes stirring, ethyl 5-bromo-6-(hydroxymethyl)-2-oxo-1-so [3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylate (2.8 g, 6.66 mmol) in CHaClz (10 ml) was added and stirnng was continued for 20 minutes followed by the addition of triethylamine (3.34 g, 4.6 ml, 33 mmol). After a further 15 minutes at low temperature, the reaction mixture was allowed to reach -15 °C and water (20 ml) was added. Stirring was continued until the reaction mixture reached room temperature. It was then extracted with water and CHZC12, washed with brine, dried and filtered.
The solvents were removed in vacuo and the residue purified by column chromatography on silica using CHzCIz as eluent to afford the title compound (1.46 g, 52%).
'H-NMR (CDCl3): 8 9.74 (1H, s); 8.31 (1H, s); 7.75 (1H, d, J 7.9 Hz); 7.65 (1H, t, J 7.9 Hz); 7.46 (1H, s); 7.41 (1H, d, J 7.9 Hz); 4.41 (2H, q, J 7.1 Hz); 1.39 (3H, t, J 7.1 Hz).
io APCI-MS m/z: 418/420 [MH+].
Ethyl 5-bromo-6-(difluoromethyl)-2-oxo-1-f3-(trifluoromethyl phenyls-lz2-dihydropyridine-3-carboxylate.
The subtitle compound was prepared by stirring ethyl 5-bromo-6-formyl-2-oxo-1-[3 (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylate (0.98 g, 2.34 mmol) with is (diethylamino)sulfur trifluoride (DAST) (378 mg, 2.34 mmol) in dry CH2CIz (20 ml) overnight. Water was added and the reaction mixture was extracted with CHZCIz.
The solvents were removed in vacuo to afford 1.06 g (100%) of the subtitle compound.
IH-NMR (CDCl3): 8 8.29 (1H, brt, J 1.1 Hz); 7.77 (1H, d, J 8.1 Hz); 7.65 (1H, t, J 8.1 Hz); 7.53 (1H, s); 7.46 (1H, t, J 8.1 Hz); 6.82 (1H, t, J 55.I Hz); 4.39 (2H, q, J 7.1 Hz);
zo 1.38 (2H, q, J 7.1 Hz).
APCI-MS m/z: 440/442 [MH+].
f) 5-Bromo-6-(difluoromethyl)-N- 4-(methylsulfon 1)ben~ll-2-oxo-1-f3-(trifluorometh~phenyl -I,1 2-dihydropvridine-3-carboxamide The title compound was prepared from 5-bromo-6-(difluoromethyl)-2-oxo-1-[3-zs (trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid [obtained from ethyl 5-bromo-6-(difluoromethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylate by alkaline hydrolysis] and 4-(methylsulfonyl) benzylamine hydrochloride using the method described in Example 17.

rH-NMR (CDC13): 8 9.79 (1H, brt, J 5.2 Hz); 8.78 (1H, s); 7.89 (2H, d, J 8.4 Hz); 7.82 (1H, d, J 7.8 Hz); 7.70 (1H, t, J 7.8 Hz); 7.55 (1H, s); 7.50 (2H, d, J 8.4 Hz); 7.47 (1H, d, J 7.8 Hz); 6.92 (1H, t, J 51.9 Hz); 4.67 (2H, m); 3.02 (3H, s).
APCI-MS m/z: 579/581 [MH+].
Example 69 6-(Difluorometh l~N-f4-(met~lsulfo~l)benzyll-2-oxo-1-f3-(trifluorometh~~henyll-1,2-dihydrop ridine-3-carboxamide The title compound was prepared by hydrogenation of 5-bromo-6-(difluoromethyl)-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-io carboxamide with palladium on charcoal (Pd/C) and ammonium formate in methanol.
1H-NMR (CDCl3): b 10.00 (1H, brt, J 5.8 Hz); 8.76 (1H, d, J 7.5 Hz); 7.89 (2H, d, J 8.2 Hz); 7.87 (1H, d, J 7.9 Hz); 7.77 (1H, t, J 7.9 Hz); 7.58 (1H, s); 7.52 (1H, d, J 7.9 Hz);
7.51 (2H,~d, J 8.2 Hz); 6.98 (1H, d, J 7.5 Hz); 6.10 (1H, t, J 53.0 Hz); 4.70 (2H, m); 3.03 (3H, s).
1s APCI-MS m/z: 501 [MH+]
The compounds described in Examples 70.1 to 70.50 were prepared by a method analogous to that described in Examples 1 and 2:
2o Example 70.1 N-(2,3.-Dihydro-1,4-benzodioxin-6-ylmethyl)-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide ~H NMR (DMSO-d6): 8 9.93 (1H, t); 8.38 (1H, d); 7.88 (2H, d); 7.80 (1H, t);
7.70 (1H, d); 6.79-6.70 (3H, m); 6.62 (1H, d); 4.34 (2H, d); 4.I8 (4H, s}.
APCI-MS m/z: 466.3 [MH+].
2s Example 70.2 6-Methyl-N-f3-(methylsulfon 1)benz~l-2-oxo-1-f3-(trifluoromethyl~phen ly i-I 2-dihydro~~ridine-3-carboxamide 1H NMR (DMSO-d~): S 9.93 (1H, t); 8.38 (1H, d); 7.95-7.45 (8H, m); 6.62 (1H, d); 4.58 (2H, d); 3.18 (3H, s).

Example 70.3 6-Methyl-N'-f4-(methylsulfon~I~phenyll-2-oxo-1-L3-(trifluorometh~)phenyll-1,2 dihydropyridine-3-carbohydrazide 1H NMR (DMSO-d6): 810.80 (1H, s); 9.62 (1H, d); 7.99-7.74 (4H, m); 7.65 (2H, d);
6.80 (2H, d); 6.67 (1H, d); 3.07 (3H, s).
s Example 70.4 N'-(4-Bromophenxl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dih~pyridine-3-carbohydrazide IH NMR (DMSO-ds): 8 10.69 (1H, s); 8.35 (1H, d); 7.99-7.73 (4H, m); 7.29 (2H, d);
6.66 (3H, dd).
io Example 70.5 N-f(5-Methoxy-4-oxo-4H-pyran-2-yI)met~ll-6-methyl-2-oxo-1-j3-(trifluorometh~ henyll-1,2-dih~op~ridine-3-carboxamide APCI-MS m/z: 435.2 [MHO].
is Example 70.6 N-(4-Cyanobenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethy~phenyl]-12-dih~Pyridine-3-carboxamide APCI-MS m/z: 412.3 [MHO].
Example 70.7 N-~ f3-(4-Methoxyphenyl)isoxazol-5- Il~eth~~-6-methyl-2-oxo-1-ao f3-(trifluoromethyl)phenyll-1,2-dihydrop~ridine-3-carboxamide APCI-MS m/z: 484.4 [MH+].
Example 70.8 N'-(4-Cvanophenyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen.
2-dih~pyridine-3-carbohydrazide as APCI-MS m/z: 413.3 [MH+].
Example 70.9 6-Methyl-2-oxo-N-f(1-phenyl-1H-pyrazol-4-yl)methyll-1-L3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 467.3 [MH+].

Example 70.10 N-(2,3-Dihydro-I,4-benzodioxin-2-ylmethyl)-6-meth 1-2-oxo-1-f 3-trifluorometh~phenyll-1,2-dil~dropyridine-3-carboxamide APCT-MS m/z: 445.2 [MH+].
Example 70.11 6-Methyl-N-~ f 1-(3-methylphenyl~ lH~~rrazol-4- llmethyl~-2-oxo-I-f3-(trifluorometh tl phenyll-1 2-dih~dropyridine-3-carboxamide APCI-MS mlz: 467.3 [MHO].
Example 70.12 N'-(4-Chlorophenyl~-6-methyl-2-oxo-1-f 3-io ~trifluoromethyl)phenyll-12-dihydrop~ridine-3-carbohydrazide APCT-MS m/z: 422.2 [MHO].
Example 70.13 6-Methyl-2-oxo-N-f2-(tetrahydro-2H-pyran-4 yl)ethyll-1-f3-~rifluoromethyl)~henyll-1,2-dihydronyridine-3-carboxamide zs APCI-MS m/z: 409.4 [MHO].
Example 70.14 N-f (1-Ethyl-l.H-~yrazol-4- 1)Y methyll-6-methyl-2-oxo-1-f 3-(trifluoromethyl~phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 405.2 [MHf].
Example 70.15 N-f (4-Benz ly morpholin-2- 1)~ethyll-6-methyl-2-oxo-1-f 3-~rifluorometh~l)phenyll-1 2-dihydropyridine-3-carboxamide APCI-MS mlz: 486.3 [MH+].
2s Example 70.16 6-Meth-N-f3-(2-methylpiperidin-1-~pro~yll-2-oxo-1-f3-.~rifluorometh~phenyl11,2-dihydropyridine-3-carboxamide APCI-MS m/z: 436.3 [MH+].
Example70.17 Methyl2-(f((6-methyl-2-oxo-1-f3-(trifluoromethyl) henyll-12-so dih~pyridin-3-yl lcarbonyl)aminolmethyl ~-3-furoate APCI-MS mlz: 558.3 [MH+]
Example 70.18 6-Methyl-N-j(1-methyl-1H-pyrazol-4-yl~methyll-2-oxo-1-f3-~trifluoromethyl)phenyll-1,2-dihydrop~ridine-3-carboxamide s APCI-MS m/z: 391.2 [MH+].
Example 70,19 N-(3-Azepan-1-yl~ropYl -6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-I ,2-dihydro~yridine-3-carboxamide APCZ-MS m/z: 436.3 [MH+].
io Example 70.20 6-Methyl-N-(3-morpholin-4-prop ly_)-2-oxo-1-f3-(trifluorometh~~henyll- I ,2-dih~dronyri dine-3-carboxamide APCI-MS m/z: 424.3 [MH+].
1s Example 70.21 6-Methyl-2-oxo-N-(3-piperidin-1-ylprop' 1 -1-f3-trifluorometh~phenyll-I,2-dih~dropyridine-3-carboxamide APCI-MS m/z: 422.3 [MH+].
Example 70.22 N-f3-(3,5-Dimethyl~lH-pyrazol-I-y~propyll-6-metl~l-2-oxo-1-f3-zo (trifluorometh~)~henyll-1,2-dih~dr~yridine-3-carboxamide APCI-MS m/z: 433.3 [lVl~i+].
Example 70.23 N-f3-(2-Eth~pi~eridin-I-~propyll-6-methyl-2-oxo-1-f3-(trifluorometh~~henyll-1,2-dihydr~yridine-3-carboxamide zs APCI-MS m/z: 450.4 [MH+].
Example 70.24 6-Methyl-N-f2-(1-methyl-1H-imidazol-5-yl)ethyll-2-oxo-1-f3-trifluoromethyl)~henyll-1,2-dihydro~yridine-3-carboxamide APCI-MS mlz: 405.2 [MH+].

Example 70.25 N-f(1-Ethyl-3-methyl-1H-pyrazol-4-yl)methyll-6-methyl-2-oxo-1-f 3-(trifluorometh~phenyll-1 2-dihydrop~ridine-3-carboxamide APCI-MS m/z: 419.2 [MHO].
Example 70.26 N-_ f4-(Acet lamino)benzyll-6-methyl-2-oxo-1-f3-~trifluorometh;rl)phenyll-1 2-dihydro~xridine-3-carboxamide APCI-MS m/z: 444.2 [MHO].
Example 70.27 6-Methyl-2-oxo-N-f3-(1H-~yrazol-1-yl)propyll-1-f3-io (trifluoromethyl)phenyll-12-dih~dro~~ridine-3-carboxamide APCI-MS m/z: 405.2 [MH+].
Example 70.28 6-Methyl-2-oxo-N-(pyridin-2- lmeth 1)-~f3-(trifluoromethyl)phenyll-1 2-dih~dropyridxne-3-carboxamide is APCI-MS m/z: 35.3 [MHO'].
Example 70.29 6-Methyl-N-1 f 1-(4-methylphenyl)-1H-~yrazol-4- llmethyll-2-oxo-1-f 3-(trifluoromethyl)nhenyll-1 2-dih~drop~ridine-3-carboxamide APCI-MS m/z: 467.3 [MH+~.
Example 70.30 6-Meth~4-meth~lphen~2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydro~yridine-3-carboh dy razide APCI-MS m/z: 4D2.2 [MH+2.
2s Example 70.31 6-Methyl-N-f3-(4-methylpiperidin-1-~~rop~l-2-oxo-1-f3-(trifluorometh~l phenyll-1 2-dihydro~yridine-3-carboxamide APCI-MS m/z: 436.3 [MH+].
Example 70.32 6-Methyl-2-oxo-N-f3-(5-oxo-4 5-dihydro-1H-pyrazol-4-yl)propyll so 1-f3-(trifluoromethyl)phenyll-12-dihydropyridine-3-carboxamide APCI-MS m/z: 421.3 [MH+].
Example 70.33 Ether 5-methyl-4~1 f (~6-methyl-2-oxo-1-L3-(trifluorometh~l)~hen~rll-1,2-dihydropyridin-3-yl )carbonyl)aminolmethyl 1-2-furoate s APCI-MS m/z: 463.3 [MHO].
Example 70.34 N-f(6-Fluoro-4H-1,3-benzodioxin-~-yl)methyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phen~ll-1,2-dihydropyridine-3-carboxamide APCI-MS mlz: 463.3 [MH+].
io Example 70.35 6-Methyl=2-oxo-N-(2-pyridin-3-ylethyl)-1-f3-(trifluorometh~phenyll=1,2-dih~dropyridine-3-carboxamide APCI-MS m/z: 402.2 [MH+].
zs Example 70.36 N-j~1,3-Dimethyl-1H-pyrazol-4~r1)methyll-6-methyl-2-oxo-1-L-~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 405.2 [MHO].
Example 70.37 6-Methyl-2-oxo-N-(2-pyridin-4~ ly ethyl)-1-f3-Zo ~trifluoromethyl)phenyll-1,2-dih~opyridine-3-carboxamide APCI-MS mlz: 402.2 [MH+].
Example 70.38 N'-~4-Fluorophenyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carbohydrazide Zs APCI-MS m/z: 406.2 [MH+].
Example 70.39 6-Methyl-N-f(I-methyl-IH-pwrroI-2- 1)v methyll-2-oxo-1-f3-~trifluorometh~phenyll-1,2-dihydrop ridine-3-carboxamide APCI-MS mlz: 390.3 [MH+].

Example 70.40 6-Meth~~,-oxo-N'-phenyl-1-f3-(trifluoromethyl) hen ly 1-1,2-, dihydro~ riy 'dine-3-carbohydrazide APCI-MS m/z: 388.3 [MH+].
s Example 70.41 N-f(1-Ethyl-5-methyl-1H-pyrazol-4- 1)Y methyll-6-meth ~~1-2-oxo-1-f 3-(trifluoromethyl)phen~ll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 419.2 [MH+].
Example 70.42 6-Methyl-N-f2-(1-methyl-1H-imidazol-4-yl ethyll-2-oxo-1-f3-io ,~trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 405.2 [MH+].
Example 70.43 N-f2-(1,3-Dioxolan-2-, l~yll-6-meth .~-oxo-1-~3-(trifluorometh~!1)phenyll-1,2-dihydropyridine-3-carboxamide is APCI-MS mlz: 397.3 [MH+].
Example 70.44 N-~l-Benzothien-3-ylmethyl)-6-metl~l-2-oxo-1-f 3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 443.3 [MH+].
Example 70.45 N-f(1,5-Dimethyl-1H-pyrazol-4- 1)v methyl]_6-methyl-2-oxo-1-f3-(trifluoromet~l)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 405.2 [MH+].
2s Example 70.46 N-C2-(3,5-Dimeth~-1H-p~rrazol-4- lY )eth~l6-methyl-2-oxo-I-f3-(trifluoromet~l)phenyll-1,2-dihydropyridine-3-carboxamide APCI-MS m/z: 419.2 [MH+].
Example 70.47 N-f2-(3,5-Dimethylisoxazol-4-yl)ethylL6-meth 1-~2-oxo-1-f3-so ~trifluorometl~l)phenyll-1,2-dih dropyridine-3-carboxamide APCI-MS m/z: 420.3 [MH+].
Example 70.48 N-(3,4-Dihydro-1H-isochromen-1-ylmethyl)-6-methyl-2-oxo-1-f3-~trifluoromethyl)phenyll-1,2-dih~p~rridine-3-carboxamide APCI-MS m/z: 443.2 [MH+].
Example 70.49 N-1 f (2R)-1-Ethyl~yrrolidin-2-yllmethyl )-6-methyl-2-oxo-1-f 3-Ctrifluoromethyl)phenyll-1,2-dih~p ridine-3-carboxamide APCT-MS m/z: 408.3 [MHO].
io Example 70.50 6-Methyl-2-oxo-N-f(2R)-tetrahydrofuran-2-ylmethyll-1-f3-trifluorometh~phenyll-1,2-dih~pyridine-3-carboxamide APCI-MS nn/z: 381.2 [MHO].
is Example 71 5-Chloro-N-14-f(dimethylamino)sulfon 1 benz l~l-6-meth-2-oxo-1-f 3-(trifluoromethyl)phenyll-1,2-dihydro~yridine-3-carboxamide N-f4-(Benzylthio)benzyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1 2-dihydropyridine-3-carboxamide ao The subtitle compound was prepared as described for N-[4-(benzylsulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide [Example 27 (b)] but excluding the oxidation step. The sub title product was purified by preparative HPLC (x-terra column, 0.2°70 ammonia, acetonitrile) to afford the title compound.
1H NMR (DMSO): 8 9.78 (1H, t, J 6.0 Hz); 8.37 (1H, d, J 7.5 Hz); 7.91 - 7.68 (4H, m);
as 7.35 - 7.16 (9H, m); 6.62 (1H, d, J 7.6 Hz); 4.47 - 4.37 (2H, m); 4.20 (2H, s); 2.01 (3H, s).
APCI-MS m/z: 509 [MH+].
b) 5-Chloro-N-14-f(dimethylamino)sulfon~enzyll-6-meth~2-oxo-1-~3-trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide To N-[4-(benzylthio)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (92 mg, 0.18 mmol) was added 50% formic acidlwater (18 ml) and CH~C12 (9 ml). The reaction mixture was cooled to -20 °C and chlorine gas was bubbled through for 1 min. After evaporation of the excess chlorine the reaction mixture s was partitioned between CH2C12 and water. The organic phase was washed with 0.5M
aqueous NaHC03 and brine, and then dried. After filtration, the solvent was removed in vacuo and the residue was dissolved in ethanol (10 ml). 5.6M Dimethylamine in ethanol (250 ~uI) was added arid the mixture was stirred at room temperature overnight. After removal of the solvent the residue was purified by preparative HPLC (x-terra, 0.2%
zo ammonia, acetonitrile) to afford the title compound (41 mg, 43%).
1H NMR (CDCI3): 8 9.88-9.81 (1H, m); 8.65 (1H, s); 7.85 - 7.67 (4H, m); 7.51-7.39 (4H, m); 4.73 - 4.59 (2H, m); 2.68 (6H, s); 2.19 (3H, s).
APCI-MS m/z: 528 [MH+] .
is Example 72 N-d4-f(Dimethylamir~o)sulfonyllbenzyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)-~henyl]~ 1,2-dihydropyridine-3-carboxamide 5-Chloro-N-{4-[(dimethylamino)sulfonyl]benzyl }-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (15 mg, 0.028 mmol) was dissolved in hot methanol (1 m1). After cooling to room temperature, ammonium formate ao (6 mg, 0.1 mmol) and 10% palladium on carbon (3 mg) were added. The reaction mixture was stirred in a sealed vial at room temperature for 4 h. After filtration through Celite, the solvent was evaporated and the residue was purified by column chromatography on silica using CHZCI2/methanol (98:2) as eIuent to afford the title compound (6 mg, 43%).
1H NMR (CDC13): 8 10.01-9.92 (1H, rn); 8.59 (1H, d, J 7.5 Hz); 7.85 - 7.66 (4H, m); 7.55 -as 7.41 (4H, m); 6.48 (1H, d, J 7.5 Hz); 4.75 - 4.59 (2H, m); 2.68 (6H, s);
2.09 (3H, s).
APCI-MS m/z: 494 [MHO].
Example 73 5-Chloro-6-methyl-2-oxo-N-f4-(piperazin-1-ylsulfon 1 benzylLl-f3-(trifluoro-meth~phenyl]'-1,2-dihydropyridine-3-carboxamide so The title compound was prepared using the general method of Example 71.

~H NMR (CDC13): b 9.99 - 9.82 (2H, m); 8.64 (IH, d, J 8.2 Hz); 7.86 - 7.62 (4H, m); 7.53 -7.39 (4H, m); 4.76 - 4.55 (2H, m); 3.86 - 2.92 (8H, m); 2.19 (3H, s).
APCI-MS m/z: 569 [MH+].
s Using the general method of Example 72, the compounds of Examples 74 to 78 were prepared:
Example 74 6-Methyl-2-oxo-N-f4-(piperazin-1- ls~ulfo-n 1)benz~-1-f3-Lrifluorometh~phenyl]_ 1,2-dihydrop~ridine-3-carboxamide io 1H NMR (CDCl3): 8 10.11- 9.79 (2H, m); 8.67 - 8.50 (1H, m); 7.89 - 7.38 (8H, m); 6.52 -6.43 (1H, m); 4.78 - 4.52 (2H, m); 3.89 - 3.62 (2H, m); 3.49 - 2.94 (6H, m);
2.09 (3H, s).
APCI-MS m/z: 535 [MH~J.
Example 75 6-Methyl-N-f4-(morpholin-4- ly sulfo~l)benzyll-2-oxo-1-f3-is (trifluorometh~phen~rll-1,2-dih~dr~yridine-3-carboxamide 1H NMR (CDCl3): 8 10.05-9.95 (1H, m); 8,58 (1H, d, J 7.5 Hz); 7.84 - 7.64 (4H, m); 7.54 -7.41 (4H, m); 6.48 (1H, dd, J 7.4, 0.8 Hz); 4.75 - 4.59 (2H, m); 3.76 - 3.69 (4H, m); 3.01 -2.94 (4H, m); 2.09 (3H, s).
APCI-MS m/z: 536 [MH+].
Example 76 6-Methyl-2-oxo-N-f4-(piperidin-1-ylsulfonyl)benzyll-1-f3-(trifluoromethyl)-phenyl-1,2-dihydropyridine-3-carboxamide 1H NMR (CDCl3): 8 10.02-9.92 (IH, m); 8.60 (IH, d, J 7.3 Hz); 7.84 - 7.64 (4H, m); 7.54 -7.41 (4H, m); 6.48 (1H, dd, J 7.5, 0.5 Hz); 4.74 - 4.59 (2H, m); 2.99 - 2.91 (4H, m); 2.09 2s (3H, s); 1.68 -1.35 (6H, m).
APCI-MS m/z: 534 [MH+].
Example 77 6-Methyl-N-(4-f(meth~lamino)sulfon lv lbenzyl)-2-oxo-1-(3-(trifluorometh~phenyll-1,2-dih~~yridine-3-carboxamide 1H NMR (CDC13): 8 10.02-9.92 (1H, m); 8.59 (1H, d, J 7.3 Hz); 7.86 - 7.70 (4H, m); 7.54 -7.41 (4H, m); 6.48 (1H, d, J 7.3 Hz); 4.73 - 4.58 (2H, m); 4.29 (1H, s); 2.63 (3H, s); 2.09 (3H, s).
APCI-MS m/z: 480 [MHO].
Example 78 6-Methyl-2-oxo-N-f4-(pyrrolidin-1-ylsulfonyl)benzyll-1-f3-(trifluorometh~rl)phenyll-1,2-dih~o~yridine-3-carboxamide 1H NMR (CDCI3): 8 10.00 - 9.91 (1H, m); 8.60 (1H, d, J 7.5 Hz); 7.85 - 7.68 (4H, m); 7.53 - 7.40 (4H, m); 6.48 (1H, dd, J 7.5, 0.7 Hz); 4.76 - 4.58 (2H, m); 3.26 - 3.16 (4H, m); 2.09 io (3H, s); 1.80 - 1.70 (4H, m).
APCI-MS m/z: 520 [MH+].
Example 79 5-Chloro-6-methyl-2-oxo-N-f4-(p rr~n-1-ylsulfonyl)benz 1 L3-(trifluoromethyl)phenyll-1,2-dihydrop~ridine-3-carboxamide is The title compound was prepared using the general method of Example 71.
1H NMR (CDCI3): 8 9.89 - 9.79 (1H, m); 8.66 (1H, s); 7.86 - 7.72 (4H, m); 7.52 - 7.40 (4H, m); 4.74 - 4.59 (2H, m); 3.25 - 3.17 (4H, m); 2.19 (3H, s); 1.78 - 1.72 (4H, m).
APCI-MS mlz: 554 [MH+].
zo Example 80 5-Chloro-6-methyl-N-f4-(meth lsulfonyl)benzyll-2-oxo-1-~3-(trifluoromethyl)-phenyll-1,2-dihydropyridine-3-carboxamide 6-Methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide [Example 1.1] (50 mg, 0.108 mmol) was dissolved in acetonitrile (1 ml) and cooled to 0 °C. KN03 (16 mg, 0.16 mmol) and sulfuryl chloride (13 zs ~Cl, 0.16 mmol) were added. The reaction mixture was stirred for 1 h at 0 °C, followed by the addition of saturated aqueous NazC03 and diethyl ether . The aqueous phase was extracted with diethyl ether and the combined organic phase was Washed with brine and dried. After filtration, the solvent was removed in vacuo, the residue was dissolved in methanol, a white precipitate appeared and was filtered off and dried to afford the title so compound (22 mg, 41 °lo).

1H NMR (CDCI3): 8 9.93 - 9.80 (1H, m); 8.64 (1H, s); 7.94 - 7.69 (4H, m); 7.57 - 7.37 (4H, m); 4.75 - 4.57 (2H, m); 3.01 (3H, s); 2.19 (3H, s).
APCI-MS m/z: 499 [MH+].
s Example 81 N-~4-f~Acetylamino)sulfonyllbenzyl)-6-methyl-2-oxo-1-f3-(trifluoromethyl)-phenyll-1,2-dihydropyridine-3-carboxamide N-[4-(Aminosulfonyl)benzyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide [Example 1.5] (16 mg, 0.034 mmol) was dissolved in CH2C12 (1 ml). Powdered KOH (6 mg, 0.11 mmol) and 10% acetyl chloride in CHZC12 (25 io ,ul, 0.035 mmol) were added and the mixture was stirred at room temperature fox 1.5 h.
Water and 1M aqueous HCl were added. The reaction mixture was extracted with CH~CI2.
The organic phase was washed with water, brine and dried. The solvent was removed in vacuo and the residue was purified by preparative HPLC (x-terra, 0.2% ammonia, acetonitrile) to afford the title compound (7 mg, 41 °Io).
is 1H NMR (CDC13): ~ 10.03-9.96 (1H, m); 8.58 (1H, d, J 7.4 Hz); 8.16 (1H, s);
7.98 - 7.93 (2H, m); 7.83 - 7'.71 (2H, m); 7.53 - 7.42 (4H, m); 6.47 (1H, d, J 7.4 Hz);
4.72 - 4.59 (2H, m); 2.08 (3H, s); 2.02 (3H, s).
APCI-MS m/z: 508 [MH+].
ao Using the general method of Example 10, the compounds of Examples 82 and 83 were prepared:
Example 82 N-f4-(Isopropylsulfonyl)benz~Ii-5-iodo-6-methyl-2-oxo-I-f3-(trifluoromethxl)phenyll-1,2-dihydro~yridine-3-carboxamide 2s 1H NMR (CDC13): b 9.90 (1H, t, J 5.7 Hz); 8.91 (1H, s); 7.83-7.80 (3H, m);
7.76 (1H, t, J
7.9 Hz); 7.50-7.48 (3H, m); 7.41 (1H, d, J 7.8 Hz); 4.68 (2H, t, J 6.2 Hz);
3.15 (1H, m);
2.31 (3H, s); I.28 (6H, d, J 6.89 Hz).
APCI-MS m/z: 619 [MHO].

Example 83 N-f4-(Cycloprop ~Isulfon 1)~benzyll-5-iodo-6-methyl-2-oxo-1-(3-(trifluorometh~~henyll-1,2-dihydropyridine-3-carboxamide 1H NMR (CDC13): ~ 9.86 (1H, t, J 5.8 Hz); 8.90 (1H, s); 7.83-7.80 (3H, m);
7.75 (1H, t, J
7.8 Hz); 7.49-7.47 (3H, m); 7.40 (IH, d, J 7.8 Hz); 4.66 (2H, t, J 5.7 Hz);
2.42 (1H, m);
2.31 (3H, s); 1.32 (2H, m); 1.01 (2H, m).
APCI-MS m/z: 617 [MH+].
Example 84 1,2-Dihydro-6-methyl-N-ff4-f(methylsulfonyl)ox~phen 11~~ meths 2-oxo-1-f 3-(trifluorometh~phen~l~-3-pyridinecarboxamide to The title compound (31 mg, 46%) was prepared from N-(4-hydroxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl}phenyl]-1,2-dihydropyridine-3-carboxamide and benzensulfonyl chloride using the general method of Example 6I.
1H NMR (DMSO-d6) 8 9.87 (1H, t, J 6.0 Hz); 8.38 (1H, d, J 7.5 Hz); 7.89 (2H, d, J 8.9 Hz); 7.80 (1H, t, J 7.8 Hz); 7.72 (1H, d, J 7.9 Hz); 7.39 (2H, d, J 8.6 Hz);
7.29 (2H, d, J 8.6 is Hz); 6.62 (1H, d, J 7.5 Hz); 4.50 (2H, d, J 6.0 Hz); 3.35 (3H, s,); 2.02 (3H, s).
APCI-MS mlz: 543.3 [MH+].
Example 85 N-f4-(1,1-Dioxidoisothiazolidin-2-yl benzyll-6-methyl-2-oxo-1-f3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide zo The title compound (12 mg, 9.5%) was prepared from N-(4-aminobenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydroproline-3-carboxamide and 3-chloropropanesulfonyl chloride using the general method of Example 56.
1H NMR (DMSO-d6) 8 9.78 (IH, t, J 5.8 Hz); 8.37 (1H, d, J 7.4 Hz); 7.88 (2H, d, J 7.6 Hz}; 7.79 (1H, t, J 7.8 Hz); 7.70 (1H, d, J 8.2 Hz); 7.28 (2H, d, J 8.6 Hz);
7.14 (2H, d, J 8.5 2s Hz); 6.61 (1H, d, J 7.5 Hz); 4.43 (2H, d, J 5.8 Hz); 3.69 (2H, t, J 6.5 Hz); 3.47 (2H, t, J 7.4 Hz); 2.38 (2H, quintet, J 7.0 Hz); 2.01 (3H, s).
APCI-MS m/z 506.3 [MH+].
Example86 6-Methyl-2-oxo-N-ff4-(4-p~ridinylsulfon~phen l~lmethyll-1-f3-so (trifluorometh~phenyll-1,2-dihydropyridine-3-carboxamide a 1-f4-(Pyridin-4- lsy_ ulfonyl)phen~l methanamine To a mixture of 4-mercaptopyridine (0.8 g, 7.2 mmol) and KZC03 (2.0 g, 14.4 mmol) in NMP, 4-fluorobenzaldehyde (0.99 g, 8.0 mmol) was added. The mixture was then stirred s at 70 °C for 3 h. After cooling, the reaction mixture was diluted with water (S.0 rnl) and extracted with EtOAc. The organic solvent was evaporated and the residue dissolved in methanol. Sodium borohydride (0.57 g, 15 mmol) was added and the mixture stirred for 3 h at room temperature. After addition of water, the methanol was removed in vacuo and the residue extracted with CH2C12. The organic phase was dried over MgS04, filtered, and io evaporated and the residue was dissolved in toluene (10 ml). The toluene solution was heated to 40 °C, phosphorus tribromide (0.25 g, 0.92 mmol) was added and the temperature increased to I00 °C for 30 minutes. After cooling, water (50 mI) was added and the mixture extracted with EtOAc. The organic phase was evaporated, the residue dissolved in methanol and slowly added to a mixture of 2S% ammonia (15 ml) in methanol is (10 ml). After stirring fox 3 h at room temperature the subtitle compound was obtained.
(0.30 g, 37%) as a white solid. .
APCI-MS m/z: 217.2 [MHO].
b) 6-Meth-2-oxo-N-f f4-(4-pyridinXlsulfon~2phenyl'Lmetl~ll-1-f3-zo (trifluoromethyl)phenyll-1,2-dihydro~Yridine-3-carboxamide To a mixture of 6-methyl-2-oxo-.1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid (0.28 g, 0.92 mmol), HBTU (0.35 g, 0.92 mmol) and DIEA (0.24 g, 1.84 mmol) in NMP was added I-[4-(pyridin-4-ylsulfonyl)phenyI]methanamine (0.20 g, 0.92 mmol) in NMP (1 ml). The reaction mixture was stirred for 1 h at room temperature, then as diluted with water (15 ml) and extracted with EtOAc. The organic phase was dried (MgS04), filtered and evaporated. To the residue dissolved in CH2C12 (10 ml) cooled to -15 °C was added m-chloroperoxybenzoic acid (0.48 g, 2.76 mmol). The mixture was stirred for 30 min and then overnight at room temperature. The reaction mixture was diluted with more CH~Cl2 and water, washed with NazS203, NaHC03 and brine. The so solvent was removed in vacuo and 25 mg of the residue was dissolved in acetonitrile/water (2.0 ml) and purified on a XterraCa~Prep MS C$ column (19 x 50 mm) using a gradient of acetonitrile/water at a flow rate of 20 ml/min. Freeze drying of the mixture afforded the title compound (12 mg, 49%).
1H NMR (DMSO-d6) 8 9.92 (1H, t, J 6.0 Hz); 8.85 (2H, dd, J 4.4, 1.6 Hz); 8.34 (1H, d, J
7.5 Hz); 7.96 (2H, dd, J 6.7, 1.7 Hz); 7.90 (4H, m,); 7.87 (1H, t, J 4.4, 1.6 Hz); 7.71 (1H, d, J 7.9 Hz); 7.54 (2H, d, J 8.4 Hz); 6.61 (2H, d, J 8.2 Hz); 4.55 (2H, d, J 6.0 Hz); 2.01 (3H, s).
APCI-MS m/z: 528.4 [MH+].
io Starting from 6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxylic acid and the appropriate methanamine derivative and using the general method of Example 86, the compounds of Examples 87 to 91, 92(b) and 93(b) were prepared:
Example 87 6-Methvl-2-oxo-N-f4-(phenylsulfon 1)~ benzyll-1-f3-is (trifluorometh ~~1?uhenyll-1,2-dihydropyridine-3-carboxamide The title compound (34 mg, 21%) was prepared using 1-[4-(phenylthio)phenyl]methanamine (from thiophenol and 4-fluorobenzaldehyde).
1H NMR (CDC13) 8 9.90 (1H, t, J 6.0 Hz); $.34 (1H, d, J 7.5 Hz); 7.90 (6H, m);
7.80 (1H, t, J 8.1 Hz); 7.78 (2H, m); 7.59 (2H, t, J 7.5 Hz); 7.49 (2H, d, J 8.4 Hz);
6.60 (1H, d, J 7.7 ao Hz); 4.53 (2H, d, J 6.2 Hz); 2.01 (3H, s).
APCI-MS m/z: 527.4 [MH+].
Example 88 6-Methyl-2-oxo-N-f4-(I,3-thiazol-2-ylsulfon I)~ benzyll-1-f3-trifluoromethyl)phenyll-1,2-dihydro~yridine-3-carboxamide as The title compound (50 mg , 21 %) was prepared using 1-[4-(1,3-thiazol-2-ylsulfonyl)phenyl]methanamine (from 2-mercaptothiazole and 4-fluorobenzaldehyde).
1H NMR (400 MHz, DMSO-d6) 8 9.91 (1H, t, J 6.1 Hz); 8.32 (1H, d, J 11.8 Hz);
8.23 (1H, d, J 7.9 Hz); 8.06 (1H, d, J 3.1 Hz); 7.95 (2H, d, J 8.4 Hz); 7.87 (2H, d, J
7.2 Hz); 7.78 (lH,t,J7.9Hz);7.68(lH,t,J7.5Hz);7.54(2H,d,J8.4Hz);6.59(lH,d,J7.7Hz);4.54 so (2H, d, J 6.4 Hz); 1.99 (3H, s).

APCI-MS mlz: 534.3 [MH+].
Example 89 6-Methyl-2-oxo-N-f4-(pyrimidin-2 ylsulfonyl)benzyll-1-f3-Lrifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide s The title compound (10 mg, 23%) was prepared using 1-[4-(pyrimidin-2-ylsulfonyl)phenyl]methanamine (from 2-mercaptopyrimidine and 4-fluorobenzaldehyde).
1H NMR (DMSO-d6): S 9.63 (1H, t, J 6.1 Hz); 8.69 (1H, d, J 4.9 Hz); 8.05 (1H, d, J 7.5 Hz); 7.60 (4H, q, J 8.6 Hz); 7.45 (3H, m); 7.23 (2H, d, J 8.3 Hz); 6.30 (1H, d, J 7.4 Hz);
4.27 (2H, d, J 6.6 Hz); 1.70 (3H, s).
io APCI-MS m/z: 529.3 [MH+].
Example 90 N-f4-(1H Imidazol-2-ylsulfonyl)benzyll-6-methyl-2-oxo-1-f3-(trifluorometh~phenyll-1,2-dih~o~yridine-3-carboxamide The title compound (8 mg, 16%) was prepared using 1-[4-(1H-imidazol-2-is ylsulfonyl)phenyl]methanamine (from 2-mercaptoimidazole and 4-fluorobenzaldehyde).
1H NMR (DMSO-d6) 8 9.91 (1H, t, J 6.2 Hz); 8.35 (2H, d, J 7.4 Hz); 7.88 (4H, t, J 8.4 Hz);
7.80(lH,t,J7.7Hz);7.72(lH,d,J7.9Hz);7.52(2H,d,J8.3Hz);7.27(lH,s);6.61 (1H,.
d, J 7.5 Hz); 5.75 (1H, s); 4.54 (2H, d, J 6.0 Hz); 2.02 (3H, s).
APCI-MS m/z: 517.3 [MH+].
zo Example 91 6-Methyl-N-~4-f(1-methyl-1H-12 4-triazol-5- 1)~n lv lbenz'rl~-2-oxo-1- f 3-(trifluorometh~phen;rll-1 2-dihydro~yridine-3-carboxamide The title compound (6 mg, 15%) was prepared using I-{4-[(1-methyl-1H I,2,4-triazol-5-yl)sulfonyl]phenyl}methanamine (from 3-mercapto-4-methyl-4H-1,2,4-triazole and zs fluorobenzaldehyde).
1H NMR (DMSO-db) 8 9.95 (1H, t, J 6.0 Hz); 8.74 (1H, s); 8.36 (1H, d, J 7.5 Hz); 7.99 (2H,d,J8.4Hz);7.89(2H,d,J8.5Hz);7.80(2H,t,J7.8Hz);7.72(lH,d,J7.8Hz);7.59 (2H, d, J 8.4 Hz); 6.62 (1H, d, J 7.3 Hz); 4.59 (2H, d, J 6.3 Hz); 3.86 (3H, s); 2.02 (3H, s).
APCI-MS m/z: 532.3 [MH+].

Example 92 6-Methyl-N-(4-f(5-methyl-1,3-oxazol-4-yl)sulfon llbenzyl~-2-oxo-1-f 3-(trifluoromethyl)phenyll-1,2-dihydropyridine-3-carboxamide a~ 1-~4-f(5-Methyl-1,3-oxazol-4-yl sulfonyllphenyllmethanamine s To 5-methyl-4-[(4-methylphenyl)sulfonyl]-1,3-oxazole (prepared according to J. Chem.
Soc., Perkin Trans. 1, 2000, 527-531) (3.7 g, 15.6 mmol) dissolved in chlorobenzene, N-bromosuccinimide (3.5 g, 19.6 mmol) and 2,2'-azobis(2-methylpropinitrile) (0.27 g, 1.6 mmol) were added. The reaction mixture was then stirred and heated to 60 °C. Bromine (0.104 g, 0.65 mmol) was added and the mixture heated to 90 °C for an additional 2 h.
io After cooling, 2 % aqueous NaHS03 (10 ml) and water (40 ml) were added and the mixture extracted with EtOAc. The organic phase was evaporated, the residue dissolved in methanol and slowly added to a mixture of 25% ammonia (150 ml) in methanol (100 ml).
After stirring for 3 h at room temperature the ammonia was removed in vacuo and the water phase extracted with EtOAc. The organic phase was dried (MgS04), filtered and ~s evaporated affording the subtitle compound (2 g, 51%).
b~6-Methyl-N-~ 4-f (5-methyl-1,3-oxazol-4-~rl)sulfon~rllbenzyl ~-2-oxo-1-f 3-~trifluoromet>~l)phenyll-1 2-dihydropyridine-3-carboxamide The title compound (7 mg, 21%) was prepared using 1-{4-[(5-methyl-1,3-oxazol-4-2o yl)sulfonyl]phenyl}methanamine.
1H NMR (DMSO-d6) 8 9.92 (1H, t, J 6.0 Hz); 8.39 (1H, s); 8.35 (1H, d, J 7.4 Hz); 7.88 (4H, t, J 5.4 Hz); 7.80 (1H, t, J 8.2 Hz); 7.71 (1H, d, J 8.2 Hz); 7.52 (2H, d, J 8.1 Hz); 6.61 (1H, d, J 7.5 Hz); 4.55 (2H, d, J 6.I Hz); 2.64 (3H, s); 2.02 (3H, s); 1.9I
(2H, s).
APCI-MS m/z: 532.3 [MH+].
Example 93 6-Meth 1~-N-~ f6-(meth~lsulfonyl~pyridin-3-yllmethyl~-2-oxo-1-L
~trifluorometh~I)phenyll-1 2-dih~o~yridine-3-carboxamide a) 1-f6-(Meth lsy ulfonyl)pyridin-3-yllmethanamine To 2-chloropyridine-5-carboXyaldehyde (0.50 g, 3.5 mmol) in THF (5 ml), sodium methanethiolate (0.50 g, 7.0 mmol) was added. The mixture was then stirred at 70 °C
overnight. After cooling, the reaction mixture was diluted with water (15 nnl) and extracted with EtOAc. The organic phase was evaporated and the residue dissolved in methanol.
s Sodium borohydride (0.26 g, 7.0 mmol) was added and the mixture stirred for 3 h at room temperature. After addition of water, the methanol was removed in vacuo and the residue extracted with CHZC12. The organic phase was dried (MgS04), filtered, evaporated and treated with CHZC12 (50 ml). To the CHZClz mixture, phosphorus tribromide (0.25 g, 0.92 mmol) was added and the mixture stirred overnight at room temperature. Water (50 ml) zo was then added and the mixture extracted with EtOAc. Finally, the organic phase was evaporated, the residue dissolved in methanol and slowly added to a mixture of 25%
ammonia (20 ml) in methanol (20 ml). After stirring for 3 h at room temperature the subtitle compound was obtained.
is b) 6-Methyl-N-~f6-(meth;rlsulfony~pyridin-3-yllmethyl)-2-oxo-1-f3-(trifluoromethyl)phen~rll-1,2-dih~dropyridine-3-carboxamide The title compound (12 mg, 24%) was prepared using [6-(methylsulfonyl)pyridin-yl]methylamine 1-[6-(methylsulfonyl)pyridin-3-yl]methanamine.
1H-NMR (DMSO-d6) 8 9.98 (1H, t, J 6.1 Hz); 8.71 (1H, s); 8.36 (1H, d, J 7.5 Hz); 8.01 zo (2H, s); 7.90 (2H, d, J 8.3 Hz); 7.81 (1H, t, J 7.7 Hz); 7.72 (1H, d, J 7.9 Hz); 6.62 (1H, d, J
7.5 Hz); 4.61 (2H, d, J 6.1 Hz); 3,25 (3H, s); 2.03 (3H, s).
APCI-MS m/z: 466.3 [MH+].
Example 94 5-Fluoro-6-methyl-N-~4-(meth lsulfon~benz~rll-2-oxo-1 j3-zs (trifluorometh~)phenyll-1,2-dih~dropyridine-3-carboxamide To 6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide [Example 1.1] (0.25 g, 0.54 mmol) in acetonitrile (4.5 ml) under argon, 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane-bis(tetrafluoroborate) (0.45 g, 1.27 mmol) was added. The reaction mixture was heated at so 80 °C for 2 h. Water was then added and the product purified on a XterraC Prep MS C8 column (19 x 50 mm) using a gradient of acetonitrile/water at a flow rate of 20 ml/min.
Freeze drying of the mixture afforded the title compound (75 mg, 29%).
1H NMR (CDC13) 8 10.02 (1H, t, J 5.4 Hz); 8.57 (1H, d, J 9.0 Hz); 7.88 (2H, d, J 8.4 Hz);
7.84(lH,d,J8.lHz);7.76(lH,t,J7.9Hz);7.51(4H,d,J8.4Hz);7.44(lH,d,J8.OHz);
4.67 (2H, t, J 5.7 Hz); 3.05 (3H, s); 2.08 (3H, d, J 3.3 Hz).
APCI-MS m/z: 483.3 [MHO].
Example 95 N-f4-(methylsulfon,~~l)benzyll-2-oxo-6-(2-oxoethyl)-1-f3-(trifluorometh 1)y phenyl -1,1 2-dihydro~Yridine-3-caxboxamide io Phosphorus oxychloride (1.8 ml, 19.7 mmol) was added dropwise under argon to a stirred ice-cooled solution of dry N,N-dimethylformamide (2.8 ml). After the addition, the cooling was stopped and the mixture was stirred at room temperature for 30 min. Dry dichloromethane (10 ml) was added and the solution was cooled to -20 °C. 6-Methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl) phenyl]-1,2-dihydropyridine-3-is carboxamide (1.1 g, 2.4 mmol) was added in small portions at such a rate that the temperature did nat rise above I °C. After 15 min. at 0 °C, potassium carbonate (3.4 g, 24.6 mmol) was added and the mixture was heated to reflux for 20 min. The reaction mixture was cooled and poured into a cooled solution of 50% aqueous sodium carbonate (200 ml) and stirred at room temperature for 5 h. The mixture was extracted with ethyl acetate. The ao organic layers were washed with water, brine, dried, filtered and concentrated at reduced pressure to give a dark oil. A part of the oil was purified by preparative HPLC to give the title compound as a yellow solid.
IH NMR (CDCl3): b 20.06 (1H, t, J 5.3 Hz); 9.47 (IH, s); 8.66 (1H, d, J 7.4 Hz); 7.89 (2H, d, J 8.2 Hz); 7.82 (1H, d, J 8.1 Hz); 7.71 (1H, t, J 7.9 Hz); 7.53 - 7.49 (3H, m); 7.41 (1H, d, zs J 8.2 Hz); 6.50 (1H, d, J 7.4 Hz); 4.69 (2H, t, J 5.6 Hz); 3.60 (2H, s);
3.02 (3H, s).
APCI-MS m/z: 493 [MH+].
Example 96 5-Ethyl-6-methyl-N-f4-(methylsulfonyl)benz~ll-2-oxo-1-f3-(trifluoromet~l)phenyll-1,2-dih~pyridine-3-carboxamide A mixture of 6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-1-[3-(trifluoromethyl) phenyl]-5-vinyl-1,2-dihydropyridine-3-carboxamide (patent application SE
0302487-4) (58 mg, 0.12 mmol), 5% palladium on carbon (11 mg) in ethanol (15 ml) and EtOAc (15 ml) was stirred vigorously under a hydrogen atmosphere for 16 h. The mixture Was s filtered through Celite, the filtrate was evaporated to dryness and the residue was purified by preparative HPLC to give the title compound as a white solid (33 mg, 56%).
1H-NMR (CDC13): 810.09 (1H, t, J 5.7 Hz); 8.55 (1H, s); 7.87 (2H, d, J 8.3 Hz); 7.80 (1H, d, J 7.8 Hz); 7.74 (1H, t, J 7.9 Hz); 7.52 (2H, d, J 8.4 Hz); 7.50 (1H, s); 7.43 (1H, d, J 7.6 Hz); 4.67 (2H, t, J 6.4 Hz); 3.01 (3H, s); 2.59 (2H, q, J 7.5 Hz); 2.04 (3H, s); 1.23 i o (3H, t, J 7.5 Hz).
APCI-MS m/z: 493 [MH+].
Screen ~s Human Neutrophil Elastase Quenched-FRET Assay The assay uses Human Neutrophil Elastase (HNE) purified from serum (Calbiochem art.
324681; Ref. Baugh, R.J. et al., 1976, Biochemistry. 15, 836-841). HNE was stored in zo 50 mM NaOAc, 200 mM NaCI, pH 5.5 with added 30% glycerol at -20 °C.
The protease substrate used was Elastase Substrate V Fluorogenic, MeOSuc-AAPV-AMC
(Calbiochem art. 324740; Ref. Castillo, M.J. et al., 1979, Anal. Biochem. 99, 53-64). The substrate was stored in DMSO at -20 °C. The assay additions were as follows: Test compounds and ' controls were added to black 96-well flat-bottom plates (Greiner 655076), 1 p,L in 100%
a,s DMSO, followed by 30 p.L HNE in assay buffer with 0.01% TritonX-100. The assay buffer constitution was: 100 mM Tris (pH 7.5) and 500 mM NaCI. The enzyme and the compounds were incubated at room temperature for 15 minutes. Then 30 p.l substrate in assay buffer was added. The assay was stopped after 30 minutes incubation at room temperature by adding 60 ~.1 stop solution (140 mM acetic acid, 200 mM sodium so monochloroacetate, 60 mM sodium acetate, pH 4.3). Fluorescence was measured on a Wallac 1420 Victor 2 instrument at settings: Exitation 380 nm, Emission 460 nm. IC50 values were determined using Xlfit curve fitting using model 205.
When tested in the above screen, the compounds of the Examples gave ICsp values for inhibition of human neutrophil elastase activity of less than 30 ~,M, indicating that the compounds of the invention are expected to possess useful therapeutic properties.
Specimen results are shown in the following Table:
Inhibition of Human Neutrophil Elastase Compound ICsp (nM) 1-(3-Bromophenyl)-N-(4-methoxybenzyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-353 carboxamide 6-Methyl-N-[(5-methylisoxazol-3-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide N-(2,3-Dimethoxybenzyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-701 dihydropyridine-3-caxboxaxnide N-(2,3-Dihydro-1-benzofuran-5-ylmethyl)-2,4-dioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide

Claims (10)

Claims
1. A compound of formula (I) wherein:
X represents O or S;
Y1 represents N or CR2; and when R1 represents OH, Y1 may also, in the tautomeric form, represent NR6;
Y2 represents CR3; and when Y1 represents CR2, then Y2 may also represent N;
R1 represents H or C1 to 6 alkyl; said alkyl being optionally substituted by one or more substituents selected independently from halogen, CN, CHO, OR7, NR8R9, S(O)m R10 and SO2NR11R12;
and, when Y1 represents N, R1 may also represent OH;

R7 represents H, C1 to 6 alkyl or phenyl; said phenyl being optionally further substituted by halogen, C1 to 6 alkyl and C1 to 6 alkoxy;
R2 represents H, halogen or C1 to 6 alkyl;
R3 represents H or F;
G1 represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; or G1 represents a five-or six-membered saturated or partially unsaturated cycloalkyl ring; or G1 represents a five- or six-membered saturated or partially unsaturated heterocyclic ring containing one heteroatom selected from O, S and NR13 where R13 represents H or C1 to 6 alkyl;
R5 represents H, halogen, C1 to 6 alkyl, CN, C1 to 6 alkoxy, NO2,NR14R15, C1 to 3 alkyl substituted by one or more F atoms or C1 to 3 alkoxy substituted by one or more F atoms;
R14 and R15 independently represent H or C1 to 3 alkyl; said alkyl being optionally further substituted by one or more F atoms;
n represents an integer 1, 2 or 3 and when n represents 2 or 3, each R5 group is selected independently;
R4 and R6 independently represent H or C1 to 6 alkyl; said alkyl being optionally further substituted by OH or C1 to 6 alkoxy;
or R4 and L are joined together such that the group -NR4L represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O,S and NR16;

L represents a bond, O, NR29 or C1 to 6 alkyl; said alkyl optionally incorporating a heteroatom selected from O, S and NR16; and said alkyl being optionally further substituted by OH or OMe;
G2 represents a monocyclic ring system selected from:
i) phenyl or phenoxy, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR17 and optionally further incorporating a carbonyl group; or G2 represents a bicyclic ring system in which each, of the two rings is independently selected from:
i) phenyl, ii) a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N, iii) a C3 to 6 saturated or partially unsaturated cycloalkyl, or iv) a C4 to 7 saturated or partially unsaturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR17 and optionally further incorporating a carbonyl group;
and the two rings are either fused together, or are bonded directly together or are separated by a linker group selected from O, S(O)q or CH2, said monocyclic or bicyclic ring system being optionally further substituted by one to three substituents independently selected from CN, OH, C1 to 6 alkyl, C1 to 6 alkoxy, halogen, NR18R19, NO2, OSO2R38, CO2R20, C(=NH)NH2, C(O)NR21R22, C(S)NR23R24, SC(=NH)NH2, NR32C(=NH)NH2, S(O)S R25, SO2NR26R27, C1 to 3 alkoxy substituted by one or more F atoms and C1 to 3 alkyl substituted by SO2R39 or by one or more F atoms;
or when L does not represent a bond, G2 may also represent H;
m, p, q, s and t independently represent an integer 0, 1 or 2;
R8 and R9 independently represent H, C1 to 6 alkyl, formyl or C2 to 6 alkanoyl; said alkyl being optionally further substituted by phenyl optionally substituted by halogen, C1 to 6 alkyl, C1 to 6 alkoxy or SO2R30;
or the group NR8R9 together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR28;
R18 and R19 independently represent H, C1 to 6 alkyl, formyl, C2 to 6 alkanoyl, S(O)t R32 or SO2NR33R34; said alkyl group being optionally further substituted by halogen, CN, C1 to 4 alkoxy or CONR41R42;
R25 represents H, C1 to 6 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, CONR35R36, CO2R37, OCOR40, C3 to 6 cycloalkyl, a C4 to 7 saturated heterocyclic ring containing one or two heteroatoms independently selected from O, S(O)p and NR43 and phenyl or a 5 or 6 membered heteroaromatic ring containing one to three heteroatoms independently selected from O, S and N; said aromatic ring being optionally further substituted by one or more substituents selected independently from halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, OH, CONR44R45, CO2R46, S(O)SR47 and NHCOCH3;
R26 and R27 independently represent H, C1 to 6 alkyl, formyl or C2 to 6 alkanoyl;
R32 represents H, C1 to 6 alkyl or C3 to 6 cycloalkyl;
R38 represents H, C1 to 6 alkyl or phenyl; said phenyl being optionally further substituted by halogen, C1 to 6 alkyl or C1 to 6 alkoxy;

R36, R37, R39, R40, R41, R42, R43, R44, R45, R46 and R47 independently represent H or C1 to 6 alkyl;
and pharmaceutically acceptable salts thereof, with the proviso that the following compounds are disclaimed:
N-benzyl-5,6-dimethyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide;
N-(2-phenethyl)-5,6-dimethyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide;
N-(2-hydroxyethyl)-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide;
N-[2-(dimethylamino)ethyl]-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide;
4-[2-[[[1,2-dihydro-1-(4-methylcyclohexyl)-2-oxo-3-pyridinyl]carbonyl]amino]ethyl]-benzoic acid; and 4-[2-[[(1-cyclohexyl-1,2-dihydro-2-oxo-3-pyridinyl]carbonyl]amino]ethyl]-benzoic acid.
2. A compound according to Claim 1 wherein X represents O.
3. A compound according to Claim 1 or Claim 2 wherein R2 and R3 each represent H.
4. A compound of formula (I), according to any one of Claims 1 to 3, wherein represents phenyl or pyridyl.
5. A compound of formula (I), according to Claim 1, or a pharmaceutically acceptable salt thereof, for use as a medicament.
6. A pharmaceutical formulation comprising a compound of formula (I), as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.
7. A method of treating, or reducing the risk of, a human disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 1 to 4, or a.
pharmaceutically acceptable salt thereof.
8. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which inhibition of neutrophil elastase activity is beneficial.
9. The use of a compound of formula (I) as defined in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of inflammatory diseases or conditions.
10. A process for the preparation of a compound of formula (I), as defined in any one of Claims 1 to 4, and optical isomers, racemates and tautomers thereof and pharmaceutically acceptable salts thereof, which comprises:
reacting a compound of formula (II) wherein R1, R5, y1, y2, X, G1 and n are as defined in Claim 1 and L1 represents a leaving group, with an amine of formula (III) or a salt thereof wherein R4, G2 and L are as defined in Claim 1, and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.
CA002504766A 2002-11-12 2003-11-11 2-pyridone derivatives as inhibitors of neutrophile elastase Abandoned CA2504766A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE0203348-8 2002-11-12
SE0203348A SE0203348D0 (en) 2002-11-12 2002-11-12 Novel compounds
SE0300388A SE0300388D0 (en) 2003-02-12 2003-02-12 Novel compounds
SE0300388-6 2003-02-12
SE0302120-1 2003-07-22
SE0302120A SE0302120D0 (en) 2003-07-22 2003-07-22 Novel compounds
PCT/SE2003/001739 WO2004043924A1 (en) 2002-11-12 2003-11-11 2-pyridone derivatives as inhibitors of neutrophile elastase

Publications (1)

Publication Number Publication Date
CA2504766A1 true CA2504766A1 (en) 2004-05-27

Family

ID=32314809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504766A Abandoned CA2504766A1 (en) 2002-11-12 2003-11-11 2-pyridone derivatives as inhibitors of neutrophile elastase

Country Status (25)

Country Link
US (1) US20060035938A1 (en)
EP (1) EP1562902B1 (en)
JP (1) JP2006513261A (en)
KR (1) KR20050086516A (en)
AR (1) AR042024A1 (en)
AT (1) ATE325096T1 (en)
AU (1) AU2003276802B2 (en)
BR (1) BR0316081A (en)
CA (1) CA2504766A1 (en)
CY (1) CY1106130T1 (en)
DE (1) DE60305061T2 (en)
DK (1) DK1562902T3 (en)
ES (1) ES2262029T3 (en)
HK (1) HK1079200A1 (en)
IS (1) IS2478B (en)
MX (1) MXPA05004818A (en)
MY (1) MY137133A (en)
NO (1) NO20052818L (en)
NZ (1) NZ539787A (en)
PL (1) PL376957A1 (en)
PT (1) PT1562902E (en)
RU (1) RU2328486C2 (en)
SI (1) SI1562902T1 (en)
TW (1) TW200500341A (en)
WO (1) WO2004043924A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (en) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200640881A (en) * 2005-02-15 2006-12-01 Du Pont Fungicidal pyrazine derivatives
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
WO2008048375A1 (en) * 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
MX2008015648A (en) * 2006-06-21 2009-01-09 Du Pont Pyrazinones as cellular proliferation inhibitors.
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
WO2008107398A2 (en) * 2007-03-02 2008-09-12 Basf Se Pyrazine compounds
JP2011502982A (en) 2007-11-06 2011-01-27 アストラゼネカ・アクチエボラーグ Certain 2-pyrazinone derivatives and their use as inhibitors of neutrophil elastase
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
JP5507567B2 (en) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azaindazole compounds as CCR1 receptor antagonists
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2011039528A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
KR20120087923A (en) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
BR112012013582A2 (en) * 2009-12-08 2016-07-05 Boehringer Ingelheim Int process for synthesis of intermediates useful for the production of substituted indazole and azaindazole compounds
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
JP5684406B2 (en) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrazolopiperidine compounds as CCR1 receptor antagonists
TWI549943B (en) * 2011-03-09 2016-09-21 杜邦股份有限公司 Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
CN104024241B (en) * 2011-08-01 2016-01-20 大日本住友制药株式会社 Uracil derivative and its purposes for medical purpose
EP2562174A1 (en) * 2011-08-24 2013-02-27 Bayer Cropscience AG Herbicidal 6-Oxo-1,6-dihydropyrimidin-5-carboxamides and 2-Oxo-1,2-dihydropyridin-3-carboxamides
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) * 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
JP5799117B2 (en) * 2013-02-05 2015-10-21 大日本住友製薬株式会社 Pharmaceuticals consisting of uracil derivatives
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
JP2017523197A (en) * 2014-07-30 2017-08-17 エービーエーシー セラピューティクス，エス．エル． Aryl hydrazides as selective antimicrobial agents containing 2-pyridone moieties
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
US11472774B2 (en) * 2018-02-01 2022-10-18 The University Of Sydney Anti-cancer compounds
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
JP2023500182A (en) 2019-09-17 2023-01-05 メレオ バイオファーマ ４ リミテッド Alberestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome, and graft-versus-host disease
EP4252850A3 (en) 2020-04-16 2023-11-15 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541960A (en) * 1895-07-02 Nose-piece for eyeglasses
DE2706977A1 (en) * 1977-02-18 1978-08-24 Hoechst Ag BENZOESAEURS AND THEIR DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US4816658A (en) * 1983-01-10 1989-03-28 Casi-Rusco, Inc. Card reader for security system
US5420297A (en) * 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
GB9216272D0 (en) * 1991-08-15 1992-09-09 Ici Plc Substituted heterocycles
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
EP1318150A4 (en) * 2000-09-08 2004-04-14 Ono Pharmaceutical Co Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
ATE438624T1 (en) * 2000-12-28 2009-08-15 Shionogi & Co 2-PYRIDONE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID TYPE 2 RECEPTOR
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2003053543A1 (en) * 2001-12-21 2003-07-03 Milton Lawrence Weinbren Gas scrubber
SE0302324D0 (en) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (en) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (en) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (en) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
HK1079200A1 (en) 2006-03-31
WO2004043924A1 (en) 2004-05-27
IS2478B (en) 2008-12-15
AU2003276802B2 (en) 2007-03-08
DE60305061D1 (en) 2006-06-08
NZ539787A (en) 2006-11-30
AU2003276802A1 (en) 2004-06-03
DE60305061T2 (en) 2006-12-07
JP2006513261A (en) 2006-04-20
CY1106130T1 (en) 2011-06-08
IS7867A (en) 2005-05-26
KR20050086516A (en) 2005-08-30
ES2262029T3 (en) 2006-11-16
SI1562902T1 (en) 2006-08-31
RU2328486C2 (en) 2008-07-10
TW200500341A (en) 2005-01-01
PT1562902E (en) 2006-08-31
RU2005113168A (en) 2006-01-20
NO20052818L (en) 2005-07-11
US20060035938A1 (en) 2006-02-16
PL376957A1 (en) 2006-01-09
EP1562902A1 (en) 2005-08-17
DK1562902T3 (en) 2006-08-14
ATE325096T1 (en) 2006-06-15
MY137133A (en) 2008-12-31
EP1562902B1 (en) 2006-05-03
MXPA05004818A (en) 2005-07-22
AR042024A1 (en) 2005-06-08
BR0316081A (en) 2005-09-27

Similar Documents

Publication Publication Date Title
CA2504766A1 (en) 2-pyridone derivatives as inhibitors of neutrophile elastase
US8501784B2 (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
AU2004272485B2 (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
US20070010551A1 (en) Quinoline derivatives as neutrophil elastase inhibitors and their use
EP1861370A1 (en) 2-pyridine derivatives as inhibitors of neutrophile elastase
UA81271C2 (en) 2-pyridone derivatives as inhibitors of neutrophile elastase, process for the preparation thereof and pharmaceutical composition based thereon

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued